var title_f13_54_14176="Gram stain CSF 5A with answer";
var content_f13_54_14176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Listeria monocytogenes in cerebrospinal fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of cerebrospinal fluid (x1000) shows inflammatory cells and small, gram-positive rods and coccobacilli. Culture of this specimen revealed moderate sized, beta-hemolytic colonies composed of small, motile gram-positive rods, confirmed to be Listeria monocytogenes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_54_14176=[""].join("\n");
var outline_f13_54_14176=null;
var title_f13_54_14177="Patient information: Hypokalemia (The Basics)";
var content_f13_54_14177=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?15/34/15906\">",
"         Patient information: Hyperkalemia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/10/33954\">",
"         Patient information: Periodic paralysis syndrome (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hypokalemia (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12037118\">",
"      <span class=\"h1\">",
"       What is hypokalemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hypokalemia is the medical term for &ldquo;too little potassium in the blood.&rdquo; This condition can cause muscle weakness and other problems.",
"     </p>",
"     <p>",
"      Potassium is 1 of many substances called &ldquo;electrolytes&rdquo; that help carry electrical signals between cells. That&rsquo;s important because many cells rely on electrical signals to work right.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12037133\">",
"      <span class=\"h1\">",
"       What are the symptoms of hypokalemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom of hypokalemia is muscle weakness. The weakness usually starts in the legs and then spreads to the middle of the body and the arms. It can get so bad that you cannot move parts or all of your body. It can also damage muscles. In fact, it can even affect the muscles that control breathing, so it can make you stop breathing.",
"     </p>",
"     <p>",
"      Hypokalemia can also:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Cause an irregular heartbeat",
"       </li>",
"       <li>",
"        Disrupt the electrical signals that control the heart",
"       </li>",
"       <li>",
"        Impair the kidneys",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12037148\">",
"      <span class=\"h1\">",
"       What causes hypokalemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hypokalemia most often happens in people who have been vomiting or had diarrhea for a while. It can also happen in people taking medicine called &ldquo;diuretics,&rdquo; such as",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?10/20/10565?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?12/14/12518?source=see_link\">",
"       furosemide",
"      </a>",
"      (brand name: Lasix). Vomiting, diarrhea, and these medicines can cause the body to lose too much potassium.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12037163\">",
"      <span class=\"h1\">",
"       Are there tests I should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You will need blood and urine tests to get diagnosed with hypokalemia. You might also need other tests depending on your age, other symptoms, and individual situation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12037178\">",
"      <span class=\"h1\">",
"       How is hypokalemia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment usually involves taking potassium in pill form or through a tube (called an &ldquo;IV&rdquo;) in a vein. If your hypokalemia was caused by a medicine you take, your doctor or nurse might change your dose or switch you to a different medicine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12037193\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/10/33954?source=see_link\">",
"       Patient information: Periodic paralysis syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/34/15906?source=see_link\">",
"       Patient information: Hyperkalemia (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?13/54/14177?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87109 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_54_14177=[""].join("\n");
var outline_f13_54_14177=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12037118\">",
"      What is hypokalemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12037133\">",
"      What are the symptoms of hypokalemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12037148\">",
"      What causes hypokalemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12037163\">",
"      Are there tests I should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12037178\">",
"      How is hypokalemia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12037193\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/34/15906?source=related_link\">",
"      Patient information: Hyperkalemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/10/33954?source=related_link\">",
"      Patient information: Periodic paralysis syndrome (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_54_14178="M mode tricuspid valve";
var content_f13_54_14178=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    M-mode echocardogram of tricuspid valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 285px; height: 188px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transducer is at the left parasternal area and two of the tricuspid valve leaflets are seen. The movement of the valves is similar to that of the mitral valve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_54_14178=[""].join("\n");
var outline_f13_54_14178=null;
var title_f13_54_14179="Acute lupus generalized 2";
var content_f13_54_14179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acute cutaneous lupus erythematosus (ACLE)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with generalized ACLE may present with a widespread morbilliform eruption that is often focused on sun-exposed areas, including the extensor aspect of the arms and hands.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_54_14179=[""].join("\n");
var outline_f13_54_14179=null;
var title_f13_54_14180="Extensor hood injury of finger";
var content_f13_54_14180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extensor hood injury of finger",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 317px; height: 598px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJWAT0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiuc8R+NND8P3kdjeXTzapKu+PT7OF7i5ceojQFgODycD3rI/4SnxfduraZ4CmS2YZV9T1SG2fHuiCQj6HmgDuqK4b/hKfFtoWbUvAVy8K8s2m6nBcN+Cv5ZP863fC3inS/E0M502WRbm2YJdWdxGYri2YjIWSNvmXPOD0OOCaANyiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAR2VFZnYKqjJJOABWX4a8RaR4n03+0NAv4L+z3mPzYTkBhjI+vI/OsD4x/21L8OtYs/DFpLdatfRiziWP8AgEh2u5PYBCxz64rifgT4T8SeAfEetaHqunWsWi3VtBeW81hK8tukyKIpFLOqtvcKHPHbrQB7VRRRQAUUUUAFFFFABRRRQAUUUUAFcf4l1XUNS1seGfDcht7oRrNqGohQwsYWztCA8GZ8HaDkKBuIPAPVX11DY2Vxd3LhIII2lkY/wqoyT+QrmfhjZvF4TttRvF/4mesf8TK8cg5LygMFOeyJsQDsEFAGn4Y8M6T4ZtHg0i0WJpW3zzuS81w/d5JDlnbJPJNcvq2v6zrWtapY+Hb+z0nS9KcQXWpTRCd5LgqrGONSQqhQy7mbPzHaAME1t/ETWLvRvDTtpOz+1buaKxst4yFllcKGI7hQS+O+2uDX7NFrOn/D/RNSSGGC0+13U6TI1wzLLlt2SSXduW47uT1FROVti4q+5vS+INf8JPbzeKrzTtU0R3EUt5b27W09sT0kdN7LIgx8xXaVGWwQDiT4p6eun2SeN9Jj2azoaee8kWAbqzBzNBJ/eXZuZc9GUEY5q3c31nLJbaT4kS0W+miku1hQs8ZjhdctuKjpuQkH1PUA1H8O1i1DwTd+Hr4Ozae82lzRycnycZi69QYHiP447GlTk3ownG2qO2hlSeGOWFg8UihlZTwQRkEU+uQ+EV1JdfDbQBcAi4tbf7DLnOfMgYwtnPfMZrr60ICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDl/im4T4beKM5w2m3Ccf7UZX+tdNEixRJGgAVQFAHYCuW+K4LfDbxIAMk2MgA9TiuroA474m292dP0jUbK1mvBpWpR3s9vAm+WSII6NsX+Jh5m7A5O3A5rD+FaafqOmXPiay0w6e+rTP+6dyzrHG7IoIP3CcElBwCa9HvLiO0tJ7mZgsUKNI5PYAZNcV8M4Gg+H+geZ/rZbOO4k93kHmN/wCPMaxqmlMxfjLpzX2j6G9tMlrfRazZrb3TR7/KMkojORkblO7lcgEV0vgDRNZsLjWdT8SNZLqOpSxloLEs0SLGgQEFgCS3J9hgdia5j4vzxrpaL5sYnt1W+C7vmURXNu2/HoCOter06S0CpucP8PydN8R+MNAlLfudQ/tO33DGYLobzj2EonH4V3FcT4pUaT8QPC2tJhY70yaLdHHUOplhJ+kkZUf9dT6121amYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcp8S0F14eg00k51K/tbXHqpmVn/wDHFeurrlPFjiXxV4NsyAc3s10QT2jtpRn/AL6kWuroA82+I+rT6zey+EtJ3GMoo1WWNsNskB2WynszgMzN/DGCerLXW2Npb2FnDaWcMcFtCgjjijXaqKBgADsK5Lw35FprvjcX7Ay2erm93c5CPaRbW464Xcv/AAGte28UafeuRYM9wipHI7qpCqroXXk98AcdRuGetc87ydjaNkhnjPS7fUdMkW7X/Rnje3uju2/6PIu2Tn24Ye6in+B/EF09zJ4b8RkDX7GIOJgMJfwA7RcJ6HoHX+Fj6EGuQt/FfiDWoUsbS2srTUIi8d59qBKbhkbUA69VIbkHBGPR+g6hceIfGXw/uxiS6i0y6vr0quPKilRFjJ9NzDgd9jHtVQTi7ClZo634uRuvgK/voVBm0t4dUQ+n2eVZT/46jD8a7BGV0V0OVYZBHcVQ8Q2K6noGp2DruW6tpYCvqGQrj9azvh3dm+8A+G7pmLPNptu7EjGWMa5/XNbGR0NFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHG+I1/wCLm+DG/wCnfUByP9mL9eP512Vcj4tQp4y8EXPAX7bcW5P+/aysP1jFddQB4l48vdWt/HXiG+8HWC3sNlYxx+ILaeQIl18haNYTtJ81Y3JJzggqME4o+C+mXFp4PD3yktdNDPG/Ten2WFFb8lq3qF0+m2Pxcgn+W/j87UUyOGhezVY2B+sLqfdTXS+HIhB4f0yFekdrEg/BAKzvqy+iKmo6XCdcsr9WAnaREKsOGCLIeOOuGPX07V5d8I518FeF9E8V2Mmoy6FcKIdfix9o8vEIKXCqBuCo3ykDOE7cV7U8aO0bOuWjbcp9Dgj+RNeD/DNpz8F18P2iut34knfT7WPBfaHlkSeTjskQLE+w9RQ2+gLU+pkZXRXQ5VhkEdxXHfB/K/DrSIS2423m2uf+uUrx/wDstdhFGIokjT7qAKPoK5H4TqE8G7VxtXUtRA9v9Nn4rQg7CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDkfiAwS88IOSPl1yIf99QzL/wCzV11ch8SRi18PyAgGPXLE8990oT/2auvoA8R/aBW60h7vUYY5JYNe0v8A4R/Mf/LKdpC0Zb/ZKySjPYgetegIoRFVRgKMCqfxnCSeDI7d0V3uNU0+KMH+8buI/wAgasz+btTyCgO9d27+7nn8cVLRSJCARyM968p/ZYiOpWcl7MrqmjRzafbhujNPMZpHH/ARCPwNer1w/wCy9pzad4Q8QxyjEg125Q/RFRcfmDQgZ7JXIfCnnwarjOJNQ1CQZOeGvJiP0NdfXH/CTcPAlmHADC4uwcev2mXmqJOwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5H4mBRoulyMCVj1rTWOO3+lxD+tddXI/Ehi9roFmBk3et2S49RHJ5x/SI111AHBfF3L23haBTjztetsj1CLJJ/7JV4K/msxfKFQAuOh5yc+/H5Vm/E24H/CReDLYoX23dzfEDriK2kXOPrMv51oQSF7WOWVfLZkDMD/AA8ZNSykSZHY1hfCJo7LXPHWiowLQasL8DPIW5iR/wD0MSVyPwf8Qx6tqniuEXPns96uoR/KV2xyoAEGRztMeCRxmt3w6ItE+OV2DKip4j0sSbT1ae2IAA+sbE/8BNCBnrdcl8MQIvD15bD/AJd9W1GL6D7XKw/RhXW1yXgjbb614xsACBDqvnL9JYIpD/48z1RJ1tFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHJeJQbjx54OtsEiE3d8fQbIhFz/wCBFdbXJgmX4rMD0tdFG3np5s5z/wCiR+VbniDVbfQtC1HVr3P2axt5LiTb1KopYge/FAHG+JJDdfFTT4cZSw0eWU8dGnmRR+kDVzHxT8RjR/BdwhZ0vdSL2lupU7lU53Px/djy31wO9L4A/tm78VeKtT8RSrJfTCziaJF2pa4iMv2deTnZ5wy3cknArmZ1Hjf412iLcu1loFz5RhX/AFZ2KJHL+rGRVUD/AKY5PUVDfUtLoTX+jyeAdT8G6zICokH2LVW3ZH79gTnPRUlMePYtW18amvNN8OWPibSR/wATHw/ex3yYH34+UkQn+6Vbn2Fdv4+8PR+KPDF3pcqhvPG0Hj5c8FhnuASR7gVzPhCc+Lvh79k1xD9raKXTNRQn5hKmYpPxJBP4iohK6HJHpHhfXbPxJoVrqunMTDOuSjDDROOGRh2ZTkEeorE07bZfFXWocEf2jpltdKfVonkjf9Giry39n7WrmTx5qujXG5Lq307ZqahdqS3cE5iEwHQs0ZXcw67RnpXqnijNn448H344WaS50yQ+0kXmrn/gVuo/GtkQzrqKKKBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHJ6aTL8UNfYY2w6VYx+4JlumP6Yqp8aV3fDTWGY4ijMEs3Gf3SzxtJ/44GqxoKlfib4u3NndZ6ewHoP8ASB/MGtPx28UfgjxDJcxJLAmnXDPG67lZRGxII7igDz3wrfpbeC9S8RzcJeyXWrkk/wDLIlmjz/2yWMfhXjfwY1++sriK30lvtd3PMLvVLySAu2bhocIh3csAshLEYyzDHevZrKwDfCrT9LwgE2lwWWHHHzxrHyPxrzH9l8y6lB4jfVZJp7qB7OEea3KLEHEY9fl6c9gKi2hdy/ea1420S8SbU7641TUUjlXTH+ybUkncRF4ZVQBVACOVJIOCx9Ku/s/a9Pqd34ptrqCa3lWeG5dJjuZpmQxzNnvl4SfqT716framLSL9kj893UkI5yC2ABj9K8w+D8My/Enx9HLnybCf7PAMABUkmmlI9+WJ/GhJBc7z4Z6baWPxQ8fSRwIt1cLY3HmdyjI6kD/gcbE/X2FdH8TlCaFYXvRrHVrCcH2+0xo3/jrtWBoLeX8bZlB4n8PAsP8AcuTj/wBGGt34ulR8PdULdmgI9j5yY/XFUiXudjRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcjYnyvixrKFuLjRrKQLnuk1yD/wChrV/4gwtceAvEsMYy8mmXKKPcxMKp3iCH4paXKf8Al50i6i/FJoGH6Oa6mVFljeORQyOCrA9waAPPPD8kF74U0aaUr5Uttbyrk4GcKy/rivM/Ato/hD4weOdMCbbG9tBrEOem0Oc49g0jj/gNdz8MQ3/CC6bZ3IDS6eX09wR0a3kaL/2QGqnizTPP8f8Ahq4ilMLTWt7ZTbRy8bRhgPwYZqCjVnvLnUfBlnfxRlZ54ra5KJkbcsjtjvwM1y/wttHTxn8Rb0/6qbVFhU+6Jk/+jBXeWts8EFraDm2jtzExOAxIChenturD8BQLAPEO1QGfWLhmPXP3QM/gBQBb0BPN+M1w6qf9G0BVZv8ArpcHA/8AIRra+LcXn+BLqH/nrdWcY+rXUQ/rWP8ADkSTfEXx7cyElIjYWcfoAsLSEfnNWz8UyP8AhG7JGGQ+saYv/k7DVIT3OwooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOZ1iMyePvDZHBjtb1yfb9yuPzYH8K6aud1BS3xA0Qg/c069JH1ktRXRUAeV+FUFj4n8a6VnLQ6qbxeMfJcRpL/wChmQfhVjWFjbxX4fZiNyG4Vc9yYwePU4/rS6sPsvxknVAFW/0OORwP4mhndc/lMB+VVfEDb/FnhIkOuLm5GCByRBIM/wCGPWpe5Rv6nBLc6dcwQP5cskbKr5xtJHXIrL8NIsWpeJI1OcaiHx6breE/1NU9T+IXhPS9bk0jUtds7TUIwC8czFAuemXI2/rV3QL6zv8AUtSn027t7u2l8qQSwSiRCdpU4I46KKQFj4TbZr7xvcp919caLJ6/u7eBT+oNaPxTBHhq0k5xFq+mSNj0F7Dms/4RL5beMozjcuvzMfo0EDD9DWj8XAf+Fd6xMAf9FWO8OBnAhkSUn/xyrEdfRQCCAQcg96KBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHOXL5+ImnJg/LpV0c9uZrf8Awro65uFTJ8RrxuqwaVCB7GSaXP8A6LFdJQB5r4xtVm+LnhyeN2SS30m8aUdmUyQqo/Msfwqv4wMcF9oF27lHS+ESME3Y3o+cnBxkDGffHei8eTWPin4iILC006wttNz0BkctNJg+uxos/hVnxAsV5d6Xasoc/almUg8AxnJB/Ampe5SK93omm6tqCQ6xptjqEISZgLm2SVQTLkfeB5wTXBW/wo8H6n4j163fSv7PuLaeNrWawneF0jaJDnAYr94tzt7V7DWPJZNF4st76MKsUtrJDLjgs4ZChPrgBxzSA8/8M+BvEFp4n1rR/C3xC17SpbWOC7X+0BHfrcJIGXdtYLjBiKnrxt+lb2r6d8YotHv9Pum8J+JrC5he3kGJLS5kR1KnHSMcE+tSeJvEFr4V+IPhvU7h44hcg6ZOHYDzIpXXDD/rm6oT/syMR0Nex1SEzxTw78U/EGlaNZQ6/wDDzxFLbwRCE3ulSx6kHMfyMzGPaAcqcjPBzW1pfx48AXky293q0ulXhOGt9RtZIWQ/7TYKj/vquo8ML/ZfiTX9HY4illGqWoJ/gmJ80fhKrt/20Fb2p6ZYapB5Op2VreQ/887iJZF/JgaYiroviPRNdBOiaxp2ogdfsl0kuPrtJq7qEjQ2FzLGcOkTMp9wCa+bvjH4J8Kaz4u0/wAF+BPDmn2/iqdluLu+tA0Uel24IJdlQhdxGMAjoR3ZTX0D4X8P2vh7wzZaJbyT3FvbQ+UZLiQu8nqWJ9eeOg6DAoA8j+DfjTxrrnhG81/VVvNSZbF54ILm1gsbWZ1cj93cKWY8KfvIBn86W9+MOta34e0XWvCGjW8en3uv2ulxm9uwJJ94G9GQIwiG47Q2WOBu28gV3+lfDXwRYQ6hBpeg2MMd3EbW7WEkeYmQSjYPTIGRV+78CeFrq2vILjRLJre7eOSePZhGaNdqNgcAgcZGDigDjJfitqJ8by6LZeFru7tbO9gsL6eBZ5GheRQWkBWEx+Wm7nc6sRyBiqvh74w6lqdzoUlz4WWDTtaS/wDsbw6gJZWktA5ZSpRQA3lkDnqfSu4vPBvg+41K01a60jS2vE8sRXDKoLbMeXz0YrgYznGBVhfB/hm3tdPt/wCybNLeyM62sbD5Y/PDCUAHrv3sCO+aAPNNN+Nl7dRLbzaDaQa3dXlrZW+ny3U8TwyTl8faPMgUqFCHLIHBOAOtadv8WdQupdHsLHwylzrV7qF/pktuNQCRRzWi7mKyGP50Yd8Aj0NdSPAngvTtLvbCPw/p32e4USTQLDveQJyuByx287cdD0q3oeheG47LQLqw0iKxWzDvp8ckBt5IDKpD/I2CGYE5BGeuaAOkjLGNS6hXIBKg5wfTNOpruiFQ7Ku47VycZPoKdQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3pjBviBr+BythYoTn/buT/WtzUbyDTtPub27cR21tE00rn+FVBJP5CsPw6vm+KfFVzuBC3EFqOnGyBH/nKazfibqMUdnDp0pBgcG7vBuAzBGQdnJAy77EweoLUAc38Onml0rUrq4g2Xd3fS3Ux8wNukkwxTjp5YIiweQYzR4onfQNJTV3gMs1lC5VEYlZLiZ0UDHUjcx+ma3tBtDZaVBFIxaU7pZWaNUZndizEheM5Y5xWJ40tYtUurPTppHhjYC4llUZwkc0T7en8Tqg+m6o6lHV1QluCmtwW5mULJA7CM4yWBXkd+hP5VerAvIG/4TbTrhQFH2OVXIPLYZcA+2WP50AYvxH0aW8jkuLCKKS+mtHtkSUEpNgMTCwBHDo0oz2YIe1dr8L9e/tfw8ttPdpd3tgFhknVs+fHj93N/wJRz6OrjtXO+NklX+y7hJzFBFcESnHTKNtb/AIC20/hiqGnzTaDrh1Szs1hsyS7pGwLzM7O1zDtzkspXzlwOTvAxuppiZ6jd6YJ9Z0/UUlMctqssbADPmRuBlT6fMqN/wH3rkfi549bwhptrY6Nbf2h4r1Zzb6XYrzuc8eY/oi5BPr0yBkjY8ceNdJ8IeD5fEN/MstrsX7MkbAtdOwyiR+pbr7DJ6A1yHwi8H6nJqV1498dqH8V6omIbcj5dNtv4YUB6Njr37dSxNCNv4SeAk8E6LNJfTm+8R6k/2nVL9zlppTk4B/ujJx+J711+sW017pF9a2tw1tcTwPFHOvWJmUgMPcE5/CrlFAHzr4V+Eus6Ro+tW9/odve3Nzox05lOoQrbXcvmKUlKJbxvkYZvMd2cdMknIq674I1vQvDmgafrGmQ+INSk8X21xPePKX/tOMwygecWDFAoxHggrjB7mvpSigD5s1f4ReKrnw5a6eNO0aS1eTUZ1sVki/4lzXDK0ccckkT/ACLtGdgRs9DireqfBzV9V0bVf7Ss7O51Y+HdNsrGaSfLR3cKYlYN25/i719EUUAeAav8L/E114/utWtrTTvKuCXnub2WO5ZwINgERMQlibPYSFe/I4qtqnwk8SXGh6RatZaXfzx+HYdIRrm5K/2Vcq+5riL5TkkY5XDfKB0r6IooA8F8XfCPU9WvvGWpLBa3OsXM2lSaTfSS7ZUMCxLO+f4CQjfXiveqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDG8O2M9k+ry3YUPdX0k64P8ABtVFz/wFBXk0uvDxD4hilfzJbPVbgTRfu1ZEsrfHlhgwz+8dt+e28eld58SNULQR+HrRiLnUEP2l1OPJtejnPZm+4v1Y/wANcBdLDp3iqwDmCGC4tDZ2sawkEOh3lQwGACo4Un+His5ztojqoUOdc0tj0msHW7WWdJrhPLDPGsSsrclfMUj+tbKv5dsHf+FMn8qw7Q3V3fi1nl4gg8y5xg4lkcMqD2UKfwZaZgzUtNQiur26togSbcLubsSS3H4baoawrpeTXZcmO2t1kVMjHEm5z65wgFXLGza31C+m48uYoV554Bz+pqne7T4mtFMPmw3NrPbySA8IQUYKfqC/5UCG3bfadSvtJlkbM8K3UDkZCEHGPwKhse5rlPFrWy+HDeX0cqx6bLFdptfBt5Y22rISewG9G7nbxy1b9/lX0cWzO8kJe3MzDkMmBk/iOf8AZLV55f2tx8XNbv49PUr4H0aTzb2VXwNSuVAJiRh1jXbk44J57qQIBfhi1t44+IGkat4kguLbRLYSnwvYTjMTuG3PI2Tw55ZE6BU44QZ+mK8O0iyefS2spWzBbukmn3kRGdnDROuOAydOmDgdjXqfhDW31fTyt2ETUrYiO6RPulscOo/usOR6cjqDRCfMa1qHs7NbG9RRRVmAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXC/HJ7iP4SeKHs2lS4FoSjREhgcjpjmgDuqK8Xk+KFvBp3gi60q/ml0dJ0s9blFlI5jJtyUBym7lwORWFH458a6zpfhoWWqSafLqH9tvNP/AGcjMFtiDANjr8pxxyOc8jNAH0LRXyt4w8S+LdZ+Huu2WvXhv4NR8K2esJGtmsX2eZrpUaNdoyeBk5zz0wOK6lvHHi6Sa6h0bWmv9Nl8Rabp9lq82mqAyTBvPTYAoZUbbzwecbu9AH0BRXgusa14m8Pav8QfsPl3GoWqaNFLqkWmqZNjq4mnKKCZNgyQvIX6ZrK8cfETXdO0+OPwz4s1DUSsF1cx6jNp0UMU5jCYhB+zsJHB3cKsYw3LDGaAPo+ivI/hDdXWo/EPxpqV7EY5rzTdEnfClV3tbSFgM+hNdP418ReMdI1WKDwx4F/4SGyaEO91/a8Npsk3MCmxwScAKc9Pmx2oA7Wq2pXsGm2E95ePst4ELuevA7AdyegHc15n/wAJt8T/APokf/ly2v8A8TXKeJfHPj7VpIYZPhwI4raUs8SeIbZ1aRTgbiF/hOePXnqBhN2RcIc7sdPbtPdXV1qV8u28vGDsn/PJBwkf/AR19WLHvWF4qdtU1TSPCtvFJJNq8pWUqxURwoCzMxBBxx2IzjHerOiavqU2jS3niHR/7HuVkKrbC6S4LjjaQy4GSSRj2q94T0W6bwz4l8VTKV1K+spo7BhIYjHAEzvV8fLvYAg4+6iHrmsIrmldnoVpqnT5YmH4jvLqxSaLwBBf6lpdtcQQPJfkNYQxxHa0UL8SNg5Z5DvH7vbkkgVB4H11oJL/AMSa5ayq2qXC2x+w77pIQjSL5r7RwpK7Q2D8qpk1vfEvUrfRPD1pomkLFHtjSGBAo2qxH7sEDsoUyN7R+9ZOhKdGg0LS4rdik5is2AJBjiCuylvfCYPuapTucqo3i5HdjXtJ8mSU6lZrFHcmyZnmVQs4ODHyfvZ7da5+XWAkl9NosV3qk1rqphntbNQp3mHbtZnIXaCVYtnjFdeFilAYKjjduzgH5hxn68V518QvFF5oEjaF4d8u68Wa7PmxhHIt02KrTSZ4AXaxHY474NWYHF+O9T1PWvGmreFdMu4oYLho5tQuLZSx0+ARFZBuz880isRtAwABySWK+xeF9MHgDR4LX7ZBL4YgRo2RolTyFaXKPuyFKhXO9myWwG9c+b6Z4Tg8H6ctvazfatUjlE19dTHLTySdXYnsW49hu7kmvQ9C1E33g2/soZLxJ7e3ZIXtVDTiNlPllFPBdeVx6pWbm76HRKilBM5vT7F/B/iS58KTsxsSGu9HkY/etyfmhyerRscf7pWtp7u70q6i1PTYjPPD8stuCB9oiJ+ZMnjcPvKT3GOhNdV8Q/Dc3iLQUbTnji1yxb7Tp88o4EoGCj4/gcZVvY56gVxui6guqabFdCKSB23JJDKuHikUlXRh6qwI/Cia5XdG+HmqsPZyPW4ZEmiSSM7kcBgfUU+sHwhdebYNAx+aE8fQ/wD181vVtF3VzhqQ5JOIUUUUyAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDL8RXrWWnM0ZxI52KfTPeuDPJyetdr4stpJ9OVolLGN9xA9MGvOtTe5nlg03TlZ767bYu3+Be7H0AHf/CsKl3Kx6OFcY03INM0tvF2vfZm/5BFoc3B5Hmdto/3uV/3d395TXq94beGxkWcItvs2FegweMVV8PaPb6HpcVlajIXl3xgyMerH/PAAHavLvjf4yuINV07wp4ftpLrWLwENJuKw2hcHazkDlgqyNtBzgZ7itEuVHLKbrT1OA0FpNW1QXty9o0On3cthEsSkRJHGQWfB5/1axqOoCjH8RrsLeaWW/wBHmnDLMbpJgpGMI5kVVb3AccetZmjabHaxpBJM0iSsC7M527cqCEBJwruqhV/ur1rU8QtLFNbTQQbxDPbSSuByR9piVUz2zuc/8BrBO8jukuSmzvrgSQWM32CGN51RmiiJ2Kz4JAJxwCepxXA+APCN7orXXiLxMyXni3VZk+0yR8rbxFgBDH1+UDGcdcDrgGvQ43WRNyHK5Iz9DiqdpM+oWRkwImWdlxkn/Vykfrt/WtzzDmfFMMS6g902HhKmG5APWNgM5/3ev0JridH1HWkv0u10tZYLGQ3CaddOYZ73btcNkcREOFcKwOSTnAr0C/RpI5rpkKo0aXMse3IIxslB/wB0eWfwNcvqsV1DCWszuvrEfu9x4kTny8n0zlCfQsfSsX7sj0KdqlOzPctF1S01rSrbUdNuIri0uF3JJE4dTzg4I4OCCPwrh/G2nyaRrMeqWyM2nX0ixXSqCfJmPCS/7rcK3vtPdjWd8Ib5dJWLSZQIrbUgby1QMSsNwRungGTwM7nA/wCunoK9WIBGCMj0rfSaOJOVGZy/gyBx9onZSEYBVPr611FAAAwBgUURXKrCqT9pJyCiiiqMwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqvFZ20U5njt4UmK7S6oA2M5xmrFRzzRW8Ek1xIkUMal3kdgqqoGSST0AHegDF8aeIovDWiNdtH9ou5XFvZ2wODcTtnagPYcEk9lDHtXhUjIkttqWoSC4kmml+1aiZBGiFxiWfngKSiRJ6KAQTW1rurSeKtWXW7hnt9L2tBpasNrLAfvz4P/AC1l4VB1CYPUsKzfFclhDpMllq8ttZ2LIJLozOFjCgHyrYYwTnbkhecK3TcKxnK+h3UKXJHme5taTYT6jdxyW6hJZ/8Aj2Ur8sKAY8wj2U8D/a/2jjR+IelxWHgnULO2ga5z5KhGkIaYK6u24+vDnitv4ZXNnqXh6HUor2wvL2eNPtLWUwkjhbAzGDnjBz155+lWvHlil3oF9Gdy+dA8IZSQQWG3Ix3561ENJakV6nPtsTWMfk6fBGECbIwNo7cdKpaXBJNoBRmAkuFkcMpz/rCWyP8AvqpdL1GO9keOKJ0SONHUseSGLD+aGqGt3d1DdslrIyhJbHIwMbHnKP8AmP5CtjmH6XMBJbzSr8vm/MCeNk45Bz2En/oNcv470qO0u7LTXhuJLaaQ48pyu62A3OrEckDaq4HJyo/iNdPN9mTVDZF1DTIyOg4IViWVv++t4Hua5fV/EF94t8cweHPDdlpy6xpVrLPLqGpLL5Syfu1khjCYyf3kZLZ4B6esSi29DajU5N9iCCAyedp/ntHJvFxZ3KnlJR8yup75xu9yJB0r2PwvrC63pEd0VEdwpMVzDnPlSj7y/TuD3BB714nYy3F2rQyW7WWrWUrQy25IYxOpBZAR95QSrqf4o346muw0W/l0bVI9R8tlt7lVjvoFG4j+7IMdSucH1X6CiEuV2Z0V6ftI80eh6lRRRWx54UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNdtiM2C2BnC9T9KdSSbtjeXjfj5d3TPvQBxHhr4naDrkGqXEwudHttNuzYXE+reXbxi4BwYgxcjcOOPcVLqfxO8HafYabeya/p8tlf3n2GKeG4R0WQDLFmzhVUYyx4G5fUVxFj8KNebSdWsdU1LSJI9Q8Sp4ifyYZMBjIrSR4Yn5SFAH1Oc1b1T4T3skt9c6beabFcHxNH4gto5rdmiwsWwxOAQeck5HoKAPRU8V+H315dETW9NbV2XctmLlDKRjPC5znHOPTnpVd/HPhNNPmvj4m0U2cOzzJlvo2Rd+dmSG/i2tj12nHQ1wVj8JLqz8bvqxvrO7sZNXOtBJ2uw8EzfeEaLMIj3AZkJAODuAFGj/CW60Xwd4QtNNvNNTXvD9y1158lsTDdE+YMOAQ3Ak4Ocgj3oA9A1Lxp4Y0ywsr3UPEGlW9nejdbTSXaBJh6oc/MPcU4+MfDY1mHSP7f0v+05gGjtftSeY4IyMLnPI5HqOa8rvvgvqiaFotnpGuW1rqFnHcK+oxrPBLE08pkfyvLkA2fMRscEcdRk1bm+EGqzeJ5bpfEK2enXHN4LRZUkvf3Pl/vIy5hDd96qCOwB5oA9H07xl4Z1JL97DxBpNwlgpa6aO7jYQKOrOc8Dg8njipNO8WeHtSsre7sNc0y4tbi4FpDKl0hWSYjIiXnlyBnb1x2rySx+Bl1/YN/pd/qlmzPpiabb3yfapJdqTRyoGSWdo1TMYyiKB8xwVHB1L/AOFmuXrXGrtrOmxeJJdbtNZAjtX+xqbeExKmzfuOQxJOQSfzoA9E1Pxl4Z0u1e51HxBpVvAlw1qzyXaACZfvRnn76916jvS+IvE9novhZtfjhutVstsbxLpkYuHnWQgIYwDhgdwOQcY5ryq9+DuvT2DFNZ05NYbVb/UhfQpcW7wm52ZMRjlBX7pyrbgQRzxz7D4dsJtK0DTtPurtr2e1t44XuWQIZSqgFsDgZx0oA80Hjr4ja8v/ABS/w6fT4WOFu9fuxDt/3oB8/wCRqjrfgr4k69pV0fFXjq2srV0Il0/Q7IKjKeo85/nxjsQa9qpGAZSCAQeCDQxp2dz5wtfh14c0CY65dG+1LULMeet5qN40jIV53HouB1zg9K9D+G/g/wC0XSeLPEdsX1KZf+JfbTqD9hhP8W3tK/BY9VGE4wc9jdeFtJuiBcW5kjEiyeWzEqSrBhkdxkDg8VuVEYtas3rVYyXLBWR8t6Npc/ge9m8UWcgSE6nefaY1QAmKO8eOaNsfeXygJFzkq0ZxwxFe++Icf2VJnu8Y6Z6uo/rXH23h2LXfC/jHQ7j5Gl1TUBG/eNpWLqw/7+Zq5Zaq918K9L1O6JWUWtrLcZ/hZWTzAfoQwrKW5K2KHgaOa3a4huAc7G2MxyxUXNxgccYClcd/WtLXbOZlvrlCu0Qwso5J3RSM/THuKuWunm2vEkjkzGElDKepLSBx+XzCuX8VeEvEeq6099o3je+0eFkVRapapNGuByRuI5PWtTM2UhN14rvt6BjHbwhMdThiw9+DmuL+C15JqfxJkkZWVUsdQvGR1w6PcahgK30jt0/Onp4L8daeLzUE+Jzx+XATJK+g28jFFy2Mls+prnPhp4c8aXWs6nf+GfFNlb6glvEk7XmjoiujPLhRtZuQ0bZ4HUUJ6jex73rHg7TNT1ZtUIlt9QaNI2libAcKSVLL0JALLnrhiOmMPtfDMMM6SSTtIFOdu3Ga4VdN+NcI2prvgy5775raZD9MKMYqRn+N8ShjF8O5v9mM3gJ/E8U3FPVjjVnFcqeh6vRXkn9rfGiBtsvhrwldf7cF7Ig/JjmpR4s+KsWGk+GljcAdUh16JC30LDAqjM9UkdIo2kkZURQWZmOAAOpJrP0rXtH1eSSPSdVsL54xudba4SUqPUhScVDqq3d94PvFktfKvriwcNbK4fZI0ZygbgNgnGe9eBfDjw9r2jfDTWrCXSPFFprYsUS2+zWdtZuJg52iO4iPmSDJUt5vG0Hr0IB9IT3EMBj8+WOPzHEab2C7mPRRnqeDxUtfOms+F/Fmp+FdGm8SW/iO/wBe03xMt1qP2S8ZVe32uBJaBWUKoBQDbhlO89yTo6do3jlPiqbzUZ9eS1GreZA0KmW3ksCMLFITdBFAGc/uS+4ZBbNAHvVFfOOh+GvHtjpHhi7e88WNql5pWpQ6vvvWneGQL/o5VJH2h8kkcjJHUZzTdE0Xx4nh14r3T9eOmJqlq10sV/PHe31qEfzdqSXDtGd5Tdsdd46AAcgH0hRXhfhzw341vdR8KWuu33iOz0pY9QafytQZZUjMqm2Sd1Y7nC5Gck44z1r3SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOV0y3a21/xEphdI5rpLhHI4fdBGpx+KGsnwzbxOniLQ7gK8VvfyMEI4Mc4Ew49N0jj/AIDXeTRCRfQ9jWaNOSG5muI4VE0wUSSKOXC5xn6ZNc84u9zaMlaxipKrzTxgENC+xs+uAePwIqSpLu2aG8llwAsoU42kHI4P6YqOtFqiHozE8cSF/Bes2cEipcXcaWQJ/g89xCGI/wCBE/hVb4L2UdkbhYUCRPpWnyKM9Axnf/2bFb9jYC41K9a5gWW3eODaHAZdyM7dPUEqc/StnSdKWz1Ke7iIjiktobZYFQKqCMuQR+EmMe1KL94b+E2KKKK1MwooooAqatqFtpOlXmo38nl2lnC9xM+M7URSzHH0BrxbV/jFqS3GqXP9n3Oi6RF4eh1e2N1ax3Fw/mXIjWTy1mUbSpHysysCCfTPtmoWdvqNhc2V7Es1rcxNDNG3R0YEMp9iCRXAD4N+FzZXlrM+q3EVzYJpjeffPIUt0kEiIhbO0AqMAcY+pNAEmrfFXTNO16608aVq11bWl9BplxfwLF5MdzMRtjwzqxxuGSqnFYVp8V7w+INC02DTLvVo9R1TULJ5YreOB4/s+cKimYhsYyWJGVGQM/LT/Evwnu9a8etqsWo29jo0moW2oz28JnLzyQheWXzPL3Erjdt4GOCRk9P/AMKz8Pq1k8P2+Cezv59RgnhumSRJZ/8AWjI/hYHBHpxQBQ0z4taPfX0UY0/U4rK7W7On3zpH5V6bXPnBAH3KRtYjeFzg1NoXxS0zWD4eKaTrdrHrsvl2Ml1BGiv+6MhbhyduBjIzz7c1Zsfhj4astRku4ILr7twsED3LtDa+fnzjChOELZOcfhipL/4c6De+HtC0dxfQwaIUNhPb3Twzw7V28SKQeRwaAMC9+NGjw2VvPaaNrl686XsixRRxAqtq+2VmJkAA6kYzkD14rc8DfETT/GGqXFjaWGo2UiWcOoQm8jVRcW8udki7WOBx0OD0qGw+FXhmxtreC3iuxHBb3lsm64ZjsujmXJPJPoT0rX8O+C9I8P6hDeackyzxabBpSl5Nw8iH7gx688nvQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABAIwQCPeojbwk5MUZP+6KlooAaiKgwihR7DFOoooAKKKKACiiigApM8471keIddj0lYoYYXvNTuMi2soj88p9SeioO7nge5wDJounTWwa51KcXOpzD97IowiDrsjHZB+Z6nmg29i1T9pLS+3n/wADz76LrbUooooMQooooAKKKKACigjNFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFZHiXxFp3hyzSfU5WDSt5cFvEhkmuJOyRxrlnY+gHucDmgDXPArh73x79unks/BGlz+IrtWMb3MbeVYwsCM77g8NjOdsYc8Y4qD+x9T8UwzXvjqT+zdCGXTQ45QqmMD713Kp+fPUxqQgHDb6oaj8SLOCwNv4G02C+srVfLOoyyCz0u2UfL/rSPnAIHEYI9xQBpN4a8aX2F1LxwlvBMP38Wm6YkTp7RSuzlfTcwY8cbTUknw80OONPtep+InwMbptfuxk+v+tAzXj9/wCPk12/l06/8a6ne3GN7w+G7eSGAf7EbRo8j/7zPj2rkvEGh+FZNTtJif7FuNr+bJ4gtryaO5bjGXl2YPXOKBn0RF4PW2dn8PeNdfsV6CJ71L6IH6XCuR+DCrA0zx3ZputfEuj6l/0zvtLaLd/wOKTg/wDAD9K+V9Wjk0vcb7w54Pks1dY0vLa3kWNvZmIby2PH+sUA8kZHNWppJrO2W40Lw7q2hXcx2RtpmoO4DjJZGCvHtfAOBtOT0ByKVxqLex9P/wDCWa1pP/I0+GLqKBcBr7SX+3Qj1JQBZgP+2ZA9a6HQtf0nxBa/adE1K0v4RwWt5Q+0+jAcg+x5r5b0X4p+LrBbeGPxWql4hLFB4lsVi3r2/fDBYH1z+VdUmr6r4kWO81/4f+E9fmm4S90+4ZCx6YEyrIB6cuPwpisfRtFfOFn4l0e3E5+w+NdFFqWWX+ytfW+ihK53Fo2lbGMf3O3SuksvGlnLLGln8UpbFygdYfEWkxRZB6fMUh3D6H8aVwcWtz2uiuGtrzx3HEJ4B4V1+1IyrW8stkz/AEJ85T+YFTr44ezJTxF4b17S2UZaSO1N7D9Q8G8gf7wWmI7KiuZ0zx94U1KVYbTxDppuDwIJJ1jl/wC+Gw36V0wIIBByDQAUUVHcTRW1vLPcSLFDEpd3c4VVAyST6UAk27Ikrmde8SvFfnR9AgTUNcYAmMtiG1B/jmYfdHfaPmPbrmvFdf8Aibf6547hOk3F9baSm62jFpEHmdG+9Iqn+M44/uj3zn3jwrpOnaTpEUek20kMc375zMrCaRm5LSbvmLeuenTig9zFZW8rhCpileUldR6L/E/0W/dW1Z4d0FdLaa7u7hr7VrkD7RdyDBbHREH8CDso/HJ5rborF8TeJ9I8NW8Umr3YieZtkECKZJrh+BtjjUFnPI4ANB49WrKrLnm7s2q5HxJ45tNO1E6Po1pPrviIrn+zrIjMQxw08h+WFenLHPIwDXP69qmu6rpdxqOu3Z8C+Eol3SyPKv8AaM6EcDIysGcgALvkJ4G0mvJPFHjzSdKs49G0qFtA0KZlKafFI0N5qAJ5mu58FoYyB0BaZx1xnFBmdnr3ia+uNV/s3XvHEkWqS7lGgeD4EeaMjJIe5kzhgvUnywME1F8NPC/g/wAZ3WszR6VqdrqWnSpH/bEOuTzvcblyD5ysFMi4+dV3KCRgnNcd4d8JwXrRXWneArnxFIPuTXpGlaZCDyDDC37yZecbpAS2MkCvTLbxT4y8E2kM/ivw94fXwtFtSRtAaQNp8fTe0bDDoOM7MYGT2pcy2KszdHhHxfoahvDPjS4vo0U7bLxDCtysh7AzoFkX6/N9DV7wv49gv9S/sXxBbLoviDLKls86yRXO08mCUcPjuvDr3WuzjdJY1kjZXRgGVlOQQehBr5l8ceDofBusx6f/AGY93o1/I7I0AzLcxkl2XP8Az9w5Z45OrplSTg5ZJ9OUVw/wj8STa74ca11G6jutV01lt57hOl0hUNDcAekkbK313DtXcUAFFFFABRRRQAUUUUAFFFFABRVHVtSi02BXkinnkdtscNvGXeRsZwB26dSQB3IrntUiubywnvvFt7Ho+iQqXktIrjblP+m8wxx/sJgdizigCe/8Sz3d1Lp/hO2j1G9jYpNcyMVtLVh1DuPvuP8AnmmT/eKZzXI6hrGjeDNamMsk3inx5PES4BVTBFjOCT8lpAODycngneea5/xL45vb/TobXwysnhrwq37i2uYrY/b9Q7COytgMoG7MRnByAMGrHgn4RvfWqP4wiW20rzftCaHE2TM+ciW9lBzNJnnbnaMDk8igZyeta1q3jZLu9u5LLU9MsiTLc3LNb6BYkEevz3sgIxyNuWGBzTdG0ax1meHU9Y8P+MPHKx4MM9zHHY2OOzQW7OpK49Rg+ld9pFnB4+1wajNDGvgzRZjbaNYIoENxLGdrXLKOCqkFEHQYJwM8+k1lOpZ2RcYX3Od8B+LfDN5L/YWm2f8AYGpwqSdGubZbWVV5+ZFHyuvBOUJGK6DxdqmlaL4b1DUPEJjGlQR5nEibwwJAC7e5JIAHckVjeLfDdl4m0z7Leb4p42821u4TtmtZR92SNuqsDj69DxXE+ItbvNY+EeoXOsRiTV/DWpw/2kkS4SY208cjOo/uvFh8e+O1VCfMKUbGLoHhHxLrF/c3mkr/AMIP4buGElvYsizXSDkttQ/LAj5BMfzAMPu55rQPwP02Cykj0zxJ4jtp3QKXe4SVGIGFLRlQDjtjGMDBGK9aBBAIIIPIIpaxc2zVRSPnnUvDHi7wmbmTULBfEGnA74ZdMhLOSceYksBJIWQjcdm4K3OMEgYmmaXJf3V3e+CLltCRpzcPLFEYwzRlUiiaIkAAuspYY5wAc5r3T4leKv8AhF/D7Na7ZNYvSbfT4Ou6UgncR/cQfMx9BjqRXlGkxp4f0uztZo3uZLeUnBYFry7K5J9lQFmdj0Iz1FNSe5tTXPpLY4fUdBsY75LTxQkGn+IJGa6nv/LFxbahlyclSFwxZiMLtIGe22tTVbtdDsbm21SS60vULiP5bmFjdafIMfKi7wxU4P3WxjOQTkA7mrx70hF/bnVLy8Ja2sVUB536GYg/cVQdqscBFy3LECs4eC9Z8J6bJe2xi1VWRjLpznzIIM5JCK5G8ds5DnrhskU79y+S2yLOneCYtESCaK3g+2TuZI0tJJbC5lcryAyOdiDrt4A4JI5rUtNa8ZaBFNJPrGu27B96W8jRapFHFgD94z/vc5z0IzjC5rm9C1KWB57rwrM1nBGFjuIL+QvZooPIRz+8t8c/KVxyPl71Ym8c3mhyrca/oNzCkzn7PN50b2ygZ+ZCxUu7AfxEEjpgdXeQONNrVHZf8LJ1K/sZV8T6D4a1O3DlBbX5bTpioJG7ypxIvIGR8w6jOOzLDWvhw0H2ttN1/wAGI52rfWUksFsWJx8sls7REZ6Fhg1lJ4wsZVgm1Dw/4ku1ljE8cklpHNHjsVWNyB14OM+5rIN74fkuluZdB1bRpt3meedMnikXtnMa4Bx1AH/AqamzOVCD2Z7Lotlq99Atx4Q+Jkeq2aDhby1t71T7M8Xlt+ZzVXxPb+N7uyW08RaDp2u6V5gaZNEv2tJZFHZo5R8wzztEoOQK8a0jwp4X8S6yI/Cfii6g1+cllkubhoGLZ3Zw2yV+/QscDt1r0EeGfix4Vi2ad4iudbtt/wB7fFK6r7xTjccDjibJrRO5gnKhNShLVbNHUeF/H3w90uEW1so8Oy58ueK+sJLQxOBnZLIy7N31c57ZrVf4p+GpAF006rqkznEMdlplw/nN2COUCH6lgPevPrn4ta9aXq6PcaLbeINXXYZNMisprW4XBU7mU+aoxlWySB3Haug1j4savoekC/17wY2lqQdgutWgHmN/cRVy7N7BKLpETlOo3ObbfdnQ+d458QkxC0tfCdiTzO8yXt4y56KgHlRnGeS0mPQ9sO/vvBvwzvNkEc+teMrtNoVpftOoXHHWSRj+6jwMknagAJA4xXD6h8T/ABR4zt47WytZvDkUzGP7DYSfaNWuvXZlQLdMHmVwMYyCeh2vCfwqWdkuPE1lZ2dkG8waPauZPNbruu5z807Z5I+7kfxDgKUlHcSi2cfeTeNPiTqLXFjDa3c4ciC6JJ0zSgDj90xH+kT8EGQBgM/Lx09E+Hnwi0bwrc/2pqLtrXiFzve+ulzsb/pmvO36nJ9wOK9IhijghjigjSOKNQiIgAVQOAAB0Fcp4g+JHhHQLtrTUtcthdJ/rIoA07RY6lxGG2Y/2sVg5ylojVRSOuqpq8Ftc6TewX4U2csDpMG6bCpDZ/DNWlYMoZSCCMgjvXA/EjWn1Ld4I8NyJN4i1aNoZduWFhbMMSTy4+7hThQSCSwxmpSbdkNux0Xwammn+FPhR7nPmf2dCvPUqFAU/kBXIavo8fxN8X6219eX0OjaFItjpzWdwYit6vzTXAx1dCVjBOQMPxmtO88UYsV8I/DWB7q6so109tRKZs9OCKFO6Q8SSKuMIuefvYwRXSeFtDtfDfh+y0mxLNDbR7d7/ekY8s7HuzMSx9zW1SdtEZwjfVnlfwpW78KeOrfRtQne4lV7nRJ7jOFmwBeWjkdmMctwuO2AOwr36vA/GEq6LP4ve4idtRstUsPFNo46y2yeTDLjH9wLKrD0dfWve0ZXVWQhlYZBByCK0i7q5D3FooopiCiiigAooooAKKKKAGTSLFE8j/dUEmvCfFN9qfiDxBZx6lam+1ORRcaV4cicGG1GSBdXT9GPuflTooZiCfeSARg8isSGx0LwpbalqIS10+KVzcXl3K+Nx9XdjnAzgAnAHAwOKAMfwP4Gh0Gd9W1af+1PEtwuJr51wsS/88oV/wCWaD826sTxjN8X+IbnxJNe+FfB0rGbd9n1PVkP7rT1P30Rv4p8cBR90nLEYxTry+1nxq4h003WieGSP3l4QYry9HpEp5hjP99sOf4Qv3q6LR9LsdG0230/SrWK0soF2xwxLhVH+Pck8k8msp1LaI0jC+rF0jTrXSNKtNO0+IRWlrEsMSDsqjA+vTrVuiisDUK8xu0jivfjHaXUg+xz6VDeOM4C77WWN/pxCDXp1eITzy+K/EviTTNNdzB4jvY7SWVTjy9NshsnkB9JJXeJfXLHtWlPR3IntY9V8EyTTeDNAlugRcPp9u0gI6MY1z+tXNd1ax0LSLvU9VuEt7G1QySyN2H9STwAOSSAKZrerad4d0efUdVuYrPT7ZMvI/AUdAAB1J4AA5J4FeDeM9R1nxrqVnNewPaWEcyyWelSDmJc4FxcjnMpGdkWDgkZz8wMpXNEm9ETQ38/ijxBN4h1ZpYpTiG1thjNpGfnWFQeDMww7n+H5c4C1K8rTaz9jsEhnv8Ayhuj6xW8WcruPVY8jP8AelIzwoFMuGU3CWVm8UKQJ++nZd62ys2csxJ3u7dE53NyxbgB15pMFvbR6dG93a2sjedPEpP2i9c8l5pPvNnuFwB0ZlHAo6ox5VZGjbTW1k9xLaym8vJCDc3bOFaTngFukcY7Acn+EHqZZHlmuVe+fzLgDfHG8bFUHqkA+Zu43PiqkbxxRDMkdpBCu1VR1DKP9/kIOekYY+rVBa+IdKbfb6ZLJeuT88GmRySsx9XMYeUn3O3PelYrmS3Eu7JNSvIrz7P/AGdqsXyQXt3Est2EwR8kCcBeTjf06lc1mroOv6XNPc/ZRrkD5+e4fytQZSfuhxuG0DPA8vriumhj8RXMGzRtA1S1UnhjDb2asf8Aa812f8fLJ9qlXwB4rv3Vr6aygyd259Vu52U/7sYhUH6UzOU4GLonhzw1qupzQaXK/hrVAg8uOC4NrMx9TbHG4f7XIPbPWuyi0jxZoEZksPEWk6gMAKNYsAjAgc4lhZffqp/Gqh+D0F//AMhzU4JsjafsunRK+PTzJ/Of8iK1LH4S6Fp9l9lsNR8Q20f/AEy1WVR/3znb+lVzR6nLJyb0ZzniXxO+sW39j+KPDOjasXTfG2m6zCZFYjh0WYRuhH94ZxV3wh8XZNG8NaNYeMNI1q51YJ9ne5svJvFndQecxyFi20Ak465q4nwf063cHTvEviuzXILRpqAdGPurqwNZfw7+GuneJ/Dtxdazq+t3dq2o3ccSC4WJZY453jVmMaKxJCc84z0AqoOPQykn1OR8KeLNQ0fwrJDbLYeHHnupjc6xqRE1/euWZgy245aQhlGGYgHIAOK3NB8Bax4guDfXK3mn+awL6xq5E2qSICTthjI2Wy8kcgMO69K6bSfB+h/D74m2VvpWnxJY63aOtu8mZZba4g+ZlWRssFkRyxGesZPfj02pnLldkVFXWph+E/CukeFbJ7fRrURtK2+edyXmuH6lpHPLHJJ56Z4xVXxN4wstGvYtMtoLjVdenXdDplkA0xXpvckhY0/2mIHXGelO8a+In0S2trXTYBea/qTmDTrPP+skxku3pGg+Zm7D3IrR8D+F7XwjoshnnW51Of8Af6nqUoAe5lxlmY9lHIVeij8amEObVjlLl0RzqeDdf8VYl8caq1lp7cjRNHlaNCD/AAz3Aw8nBwQuxcjvXWW/hDQLXw7eaFY6VaWel3cLQTw28Yj3qylTkjknBPJ5rktY+Jy3TTQ+CrWHU1iDeZqlzIYrCLGckMAWlwRzsG3/AGhXAXXiXWfE2oG1i8S63qbI26az8OWQhjHohkRiyA88vMv4VuklsZNt7ncr8P8AxQbZNOvfiDepocK7B9ms44bx4x90NcZOCBgblUE9TT/EcPhf4YfDbX/7CmsdLu5bOdoZZJwZ7q58timWYlpG3Hgc4zxgV57H8IfEuu3Ty3Om6Ro1u7kbtQmOoXCp2IHIz9ZT+NbGjfs6WFkrLceIZpA+ctBpttG4JOcq7K7Lg9MHjtQklsDd9z0P4f2+n2fgrRbXR3iezhtIlRo8fN8oJY47kkk+5roK4bTfg9pukWf/ABKPEHiS31RTujv5L8ysD6NGR5bqeMgrzjqOtLeWXxC8OwfbRf6b4qt4zuns0sTZ3JTHJhIdlZu+1gM8gHOKxlTfQ1U0M+K9vb2tjp/iC4jV4NNnEN6jKWWWxuCIrhGHcbSH+sYrV+E13PBYar4Yv5mmuvDl39hjkc5eS2Kq9u7cYz5bBT/u571b03UNI8aeGXkt2F3pt7G8E0TgqwyCrxuvVWHIIrzrQ1v9F1lNHRhD420+Ipp807bYfEdhH92KRunnInGT8ykBuVLCqpPoyZrqe60Vj+FPENl4m0hb/T/MTa7Qz28y7JraZTh4pF/hdT1H0IyCCditTMKKKKACiiigAorzX9o/Ur7SPgx4hvtKvLmxvYvs/l3FtK0UiZuYgcMpBGQSPoa5b4IaxqC/EbxHoepX+qPGbGG8trO71VdVWNQ2x2+0AnaSSPkPbmgD3OsLXNIs9Q1Kzub6Mzm0+eCNzmNH/wCem3oXHZjyMnGMmt2q93HuTcOq1E78uhUNylRRWF4o8SW2gxwRCGa+1S7YpZafbDdNcP3wOiqOrOcKo6npnmSublrxJr2meGtIm1PW7uO0soh8zuep7Ko6knsBzUuh6tY67pFrqelXCXNjdIJIpV6EfzBByCDyCCDXOaD4Am1PV4vEXxBeDUdVjO6005fms9OHoqn/AFkncyMOuMAYFYXxE8P/AA20a7updWubuyub0mW40jSryVGv8jndbxnkNjlgFHcnqa19loZ+01LWqaxfePdTn8N+Dbl4NKiPl6tr0PSId4LdujSkdWGQgOeTjFPxHqGgfCvxbay3UJttIn0SOw0+K3jMjmSCV2MSgc7nEynJ4JU5Oa5LxJ8QvEtt4fWw8G6RbeGdOWMpaRQwfarpwD/Ci/u07kn5+5zmsLSfC+ra/rt2mnakY5rePGr+Ib6QytaADLKJGOd+MnYCqqPvDJGLsrcqHyy+KWha17xLqPiC+i1fWoILeeKcRaZpkzGSOycj5ZJEX5prps4WJRle+3Oa89v/ABBqsmpW1ubu6h0iK6EV3cy5ea7mOWdMR9yOPLVsAYUt6ejLpOj2qGHwvFPHpCoftGu30pF5qKfxLFIR+4t8N8zqAX6KOdxl8EeAdQ8XXRvbFxZaMJB5Gp/Z/KAiU/KlpAScL6yNwSSfnyVCSWyNea0bvRGedVOnXFpFcQmK9mkMsFog+03jOeMiJQQZiMZcghB8qrgZPZ6R8OvFmuyRXF9LB4asyQ7qT9qvZh2DnO1e/O5j7AcV6r4P8E6D4Rif+xrFUupR+/vJT5lxOe5eQ8nJ5x09AKm13xj4b0CQxa1r2l2MwGfKnukV8f7pOf0qlBIznXk9Focq3wY8HXNqsWr2t7qjBt5kub2VSx91jKJ/47V62+Evga1iEVv4fgjj7qJZMN06/Nz071QvPjd4Ctywj1l7spjd9ktJpVGemWC4/Wkj+M/hl95W114qn3mGlTEAepwKsxbb3NU/CrwIV2/8InpGMY/49xn86qf8Kk8LW6k6OmqaPMeBLp2p3ERH/Ad5X9KZbfGbwJJOsFxrf2CdgGEd9bS25wehy6gY/Gt+Lx54Rlt/Pj8UaEYf7/2+LA+vzcUCOY/tDVPBWs2OneKNQTUNDv2MNlq0wWKWGYDKw3GAEO4A7XGMlSCMkE9tXEa78UPA2pW91piCXxOhGJrTT7B7xGHudvln/vquCSPwmYfLXwX8RU0luBYLelbUc84QXXH06dsVlKnd6Ginbc77xX4wLXb+HPB+zUvFU37sJGd0VgDwZrhhwiqOdv3mOABzXZ+ENBt/DHhjTNFs2Lw2UCxeYwwZCPvOfcnJP1rg/D3jzwT4X08Wdvoeq+HLNfmZX0aZUz0yzRqwJ9yT9auyfG34fJbSTjxAJI4xljHaTtj0zhOPxq4x5SZNsbrEja98YrC2hyLXwxZvcztn71xcqUjXHtGshz/tCt3xNrkWhWMchhe6vLmVba0tIyA9xM33UBPAHUknhVBJ6V8z/E3402uq+KxeeAFv9NuJ7VrG8vnXm5TOU2xDPzqd218hvnI4FXNM8S+O7m5tNY1VLPQ5FtksNPv9UVpZo1IUSNb2+C0s8hAJbaeBt45qZQ5pXKUrI9eutU034fXR1nxdcDVfHGrKILeysEMjrHn5be3U8iMHq7Y3MMnnCjj7vUNf+IesyWer2v25YXH/ABT2mT5tLY5yDfXWNjMCP9Wob7v3Km8D/CjUNQu5NR1OXUrT7Tzc6lqD7tSvOP4EyVtl5IyS0mOBs616/LP4b+H2gW1siw6dZBvLt7aFC8s8h/hRBl5HJ64yT1PrWiViDlrP4Vxam0MvjS7F9BGQ0ej2e6GwjIxgsM7pmGPvOQOvygcVoSeJoxLJ4c+G2l2d5c2mYpZUAi07T2H8MjJ95sn/AFcYJ65K9aU6Zr3jX5tea40Hw8/TS4Jdt3cr/wBPEqH92pH/ACzjOeeX6rXZ6Zp9npVhDZabaw2lnCu2OGFAiIPYDigRxkPiDx3YlbfVPBUOpSqPmu9J1KJYnPsk5Rl+mW+pq94N8ajXtU1DR9T0u60TXbICV7G6ZXLwscLKjqSrrngkE4PFdfXI+PvCs+tiy1TQrmOw8TaWxksbpwSjA/fhlA5Mbjg9xwR0wQDrqK4/wf44ttZvG0bV7dtH8UwLun0u4b5mHPzwt0ljODhl9OcVuaXqh1K+vBbRg2FufKFxn/WygneF9VXgZ9cjtQXGnKSclsjg/H9ovgvW7XxfpZe3sbq7jg16JRmExNlRcsv8Lq2wFh1B5ziuj8RaJY+JtKSG4dhhlntbu3fbLbyDlZYnHRh69CODkEg9TcwQ3VvLb3MUc0EqGOSORQyupGCCDwQR2rz2L4YvYhrfQfF3iDStLDb4bGJ4pEgPZUaRGbZ/sZxWc4Xd0EZW0ZysF3rum+INS1K1t1m8W6ZFGdYsbddkeu2XIjuYl7TKFYcZ5BTkFRXrfhjX9N8T6Ha6totytxZXC7lYdVPdWHZgeCOxrzO9sdQ8Da0Na1HXH8U+K9Qt/wCyNGsBbR2pcFw7F9pOQuAzSfKFAP8AeFbXwu8I61o2veItd1wafYSaw6OdL013eCN1HzSktj52PXAx6kk8Wr21Jfkej0UUUxBRRRQBU1XTbHV7CWx1Wytr6ylx5lvcxLLG+CCMqwIOCAfqBVbQ/Dui6Asq6Fo+naYspBkFnapCHx0ztAzWpRQAUjDcpB78UtFAHOa1LfwCO30uz+0Xs5Ko0mRDEB1eRh2GfujlugxyQ/QPD1l4fW61C5nNzqUy7rzUrkgMyjnA7RxrzhBwOpySSdq6uYLSISXMqRRllQM7YG5iFUfUkgD615j8VPEFi17Fps8slwkB3y2MZ4lPGGkHTavH3jt74JAxmkoHVQw9XFS5aa/rqR+JfH19q6tb+FnOnaa3DazNFueUDr9mjIwf+uj8dSqsOa88ltbLQvOYHfcT/vnuHkE9xc7jw7E5HJP3n3c8Iv3au3N7qGqTbGhY3K8mFOPJHUElhiMYxl3BY4OxBwaylht1UXct03lSbnha2fZLeMflP2dmyUi7Pdvlm6R9VAm7kbuEaGi1YsFt/aUz3WoXI02xspcXd8oLyW7lcCGLOTJdMDjHzFAcnnagbquuy3FpZafDplrpPhKB0Gn6U8o8uaNSCbi4kBKsMnJyWUMyk72IaptUs0NjB/aMUIjhUxW1lGCkFuvUqqHnHOXLfO55fqsVP8PWmkR2TeMfGpd9GcrDYaeI98+qGM5RRHnmJW5CDhiNzHaoJpa6Iyn7vvT37HW+DfCJ8YOviHxWWHh1AJ4LSbKJeEDPnSKcEQD+BG+8Pmbg4Oz4h+MelQQ3MfhG1Otm2ys17vEGn22P79ww2nqMBc59RXl174s1n4oQy6neyQaf4QtSGlF5vi0+AhsgTNw13KPlxEuE3Fc/7U6W1vHZpqiA2+m2S5TWdcgWSUAbebWz4t7ZePlypfkfKatK2hzSk5u7J9b1vxb4rsft+o6ytjoDDm4lmbRtObI4VH5uLjIz0wp7VzNvZaBbW7Qac+qauAoZl0qBNJs+nzeZcz7p3H+337eldP4S8I6943vf7Ut7BrOwYYj1zXma6u505w0cbEYB4I+4mD909K9U0f4P+ErO4a81OyOt6i7BpLjUSHDEDAxEAIgAOBheBTJPnC40nT/EMlxZ21lbrHuzJHoMV5q1wenDzuWUHOOi1sxfCiSe2D6R4I1YBcbmuVMbyD0Ie6THf+D8K+tba3htYEhtoo4YUGFSNQqqPYCpKAufLEfhzQfC0Usmr+FNQ0Kdiubi/s457PkgbfOAmCZ99o+nWlsfC3hq8u76V/DcU5gszcvEjwtLdISebVEVVZePvkA8rtxnJ+pWUMpVgCpGCDyDXj3jH4WzWU41DwXa2UsUbmZdJnVV8liSWNrIeI9xPMZ+Qk5BQ80AePw6gmtQIIdb0XQdIj2rBpNv9leeNVAx5rXLoS/XP3gCOPeC4Oj6ZaeXp3i64gHmM583VraZeTkny4UkySc16jq2pXlyhjutG8QwTx/KYLrw3JfqeScoyMyE89dxGMcVa0rT/GGpRwpp/h4Wq7Mfa9c8q3iQ56paQlmJxyNxH1HYA8fu7910kalJqXiy6sIz5r6jp9qtvEoJ4IdoU7kc7ua67w34Q1rxfZW18PDmo6lZN80MvivV5I0P+0LdAePcjB6j1r0KXTPCPhXVLbUPH3iVdc8QxH/RoZwG8k548i0Tcc9PmIZuB81av9vfEDxHMJfDOg6foelbtvn+IDJ9plU8b0gj+5jk4cjPHSgDH0X4RXgmSbUtWs9LjC4+y+H7NbcL9JXyfqyqjH1rsLPQfBngCGTVGjsdOkPyyajfTb5nz2MshLHP93P4U8eH/Et5xq3i+WOPGCmk2Mdtn6tIZW/Iiruk+DdD028S9SzN1qSDi+vpGubgfSSQkr9FwPagRmnXtd8RfJ4T0/7FYt/zF9ViZAR6w2/Dv7F9i9xuHFaPh7wlY6TePqM8k2p63Iu2TUr0h5iP7qYAWNP9hAo9cnmuiooAKKKKACmLLG8jxq6l0xuUHlc9MjtXL/EXxlaeDdEN1NtlvJcpa2+eZG9T/sjjJ+g6kV4x8P4vFniHWLl9St9Zm0bVZlkv5YWEHmgZAG9sfJg4KqRxwOgoPawOSzxOHniqklCC2b697bbL73p3t6f4ltrD4iX0elW1rDcWOnziSfVtvMEikHy7Z+vmHA3MOFHHJIAjt/DHjbwzbLbeFPEWn6np0YCQ2eu25DQoOwnhwT/wJD9a7+ws7bT7OK0sYI4LaJdqRxrhVHsKsUHm160ZWhTVor735vz/AAX3t+ey+I/iHasI5PAVjet0M1priKh98SRgj9aP7S+JWqLstvD2g6AM4aa+1BrxgPVUjRQT7FhXoVFBznK+EfBlvod3NquoXUmseJLlAlxqlygDleuyNRxFHn+BfxJPNdVRRQAUUUUAFFFFABRRRQAUUVFcwR3NvLBOu6KRSjrnGQeCOKBq19T5/wDib4i1bxz4kj0fwfBc3Nlp8obzbcHDzD+Mt0CjoCTjqe4ruPDXw/kufD9uniGIWWpeaJp5ba4Mslw2D80jsCQxJPKt9COlei2NnbWFsltY28VvbpwscSBFH0AqPV9RtdI0y51DUJRFa26F5HPp7epPQDuaTV9z28TmzrUIYLC0+WK23cm/Ppq+ljyD4l6LZ+HzpVpaw3Gordlo7XRUh228so5aW5kGMxKCCY8jeeuRnbzVhcW0N3NP58Oqa4zbpmLARQBRgzSvjAVRkLgAADaigBjXb3uqX/xN0uEaBaz2WnRoTdXMhw7sRzDF6n1bgf15zw98OtTmvE0kWsul6Z8tzdXHVmbJGAxH7yY49NkYxwx21nKPREVKCwkP37/e9v5V5+b6L7zmL4w3oUFJ7i03+Syp+7lupMbhAn/PPglj2iQl3O9lxGtuniCNfEHisyHRpf8ARLS1sVKS6mF4FrZpwYrQY5fhnAJYgYC9R4i8KTaXcTtrVpN/YdughEFiCWukdz5Wn2/8QDkBp5Wwzk4JC52y6bZazq/iSa10qSAeIvKWC+1FIw1poVuRlbW3XgGTAHHc/M3GANErI8qc3N3ZmBWn1W0g1rQYtV1qBd2k+FtOYfZdOiAwjyDGxc55lk5yRtUYr0bQfh297qcOt+PJrfU9RibdbWESn7FZEDA2qeZHH99uhPAGM11XhDwtpfhPTDZ6TE+ZG8y4uZnMk9zIeskrnlmP6dAAOK3aZmFFFFABRRRQAUUUUAFNkRZEZHAKsMEHuKdRQBl6J4e0bQUZdF0qxsA/3zbQLGW+pAyfxrUoooAKKKKACiiigAooooAzptE0yfVBqU9jBNfKoRZpUDsgGcBc/d6npitGiigqU5StzO9gooooJCiiigAooooAKKKKACiiigAooooAKKKKACvJ/iRovibx7qY0rTohp+g2j/vLi5JX7RIOpVR8xUduACcnPSvWKKDswOMlgqntqaTktr6287d+xw/w7+H0HgxGaPVL66lkGHQvsgJ9RGO/uSTXcUUUGeJxVXF1HVrO8mNdFdSrjKnqDWd4c0LT/DmlJp+kweTbqzOcsWd3Y5Z2Y8sxJ5J5rTooOcKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiqV3dXMbMttYSzkdGLoin8Sc/pQBdorEm/4SKfiE6VYj1cSXJ/L93/Oqv8AYWtT5N34rvkz/DZ2sES/+Po5/WgDpaK5OTwX5qsJvEviZyccrfeX/wCgKKzbzw1o9gwF94y163PYTa4yZ/M0Ad9RXmVwvgm2B+1eP7pGXgl/FDqfyEgqD7X8PxyfiHOO2T4qk/8AjtAHqlFeUR6h4B85j/wsi4K4+63iVgo+h38/nV22TwPNhY/HNzPuxgDxVKT+GJaAPSqK4208NaHfAfY9e1q4XGf3PiC5bI+olqxJ4D0eZVE8+uy4GPn1y95Hv+95oA6okAEk4A7msrUvEmh6WM6nrOm2Y9bi6SP+ZFY4+HHhItuuNEt7xjzm9Z7k/wDkQtWpY+FfD1g++w0HSbZ/70NnGh/QUAZMnxL8GqSI/ENjcEdfszGf/wBABqTTPiJ4U1KaGK31q3R5nMcQuFaDzHBwVUyBdxz2HNdUoCjCgAegrjPiN438IeGtNlt/FlzbTpMpDaf5YuHlXqcx8/L7tge9AHaUV594e0K2vtA0/VvAfiDVdPtbiJZLeO5d7u3KHophmOVA6AIyY7HFbfhrxDcz6hJoniG3is9ehj83bESYbuLOPOhJ5xkgMp+ZCQDkEMQDpqKKKACiiqWsarY6Np8t9qlzFbWsY+aSQ/oB1J9AOTQVGMpyUYq7ZBrniDSdCiEmsajbWgIyolcBmH+yvU/gKxfDPjmx8U6pJbaBa3VxZwf6++dfLiXjgKD8zE+mBgc15p4v8B6h431q11fTtJTR7a8mCSGXImZMEmeRM4XpgKOSTz1r2Xw1odj4c0a303TItlvCOp+87d2Y9yf88UHtYrC4HCYaL5nOtLppaPra93219V0NSiiig8MKKKKACiiigAooooAKKKKACiiigAooooAKq6nerp9jNctFLP5alhFCAXkP91QSBk+5FWqo6tYNqFsIkuprVw2RLEFLD2+YEfpQBwepfELXrWJ5YvBzMgOFjk1BfObnH3I0kGfoTiqDeMvHN4U+z6Rp9hvOMSQT3JX6nMY9fyrq38ERygifXtccEknZNHDn8Y41ob4deGptv22zub8gY/069nuAfqHcj9KAPP7rxB4pt2c+IfGlpoyKCNsVtaREk9D++kfGPfrXOHWtFuvlvvHXiPXJWOHjtJ5WT6bbX5cV7M+jeCPCcQupNP8ADmjIvImeGGDH/AiBWb/wsuwvTs8K6PrPiFeQJ7O3EVtkcY86Yoh+qlqG7DPJZNM0C4fMngrxhqikZUJpc5Uf8CnwT+datv4fdUzpPwhuZAwHN5c2tsSPcbzXoQ8e6tp4abxL4N1KxsBgm5s5477yh3MiJhwB1+UPxWn4q8VxweBH1rw3PbX0t55Vvp0isGjeaaRYoycdQGYEjr8pFJNMLM8Rv49W8O6vYW2reAtA077esjQyRzwu/wC7XLIjCM4fB+UNwcHn06W61PiJ4fBFq7TthG+0wBXG3PGcHOAT07VL498KaXoelaLehJb7XpNYslfUrk+ZcTEyYfLH7q7C/wAi4UdhUeoXcWoPZpZMQkb3AVlxjcgMPGP9qTH4Vk6nY6qVCMl7xnaXfQ3l3Y2+qaJfW8twp+yvNHbSRTYUt/rIiFUlQTyBWHq0Vzf6ndSeGbXQZ1XCm2uUDNkDkbonODn+/GvXqa6i9kEmrQw2bKDBCLa1Yc4kkALMPXZGoP8AwP3q3r2maHqOmJLq1jDfwqoEbugeQ54UK3XJOMY6k0Kp3LeET+FnDWD6deNbWOuweDNK1QplotUsxbbumSk4Vo354G18+ozxTJ7PSrO/3WfjTSYnJ5TTdZvJ+P7qiFensD2roL7w9cixt7VrsXU93uH2PUR9pjUYLbRI2WUKMLlt69Pl5qjDcT+Gb2CHR0vfDskh/eW1uwnid+CXW2b93OuBz5JjlHdK0Uk9jnnRlD4ig17q42jT/G9+kAPINvrUh47Z28Vdx4jmChPF+vEEZ/c6XrUhI/Hb/MV6DpnxEeztkl8VWsS2DHaNZ03dNZ5/6ar/AKyA8gEMCo7tXf2V1b31rFdWU8VxbSrujlicOjj1BHBFQ6jW6Eop9T5zv/Cuva24juNc+IV7bnJKxWEtuCPT/SbvGP8AgNafhn4U2+lav/aMXgSXUpVIZTr+sQRqGx1ENvE6H6MT/Wvf6Kj2rHyI5zTvHf2a9ttP8WaNc6BcXDiKCYuLizlY8KizqBtY9g6pnoM1u+KvD8WvWcQWZ7TUbV/Psb2MZe2lwQGA/iUgkMp4ZSQai1bTrTV9NudP1KBLizuUMcsTjIZT/nr2rN+GF/eS6Tf6Rqkz3F9od42nPcSHLzxhVeKRv9oxumfVgxrSE+bciUbGl4P1+TWILm11GFLTXNPcQX9qrEqjEZV0J5Mbj5lP1B5UgdBXF/EKMaK1t4xtRtn0sBL4L/y3sS37xW9SmfMX0KkfxHO54m12HQtNFwYpLq5lby7a1h5e4kPRV/mT2AJrQKdOVWShBXbF8S69aaBZLNdb5ZpW8u3tohuluJD0RB3P8qxNF8N3mo6nFrnjExTX8fNpYId0FiPb+/J0y3r06CrXhfQblLo634jdLjXplwAv+rs0P/LKIdvduprqKDsnWjhk6VB3k95fpHsu73fpuUUUUHAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAI7KiszsFVRkknAAqlpesaZq3mf2XqNle+WcP9mnWTYffaTiuG/aCsdT1H4YahBpMNzc/vYXure2z5s1uJAZUXHJyvYdQCPapfhvqHgTUdUnfwPpkVvNHaqk00GnPaoEzxGxKqCw645IoA9CpGOFJ9KWkYZUj1FAHH6t4X07VtRlvL6TUnlk2/KmpXEUaYGPlRHCj3wOTVX/hBtCwwaK/dWGGEmpXLg/gZK6aiuTmfc6LI5vT/AAL4XsLtru30KwN2zBvtEsQllzjHDvkj8DXRgAAADAFLRSvcYV5r4p0C1sdVfTAxttB8WO1vKEJAs9SxvhuY+flZmTBxjLrGepOfSq4r4zSi3+G2sXA/4+LcRTW2Dg+esqGLHfO8LwOT0qoOzFJXRxWp+JH8Q6nothqqCG88Oedd61EAdsdygMMeDjlWDSyLjttqKy0mPR9EtreV5ZLh4CJRxlNztJKw/wBpmcKPfb6Gqml219Lrl1eaw6GeRvt+qRW/Pm3T48m3HfbEirgZ5JUnvnpVtltv9N1Jo41U+dIF5G/nA6c4zx6sc9cU5W6HZRhaOu5FZaatpZXU+oyJCXU72UgCNTywB7dl+ir6VPEdzLfX6+TCh22ttt5XPAYju57DsOOuap3d6GmWa/XlGBgss9D/AAvJjPPooyR2BPQJJkSfVrgws4+SMZErDuEUZKj6ZY9yOlI1LKzSNdyzrGJLsIUAZv3VsnUhm/vHAJAz0HbmqVxcafdwSrJbPrzHO8iNTAvsGciMD6En1zRqZtTHEZYILOyQbY2v22xk/wCzDkbj/vYPpmqd3fWccSSz2096OiT6m628BP8AsowB+hWMn3oE2Upr3VvtNvP4fhsIZYh5ckcLS3K3K4wI5ZFTap9GJYDvkU/RUFteXd14Gmk8O6tA3mXujXSH7HLnu0WcR5xgSxnbxjIzirWpalqxs45o9RtbCADLlLIkKvbEszon/jv4VgS3EV9P5+nanfahq8SMILy3mkuHhJ6/u7aFoyDgcc/nzWkZPZnLVpR3WjPX/CHji01y+l0jUITpfiO3UNNp8zZLL/fibjeh9RyO4HGevr55nS51Owjg8cade2y2xR7PX4bCaw+zyE4++6jyWzg5wImJAIU4J7nwB45uPtUeh+KZg935ptbbUWi8kTyAZ8mZD/qp8cgfdccoTUzp21RzqXRnptcz4UT7N8T/ABdDG2Y7mzsLxh/dkPnRH81iT8qv+I/EmkeHLUTaxfw227/VxFsyzH+7Gg+Z2PoATUfw50u8gt9S1rWLb7NqmtXH2l4GOWt4VUJDExHcKMn/AGnanSTvcKj0On1Sxt9U027sL1PMtbqF4JUzjcjKVYfkTXL/AA6ke50v7Jq6rPrOgTyaXJcOo3sAFKyA9vMiMTH3JrkPi58Tb+yv4vCXw8jXUvF902wmMK62ffLZ+XdgE4bhQMt2B3fBaajp/jy6t9bML6pqGh2V1dvb/wCra4ieSORgMDqGi/759q3Mk2tUeh0UUUCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM2ddkrA+uRTKuajZQahayW9yJPLcYPlytG34MpBH4GuWufhl4Suv+PrS3uM9fOu53z9cvzWLpamqqGys0TSmISIZVGSgYbgPXFSVxfiH4aaTpmkG/8C6Raab4hsCLi1e2HlGfactA5/iV1yvzcDIPap1+IfhlNJe9vdTjsXj+WWzugY7qKTH+rMJ+ff6AA57ZHNRKDRUZXOrkdIo2klZUjUFmZjgADqSa8a8Qa4/i/wAQWk9lGJdLtJC2lxv926mHDXjj/nkgOE/vEkjqtRa3reqeONRS0mtJLXQ0O5tNkOHn4+U3TKSFXPPlDPQ7s/dGjHcQaaWitiLvUJfvuAe3YAZO0dlHTuRkmklY6aVK/vSGoIdCinuNQMSwo5ZJCw3zSMPmkcnCgnoOwHHHQVrua6uZIpZGSJmP7oYLMo7mNMZY/wC22PYAclu37Tes93K8tzGeI4lEskR9lGUi+pJbB+8KhOppPdTaXpdrJd3pwJbWwX7XcjnjzXP7uL/toxFCVzdySWuw5XjsmO19k2TkrtkmLHrlidkZ9skn61Uvdbj0qVUmSSwFw21pguZZD2+eXBc/7Kq59K67RfAHiG+RW1C5t/D1sQAY7Mi6vCO4Mrjy4/oqsB2NdTbaR4M+HsJ1C6ks7K4cbG1DUbjfcTHHK+ZISxz/AHRx6CtFTfU5p4lL4Tz7R9F8QanILjRfDptS/H2/VWMTkfV1aUj22KPQ10ul/CcfaXvNZ1mVruT750+EQMR/dMrl5cf7rKPYVU1P46aF588Ph2xvdXaAkTXEmLK1hI/heWbbg+2DntmvNZvil4x8T3afa9atfB2kyAzK4ttvnwAAkRzS4LyZOPlCjg81ooJHPKtOXU9/07wD4WsJlni0S0muVORcXYNzMD6+ZIWb9a6N3igjy7JGijuQAK+RYtSm1i0kvZvDviC9slO17nWbu6m4A5ZgQUA9geK5LTL61vv7Tk/sHRo/sD75Gh0d7uLygfvsyvhAMjOf58VRkfWvinxxp0F1b6LpdmniPUb6OXdY208O0RLgOZC7BQPmAwc5544NeKa/od9prTtc+GdS03wskSLJJeSRXYtotx3W8gikZ3txwyv9+E5K8ZFWPh1oEHiHWprrSr7S/D3iTSyZdNs7OxVYZ4yqh3lbaryo2WUqNrR5BOcqT65oPieSfUzofiOwOk6+FZlgZ98N2g6vBJgbxjBKkBlzyO9ROTjqiopM8z+H1xc6RqcWjeHND8MRapJEZINcvpGeWeI87TsTMrhCGyJFV1+YYwwXvbjwXrF2j3F3468Rf2qVystrIkFujdsQBSpX2YsT/e71xfxC8HL4dH2zTWe38P8AmiZfJO1tJn3bt6HHyws3JHSNjuxsZ1r0DwJ4mk1m3ex1VVh1y0RTOijCzoeFnj/2GwQR1VgynpkxKTauiopXszjv2U/CceleD7vX7wLNq+qXMqPO3zMI43KFdx55dXY+vy+lei3gW1+KWmSsf+P3SriBf96KWJ8fiHb/AL5rP+CiC38EPY9HstT1C3cY4BF3KePwIq94+AtLzwvq4X/jy1WOJ29I7hWgOfbdJGfwrZGbOuooooEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADJpVhieSQkIoycAk/kOa8m8afGa30lnt9I0q6nuOgmvI2gj+oUjc30O2vXKjn8vyXM+zygMtvxgD3zQduBrYejPmxFL2i7c1v0dzx74a/EbV9Tsb+a/0rVNXufPyTZRx+XChUbUCkg9m5OapeN/GPjSW6uV0G11fSXGzylmtYZBjI3ZUoxBIzzuP0r0vw5qvhi81u+tvDq2cl3HGGuZrSEBMZ+UGQDDHrjk964L41LazahZvZmxjuYwTczzX0VupGMKrhoZS2O2MY96mR6eIq0KmJlbC2vbTVNadvy0RwEGv+ILqS4N74ku47iBsSw3GoyWxOeoUREEHpzs49K031nxRaWdvLpur+Ip7ibcjLZzreQrg4+/PB+vHOa5oWvivUC7Wviy1s7FCcjT7JrnacZyWESDOO/FPXwXplxDFd+LdZ1TUyctEZ7xzuXoD5aj92Cf9o8enbNt9ziq048zShy+T6G9H/wAJ3dQiOfWdfgkkH3ZdUt1Y+4EcWRgc/e7Ur+Hl0u+imliv9X1qRP3l8N0lwRgjm4mfEYxx8pBx0FY2j2Wm6XqdwfBNhZX18i7YVsrV72aNjwTJIHfb6csox168dlpnw18Ra0HvPF15Hp1sD5rfapFuZE4GdsQPkRAYzlvNPXpRaUjPmp0/Uz4pVh015tQ1PT9P0dMgW9hIGAI4PmTtgE9sYHTqa0NJt9W1mHZ4W0C5FlIQDdXLmzicdmMjAyuPdEI/2q0oLr4b+Eljv7SFtdu7Y7V1CRlljib/AGJpCsEZ7YjK/Soz8SfFHicMvhPSZmhbKrJY2xuMkf8ATzN5cCfgJfxqlTXUyliX9lG7pnwxV7VT4t1UzWqAk6dp4NnZqO+4g+ZJ77mCnutO1H4meB/B9n/Z2hql2IOlpolurRx9yS4xEvqcsK828Q2N3LeBviDrcFtOE3ppQnfVr1m6ljEuyCMY6Hy9o7msCwmn1m/e18A6A93LA237ZMq3k6HO4fvWX7JbHGPuByOxzxVpWOeUnJ3bNvxb8afFmo2cX9i6Tc6VFdcW3lorzT+u15BggDklI2A/v964nRrHUvEN9cQSzRalr7yhpDZBr28hGBhTcOxCAc8q8aAnlz9yvWPDHwLnvLiW/wDHWry3E1wAJra1mZ3lX+7NdP8AvHBGMquwcd+K9m8P6FpXh3TksND0+2sLReRHAgUE+p9T7nJNMR5d4T+EAEFs+vS/Y4osGKysJP3i+vmXOA2T3EIjXr97rXWXXwq8GXibL7RvtYzkfabqaYg9Mgs5wa1tX8YaPpl09l9oe81NR/x4WMZuLj8UTJUe7YHvVHPi/W2JX7L4asT03Bbu9Yfn5UZ/7+0COb8ReFfhd4c1DTm8TWdoLi53panUpprlTsALD94zKAAR1x7V2fhPVfDGqaZ9m8LXOlzWUQKG3s9gWMZwQYx90fUU7w/4XsdGu5b0S3l9qcyeXJfX05llKZztHRUXPO1Aoz2rI+IOkxWcC+KtLtVTWtJcXLyQqA9xbjAmib++DGDgHoyqR0oA4D4kfD8eGmGv+GZHsbC2fzx5QydKl/57Rr3gPSSLkBWYrgZU9FJdy/EnwBK9vFHY+L9IkS4jjVgRBeIA6FTnmKRTjPdXI6g49Lje21GxV0MdxaXMYIONySIw/UEGvDNC/wCLefFew0dnddPuZDp8TOxO63m3SWoPrskSWIE8jdz94UDPTvDeq2vijwvZalHGptr63DPDIA20kYeNh3IOVI9jXlWsaRfeDdcsrayObeN3k0K6djiNtuXsZT/cZVwCeyhvvR5Pd+EIzo3i/wAWeHjkQC4XVrME/wDLK53FwB2AmSX/AL6FbXizRIvEOgXenSOYnkXdDMBkwyqdyOPcMAffpXOnySsbfErmF8E9VtdVtvFclizeT/bckoRl2tGZIonZWHZg7OCPUGun+IenNqvgfXLSL/Xtau8JH8MqDfGfwdVP4V5t8JtUTR/EU6XkC2w12QJPgnEGoxArJG3++FOD3Kg8+Yte1OodSrDKkYIPcVujF7lLQNQXV9C07Uo12peW0dwo9A6hv61erj/hVKYvCaaPMxNzoUz6VKD6RHEbf8CiMbf8CrsKYgooooAq32oW1i9qt1KsZuZhbxZ/icgkL+SmrVeJ/tCeIpdN1Tw3bWj4ntpf7QI91ICH9Hr2PTbyLUNOtb23OYbiJZkP+ywBH86D0cTl8qGFo4l7VL/g/wBSzRRRQecFFFFABRRRQAUUUUAFFFFABXnHjj4b3niqVmm8VagkJOVt5I1aJfTCqVHHqcn3r0eig6sJjK2Dn7Sg7S72T/NM8X8K/Bg6bq0q63cQ6lpEsZVkjllgfeCNpKrww+8Pvd67F/hd4UC4t9LihOMZyX/9CJrt6KVjrxGd47ES55VWvR2X3LQ8yi+ElkYzFPq1ysRbdstbS2hGfr5ZP4gg1jvF8L9IuWj+yyeI9QQmPayS6iSwOCBuzEpB4xxivZa4Xxd4f0O0km1TUrbW9Red1RLKzmlK5x0CIyqF4yS5288nmiyR506s6jvNtnI3XxN1SS5j0nwx4a/szjiO4QTXSLjtZwk7fZpHRfWqt74G1/xCJL7xnqIstLjIkL6lKlxOgBGWESlbWAY5ziRvU1TPizxXPMdB+GvhnSNNCk+clo8c5tjnrNIAIInxztzKx9DWlZfBK68QTxX3xR8Uajr84O/7DDIYrWM9wMYJHuoT6UyDFfWvhx4bvIptA0lvFWrs3lR6jey+ZGWB/wCWcjgg49LeNvTHat+5sviJ43Rla6m0TTm7KDZKR7KN1w/4tBn0r0rwx4Q8PeFofL8P6PZ2Hy7S8UY8xh1wzn5j+JrdoEeW+Ffgj4X0fdLqazaxcOQXW4Yrb8HOBCDgjv8AOXOepruNQ1Kw8OW1vbRWN2Y9uIbfT7CSUKB2xGpVR9cVtUUAcsNY8SahkaZ4dWxjI4m1a5VD9RFFvJ+hZaD4Zv8AUufEeu3VzGc5tLAGzgIPY7SZG/GTB9K6migCnpOl2GkWa2ulWdvZ2y9I4Iwi59cDv71coooAKRgGBDAEEYINLRQBynw4zaaPdaI+7fot3JYqGOT5PDw/+QnjH4GuL/aE0YXcXhrUImeO4W9On+ag/wBWJ1PlyH/cmSFvbmux1If2J4/0/UF+W01uP+zrnsBPGGeBz9V81Pc7BTvirp8upfD7W47YE3cEH2u3AHJlhIlQD6lAPxoA5afVFvNW+H/i8IkP9q276Vdr/daRPNRf+Aywso/3/evQK8Z0vVI7/wCF2m2cYVbn/hJLH7HnlgJZ4rxWx7RyP07KfevZqwqrU2p7HkvxHt4LTxfBYtL9mXxLEfs04wPI1C32mN+e7jYPrEleneA/EI8T+GLXUHRYrvmG7hH/ACynQ4dfpnkeoIPeuP8AjLosWp+FEvZInkbSZ1vSIx+88oArKU9GEbMy/wC0q1gfC/X303XkF5cRsmpTGxvthGz7Yv8AqbhB2SZCFz7Q+taU3eJE1qdvqjf8Ix8RLXUiduleIgljdHtHeIP3D+29cxn3WMd67ms/X9Is9e0e60zUovNtLlNjgHBHcMp7MCAQRyCAawPh/rdxPHd6Brs4k8RaQ3lTsy7Tcw5/dXIHQh1xnHRtw4qyDr6KKKAPNvi54X0qXQdb125gM+pfZ0hieR8iIbwAEHQZJ69eTXdaFpVvomlQadZeZ9lgBWMSOWKqSTjJ5wM4HtWL8R1Wfw9DZNnN5f2kAHrmdCf0BrqaD0a+IqzwdOnOTaUpaeSUUv1/EKKKKDzgooooAKKKKACiiigAooooAKKKKACiiigArO13RNN1+zW01i0ju7ZXEnlSZ2lh0yO49jxWjRQBXsLK1061jtdPtoLW2jGEhgjCIv0UcCrFFFABRRRQAUUUUAFFFFABRRRQAUUUUAY3jDSG13w5e2MMnk3TKJLab/nlOhDxP+Dqp/Cl8LawniDQLe9MRhlcGO5t3+9BMpKyRt7qwYe+M962K4rUT/wifi9NSHy6HrciQXvXbb3fCxTewkGI2P8AeEZ7k0AeIaNOvhX4jaHoN5vEcWsC0hD4wfKS4jjb2Jiu7c8+nFfR9eK/tM+CpWksPGuhxKup2bRxzODt2lXDQy+mQw2Ens68gLXd/DjxzY+NNGt50BtNT8oPc2EuVkjPQsAeWQkHDDjscEEDGquprBnXEBgQwBB4IPevmbxDolxaeHXuNEineeHV7jw+sEeTJK0Ujm1I+kWE3dV8uJv4TX0fq2o2ekabcahqdzHbWduhkllkOAo/z2715vo9ncweGvAV1qFu9teal4luNTlhcYZPPhvJFBHYhWTI7EUqWl2OfQ7L4ceMv7dsbfTNcR7DxbbW6tfWE8fluSDtMsY6PGSM5UkDIBrT8XeDdK8UyWdxfC6g1Cy3GzvrOdoZrctjJUjg9BwwI9qoeK/DsevQW0kVzJYatZSedY6hCoMltJjB4PDIw4ZDww49CKFt4/k0PFr8QbI6VKuFGp26NJYT+4cZMR/2ZMezN1rSM1IiUWjR8F61frqF14Z8TSJJrtinmx3KqEXULUnCzhR91gfldRwG5HDCuwrh9Wh8A/EFrE3V7pOryWrM1u1vfjehYYbBjcHnA49QD1ArMvdK1nwxeiDT9U8VzaK6hlnRoNQaBtxyjJJGZigG3BVnPUEDAJsg73UdOjv59PkmY4s7j7QqjozbGUZ+m7P1Aq9XnK6lLcSBIfiF9kmHWG+0+GFyf9x1Rq0Da+O4IVl07XfD2rxn5gl1YyQFh7SRyMB9dhoKcm0k3sdtRXP+EPEZ12O8gvLJ9O1iwkEN7ZPIJPKYqGUq44ZGByG4zzkAgiugoJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqpq2nWur6ZdafqMKzWd1G0UsbfxKRg/T61booA4jQL0hpvBXjAi5vDA6QTz8rqtpjBb08wA7ZF65+YfKwx44NKtfh74ql8N+OrQax4Uup2uNLuZYi01qpxuaKRfmyuB5ighukgzlhXu3jvTru70uC/0hBJq+lTC+tEPHmkKyvFntvRnTPYsD2o1LT9E+IHhKETqZ9Pu0WeCZDslgfqro3VJFP4ggg9xQBnaT4C8HK1pq1tai/RAs9tPd3017EgxlZI/NdlHqGH4Gs6wnPjPxXFri5Ph7SgyaYeQLudgVkuQO6BSUQ99zsOCpryyXw54q0Tx5aeDdW1+yk8KXxW7W2kDWsV+u8LLECvSTne0SkI2ckcmvddT1DTfD+lNdahcW1hp9uoXe5CIg6BR/IAfQVlUlb3UaQj1ZfoPIwelcjDd+KPFGDodsugaSx41DUYS11KvrFbnGwejSHP8AsGri+CNTjcvD458Rhn+/5kdm4z7AwfL+FQqcmU5pEuo+D/DWpOz6h4f0i5dury2cbN+ZGaxh8MfDNsWk0a3u9FuiMC50u8lt3H5NtYezAj2q/N4T8VxsxsfHMrrt+Vb3S4JOfcx7P0xWF4e8QeJdFtJLXxhoniLUdXMhJewsYpLYjOAImjI+XAzmXDc84o5JIOaLL1x8O7O5ttlzr/iqa5/5+X1ebdn/AHAfL/DZj2o+F5lsPFHiHQZPsF8LCOFjqdtaJbyEyFz5MwQBWkUANlQOGGQCaf8AZfFHjGYRSRXvhPQAD5jeZH/aF1kcKu0sIF65bJc4GNvWulRPDfw98MsR5Gl6VCxZmYlmkdu5PLSSMfqx960gpbsiTWyM3SY1Hxg8Svhd50jT8FOOPNus7vVuBg+ldrXH/D6yvJX1XxJq9vJaX+tyJIlpIMPbW0a7YY2HZ8FnYdmkI7V2FaEBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcVeWGr+F9ZuNR8PWjano14zS3mlJIqSwzE5M1vuwp3cloyRk/MDkkHtaKAOLuvEng3xNavpWvtaIXxv07WoPs8mexEcoBPsy5Hoam0HwB4U0u8h1DTtNSWeH/AI95Z7iS5EH/AFy8xmEf/AcV097Z219A0F7bw3ELdY5kDqfwPFc7P8P/AAtIxeDR7exlP/LXTy1o4990RU0AdTRXIjwJaq26PXPE6nP/AEGZ2H0wzGmHwFbsQX8QeKmA7f2xMufyIoA7Gobu7t7KBpryeK3hXkySuEUfUniuVHw80V2LXVxrl2xGCbjWbts/h5mKns/h74RtJBJH4d0ySUHIkngEzg+u58mgCtN4/wBPu5Gt/CltceJbsHbnTwDbRnH8dwf3a/QEt6Kak0Xw1e3OsR694ungutUiBFnaW+fstgCMEpu5eQjgyEA44UKM56yNEjRUjVURRgKowAPanUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Posterior view of normal dorsal extensor expansion. The extensor expansion near the proximal interphalangeal joint splits into three parts; a central part, which is inserted into the base of the middle phalanx, and two lateral parts, which converge to be inserted into the base of the distal phalanx. B) Mallet or baseball finger. The insertion of the extensor expansion into the base of the distal phalanx is ruptured; sometimes a flake of bone on the base of the phalanx is pulled off. C) Boutonni&egrave;re deformity. The insertion of the extensor expansion into the base of the middle phalanx is ruptured. The arrows indicate the direction of the pull of the muscles and the deformity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Snell, MD, PhD, Clinical Anatomy, 7th ed. Lippincott, Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_54_14180=[""].join("\n");
var outline_f13_54_14180=null;
var title_f13_54_14181="Doxepin (topical): Pediatric drug information";
var content_f13_54_14181=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxepin (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?14/8/14470?source=see_link\">",
"    see \"Doxepin (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/23/20852?source=see_link\">",
"    see \"Doxepin (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8082212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prudoxin&trade;;",
"     </li>",
"     <li>",
"      Zonalon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8082218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zonalon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10811165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/8/14470?source=see_link\">",
"      see \"Doxepin (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Adults: Apply to affected area 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8082338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prudoxin&trade;: 5% (45 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zonalon&reg;: 5% (30 g, 45 g) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8082220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10811166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply thin film of cream to affected area with at least 3-4 hours between applications; do not use occlusive dressings; do not use for &gt;8 days; avoid contact with eyes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10811105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Short-term (&lt;8 days) therapy of moderate pruritus due to atopic dermatitis or lichen simplex chronicus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8082209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxepin may be confused with digoxin, doxapram, doxazosin, Doxidan&reg;, doxycycline",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zonalon&reg; may be confused with Zone-A&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxal [Finland] may be confused with Doxil brand name for doxorubicin (liposomal) [U.S.,  Israel]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxal brand name for doxepin [Finland] but also brand name for pyridoxine/thiamine [Brazil]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8082253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, emotional changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Stinging/burning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Taste alteration, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anxiety, contact dermatitis, tongue numbness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10811144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to doxepin or any component; cross-sensitivity with other tricyclic antidepressants may occur; narrow-angle glaucoma; patients with urinary retention",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10811146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiovascular disease, conduction disturbances, seizure disorders, urinary retention, hyperthyroidism, or those receiving thyroid replacement; avoid use during lactation; use with caution during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Drowsiness may occur with topical use; incidence with cream is 22%, especially if applied to &gt;10% of BSA; occlusive dressings may increase absorption of doxepin; if drowsiness or sedation occurs, dosage adjustment may be needed (eg, reduction in area treated, number of applications per day, amount of cream used); discontinue therapy is excessive drowsiness occurs.  Allergic contact dermatitis may occur with topical use; risk may be increased with use &gt;8 days.",
"     <b>",
"      Note:",
"     </b>",
"     Cream is not recommended for use in pediatric patients; overdoses from topical administration in children have been reported.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10811145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doxepin causes a high degree of sedation (relative to other antidepressants); may cause orthostatic hypotension and anticholinergic side effects; may worsen psychosis or precipitate mania or hypomania in patients with bipolar disease; may increase the risks associated with electroconvulsive therapy. Cream contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates; avoid use of doxepin products containing benzyl alcohol in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8082256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8082257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8082244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8082245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Following topical application, plasma levels may be similar to those achieved with oral administration",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10811168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and effectiveness of topical cream when used for &gt;8 days has not been established; use &gt;8 days may result in an increase in serum concentrations and systemic effects.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15972 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_54_14181=[""].join("\n");
var outline_f13_54_14181=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082212\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082218\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811165\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082338\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082220\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811166\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811105\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082209\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082253\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811144\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811146\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811145\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082256\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082257\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082244\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082245\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811168\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15972\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15972|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/32/44551?source=related_link\">",
"      Doxepin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/8/40069?source=related_link\">",
"      Doxepin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/59/24503?source=related_link\">",
"      Doxepin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/8/14470?source=related_link\">",
"      Doxepin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/23/20852?source=related_link\">",
"      Doxepin (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_54_14182="Cortisol production PI";
var content_f13_54_14182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F52283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F52283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Normal cortisol production by the adrenal glands",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 628px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cortisol levels are normally regulated by the hypothalamus and pituitary gland. The hypothalamus sends corticotropin releasing hormone (CRH) to the pituitary gland. The pituitary gland responds by producing several hormones, one of which is ACTH (adrenocorticotropin hormone). ACTH stimulates the adrenal gland to produce cortisol. Cortisol levels help to control the pituitary's production of ACTH.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_54_14182=[""].join("\n");
var outline_f13_54_14182=null;
var title_f13_54_14183="Intimate partner violence: Intervention and patient management";
var content_f13_54_14183=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intimate partner violence: Intervention and patient management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/54/14183/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/54/14183/contributors\">",
"     Amy Weil, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/54/14183/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/54/14183/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/54/14183/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/54/14183/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/54/14183/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24185041\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intimate partner violence (IPV) is a serious, preventable public health problem affecting more than 32 million Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/1\">",
"     1",
"    </a>",
"    ]. Although IPV affects both sexes, more women than men experience IPV. Lifetime estimates for IPV involving women in the United States range from 22 to 39 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In countries around the world, 10 to 69 percent of women report physical assault by an intimate partner at some time in their life [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term \"intimate partner violence\" describes actual or threatened psychological, physical, or sexual harm by a current or former partner or spouse. IPV can occur among heterosexual or same-sex couples and does not require sexual intimacy.",
"   </p>",
"   <p>",
"    Care of the patient experiencing IPV requires a team approach involving medical, institutional, and community resources. The clinician's role is to make the diagnosis, provide ongoing medical care and emotional support, assess patient safety, counsel the patient about the nature and course of domestic violence, educate the patient about the range of available support services, document findings, make appropriate referrals, and assure follow-up.",
"   </p>",
"   <p>",
"    This topic will discuss the clinician&rsquo;s role in managing the patient in whom IPV has been identified. The clinical manifestations of IPV, and screening and diagnosis of IPV are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=see_link\">",
"     \"Intimate partner violence: Diagnosis and screening\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5784?source=see_link\">",
"     \"Intimate partner violence: Epidemiology and health consequences\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12233035\">",
"    <span class=\"h1\">",
"     INITIAL APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Family Violence Prevention Fund has identified four guiding principles of intervention for clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Survivor safety &ndash; being always aware that the primary concern is to maximize safety and not increase risk for further harm",
"     </li>",
"     <li>",
"      Survivor empowerment &ndash; facilitating the patient&rsquo;s ability to make his or her own choices",
"     </li>",
"     <li>",
"      Perpetrator accountability &ndash; framing the violence as occurring because of the perpetrator&rsquo;s behavior and not the survivor&rsquo;s.",
"     </li>",
"     <li>",
"      Advocacy for social change &ndash; collaboration and advocacy beyond the healthcare setting",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When IPV has been identified, the most important first consideration is to offer support to the patient. It is crucial that providers affirm their understanding of how difficult it must be for the patient to share this information, recognize the patient&rsquo;s strength in doing so, and provide assurance that they will be available to the patient for the future. This should be immediately followed by an assessment of the victim's safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266712060\">",
"    <span class=\"h2\">",
"     Support",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immediate expression of empathy, acknowledgement, and continued ability to support and assist the patient are the most important components of care after a patient has disclosed abuse. Some suggest explicitly thanking the patient for the trust shown by their willingness to share difficult information [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/6\">",
"     6",
"    </a>",
"    ]. Close follow-up is often warranted, especially if the patient is in crisis.",
"   </p>",
"   <p>",
"    Empathy may be shared with the following comments:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      \"I am very sorry this is happening to you.\"",
"     </li>",
"     <li>",
"      \"I am glad you were able to tell me.\"",
"     </li>",
"     <li>",
"      \"This is a common problem.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Validation may be expressed with the following statements:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      \"You do not deserve this and it is not your fault.\"",
"     </li>",
"     <li>",
"      \"You must be very strong to have been able to go through this and now to be able to ask for help.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Assistance can be offered by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      \"I want to help you through this in any way I can.\"",
"     </li>",
"     <li>",
"      \"I have worked with others with this problem and can assist you in improving your health and with resources to support you through working on this problem.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients may not be ready to take action at the initial disclosure, but may be helped to move toward action, with understanding of their stage of readiness on a continuum of stages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Precontemplation &mdash; The patient is not concerned about the situation",
"     </li>",
"     <li>",
"      Contemplation &mdash; The patient has considered change but is not ready to take action",
"     </li>",
"     <li>",
"      Determination &mdash; The patient has decided to make changes in their situation",
"     </li>",
"     <li>",
"      Action &mdash; The patient is actively seeking help and taking steps to address the IPV",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physician should help the patient along this continuum and assure the patient that he or she will not be abandoned, regardless of where they are in the process of change. Not all patients will move in a linear fashion through these stages. Clinicians should support the patient in making changes for which they are ready, and not re-create the dynamics of power and control by insisting on progress through the stages to departure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185048\">",
"    <span class=\"h2\">",
"     Assessing for safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician must assess the safety of all patients who are experiencing IPV. Although the vast majority of patients are not in imminent danger and are not planning to leave their relationship, it should not be overlooked that IPV can result in death. Assessing for safety and making a safety plan can decrease the risk of mortal harm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5784?source=see_link&amp;anchor=H86601681#H86601681\">",
"     \"Intimate partner violence: Epidemiology and health consequences\", section on 'Homicide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician should ask the patient how afraid they are and what they think are their immediate and future safety needs. Unfortunately, many people minimize or deny their danger. Clinicians may be surprised or frustrated with the severity of abuse patients are willing to tolerate and should understand that love and other family concerns, such as children in the home and economic factors, often confound the picture.",
"   </p>",
"   <p>",
"    In an open ended way, patients should be asked about their concerns and fears. A",
"    <a class=\"external\" href=\"file://dangerassessment.org/DA.aspx\">",
"     20-item Danger Assessment tool",
"    </a>",
"    has been developed and validated to predict the likelihood of lethality or near lethality in an IPV relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/7\">",
"     7",
"    </a>",
"    ]. In a validation study, the sensitivity of the tool for attempted femicide was 38 percent for scores between 14 and 17, and 85 percent for scores 18 to 20.",
"   </p>",
"   <p>",
"    Patients should be offered referral to someone to talk to about options and safety. For patients who are not ready or are too fearful to proceed with referral, support and concern should be discussed on subsequent visits, and the patient should again be asked to consider referral to someone to help him or her think about their options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185055\">",
"    <span class=\"h3\">",
"     Risk factors for escalating abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"external\" href=\"file://dangerassessment.org/DA.aspx\">",
"     Danger Assessment tool",
"    </a>",
"    identifies risk factors for violence and includes perpetrator and victim factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185062\">",
"    <span class=\"h4\">",
"     Perpetrator factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perpetrator factors associated with increased danger to a patient include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Violent outside the home",
"     </li>",
"     <li>",
"      Violent to children",
"     </li>",
"     <li>",
"      Threatening to kill victim, children, self",
"     </li>",
"     <li>",
"      Escalating threats",
"     </li>",
"     <li>",
"      Using drugs - especially phencyclidine (pcp), crack cocaine, amphetamines, or alcohol",
"     </li>",
"     <li>",
"      Abusive during pregnancy",
"     </li>",
"     <li>",
"      Obsessive controlling relationship",
"     </li>",
"     <li>",
"      Has provoked serious prior injury",
"     </li>",
"     <li>",
"      Owns weapons, especially handguns",
"     </li>",
"     <li>",
"      Threatened others, including friends",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      family",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185069\">",
"    <span class=\"h4\">",
"     Victim factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Victim factors associated with increased danger include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Attempting to leave the relationship",
"     </li>",
"     <li>",
"      Has sought outside intervention",
"     </li>",
"     <li>",
"      Acknowledgment that he or she is afraid for their life",
"     </li>",
"     <li>",
"      Suicidal (with a plan, or with prior suicide attempts, or has means)",
"     </li>",
"     <li>",
"      Homicidal",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185076\">",
"    <span class=\"h2\">",
"     Safety plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;If any significant risk factor is present, it is imperative to devise a safety plan as the patient may be at risk of serious harm or death. Depending on availability, a hospital or community domestic violence advocate, hospital social worker, or local domestic violence hotline can provide advice about the recommended plan in the community. The patient may need access to a shelter.",
"   </p>",
"   <p>",
"    A safety plan should include the following elements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preparing an emergency kit with important documents, keys, money, and other essential items, to be stored outside the home in case they need to escape urgently (",
"      <a class=\"graphic graphic_figure graphicRef85533 \" href=\"UTD.htm?1/51/1841\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A place to go (friends, family, shelter)",
"     </li>",
"     <li>",
"      A signal to alert children or neighbors to call 911",
"     </li>",
"     <li>",
"      During times of escalating conflict, avoiding rooms with potential weapons (kitchen) or risk for increased injury (hard bathroom surfaces)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185091\">",
"    <span class=\"h1\">",
"     INTERVENTION, COUNSELING, AND REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Providers should assure the abused patient that they are available for support. In addition the patient should be offered referral for counseling about options and safety, often to an onsite or local domestic violence agency where available. Patients may be reluctant or resistant to talking with anyone else because of fears about safety. On subsequent visits, you may emphasize ongoing support and concern and ask the patient again to consider referral to someone who can help think about options.",
"   </p>",
"   <p>",
"    Caution should be taken in providing the patient with written materials since safety may be jeopardized if the batterer finds this material. One institution provides an unidentified phone number for the Family Violence Program as one of many important numbers printed on the back of physician business cards. If brochures are distributed, it should be made clear that the patient has a place to keep them that would not be accessible to the perpetrator.",
"   </p>",
"   <p>",
"    DO NOT confront the perpetrator, as this can endanger patients and, potentially, providers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5052650\">",
"    <span class=\"h2\">",
"     Effectiveness of intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of intervention for domestic violence has been studied, showing benefit for some, but not all, outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review found insufficient evidence to determine if advocacy (providing information, support, and resource access) in healthcare settings is effective for women who live with their abusing partners [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/8\">",
"       8",
"      </a>",
"      ]. Intensive advocacy for women in shelters decreased physical abuse, but its effect on depression, quality of life, and psychological distress was uncertain.",
"     </li>",
"     <li>",
"      In a 2012 meta-analysis of six trials, counseling interventions for IPV reduced IPV, improved birth outcomes for pregnant women, reduced IPV in the post-partum period, and reduced unsafe relationships and pregnancy coercion for women seen in family planning clinics [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185098\">",
"    <span class=\"h2\">",
"     Counseling the victim",
"    </span>",
"    &nbsp;&mdash;&nbsp;Counseling may strengthen the victim's sense of self-worth and provide ongoing support, although objective evidence to support these benefits is limited. Counseling can also assess the degree of danger for victims and their children, and help them develop a safety plan. Brief advocacy has been shown to increase the use of safety behaviors by abused women [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many victims of abuse are not ready to leave their abusers because of fear of reprisal, economic dependence on the abuser, especially if there are children, no acceptable place to go, belief that the abuse will stop, or belief that the abuse is their fault. Victims may believe expressions of remorse and promises that the abuser will change his or her behavior. Drop-out rates from treatment programs are high [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attempting to or leaving a relationship with a perpetrator often increases the risk of injury. Providers should not encourage their patients to leave a relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/10\">",
"     10",
"    </a>",
"    ]. If patients come to their own decision to terminate a relationship, close attention should be paid to devising and implementing a safety plan, and seeking assistance from hospital and community resources where available.",
"   </p>",
"   <p>",
"    Clinicians should screen the patient for possible psychologic issues (depression and anxiety) as well as substance abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition to concerns about the patient, clinicians should consider whether child protective services are required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31097?source=see_link\">",
"     \"Childhood exposure to intimate partner violence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185105\">",
"    <span class=\"h3\">",
"     Local resources",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient appears in danger, referral to in-house",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    community resources is important. Referral should also be considered, in the absence of imminent danger, for those who screen positive for current IPV. (See",
"    <a class=\"local\" href=\"#H24185048\">",
"     'Assessing for safety'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Familiarize yourself with local resources for referral. These may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hospital programs",
"     </li>",
"     <li>",
"      Community hotlines",
"     </li>",
"     <li>",
"      Shelters",
"     </li>",
"     <li>",
"      Group support, including batterers&rsquo; groups",
"     </li>",
"     <li>",
"      Legal Aid",
"     </li>",
"     <li>",
"      Social welfare services",
"     </li>",
"     <li>",
"      Support for specific groups: immigrants requiring interpreters, victims in same sex relationships, victims with physical or intellectual disabilities",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5052423\">",
"    <span class=\"h4\">",
"     Resources in the US",
"    </span>",
"    &nbsp;&mdash;&nbsp;Governmental resources at the state and federal level are available. Some helpful resources web-based resources include:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.futureswithoutviolence.org/\">",
"       www.futureswithoutviolence.org/",
"      </a>",
"      <em>",
"      </em>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.ncadv.org/resources/FactSheets.php\">",
"       www.ncadv.org/resources/FactSheets.php",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.womenshealth.gov/violence-against-women\">",
"       file://www.womenshealth.gov/violence-against-women",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.cdc.gov/ViolencePrevention/intimatepartnerviolence/index.html\">",
"       file://www.cdc.gov/ViolencePrevention/intimatepartnerviolence/index.html",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Telephone resources include:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      National Domestic Violence Hotline: 1-800-799-SAFE (1-800-799-7233)",
"     </li>",
"     <li>",
"      The National Sexual Assault Hotline: 1-800-656-4673",
"     </li>",
"     <li>",
"      The National Teen Dating Abuse Hotline: 1-866-331-9474",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185112\">",
"    <span class=\"h2\">",
"     Intervention for the perpetrator",
"    </span>",
"    &nbsp;&mdash;&nbsp;Court-mandated interventions to assist batterers have been minimally successful, decreasing recidivism by only 5 to 7 percent according to two meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Attrition rates from batterer intervention programs are high (about 50 percent), and those who drop out are most likely to be involved in IPV again [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suggestions for improvement of these programs include shifting the program from court-mandated group therapy to models based on stages of change or individually tailored treatment. Further suggestions include concurrent substance use",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mood disorder therapy or treatment of couples together [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/12,14\">",
"     12,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185119\">",
"    <span class=\"h1\">",
"     LEGAL ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185127\">",
"    <span class=\"h2\">",
"     Documentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful documentation is important if the patient seeks legal redress. Reports of abuse need to be specific and detailed.",
"   </p>",
"   <p>",
"    The following data should be recorded:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Quotes from the patient about the occurrence, nature, and time of abuse.",
"     </li>",
"     <li>",
"      Quotes that identify the perpetrator, where permitted by the patient.",
"      <strong>",
"      </strong>",
"      Patients do have the right to ask that information regarding IPV not be included in their chart. Often information in the chart can help with incriminating the perpetrator; however in situations where perpetrators have access to the records (shared children) this information may increase danger to victims.",
"     </li>",
"     <li>",
"      Findings from the physical examination",
"     </li>",
"     <li>",
"      If possible, photographs of any physical injuries after obtaining the patient's signed consent. The photograph must include the patient's face or identifying features with the injury to be useful as evidence. If a camera is not available, the physician should make a sketch of the injuries.",
"     </li>",
"     <li>",
"      Orders for appropriate laboratory and radiology studies.",
"     </li>",
"     <li>",
"      Comments on comorbidities, if present, and degree of disability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Language should be chosen carefully. Words such as",
"    <strong>",
"     denies",
"    </strong>",
"    or",
"    <strong>",
"     claims,",
"    </strong>",
"    although commonly used in medical records, suggest the clinician may not believe the patient. It is helpful to state: \"Patient reports that she does not drink or use drugs\" in lieu of \"Patient",
"    <strong>",
"     denies",
"    </strong>",
"    alcohol or drug use.\"",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    Where relevant, rape kits such as those facilitated by Sexual Assault Nurse Examiners (SANE nurses) should be obtained and documented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185134\">",
"    <span class=\"h2\">",
"     Mandatory reporting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician needs to be familiar with state or country law regarding situations for which reporting is mandated. Requirements for reporting vary by state, with mandatory reporting required in only a minority of states as of 2012.",
"   </p>",
"   <p>",
"    Domestic violence programs, either hospital-based or in the community, can often provide assistance with reporting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    guidance about whether reporting is indicated.",
"   </p>",
"   <p>",
"    Situations that commonly require reporting are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Abuse of disabled persons",
"      </strong>",
"      &mdash; Harm to disabled persons must be reported to the Disabled Persons Protection Commission.",
"     </li>",
"     <li>",
"      <strong>",
"       Weapon use",
"      </strong>",
"      &mdash; In most states, injury resulting from assault with a firearm or knife or causing \"grave bodily harm\" is reportable.",
"     </li>",
"     <li>",
"      <strong>",
"       Elder",
"      </strong>",
"      <strong>",
"       abuse &mdash;",
"      </strong>",
"      Many states have mandatory reporting laws for elder abuse. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17850?source=see_link\">",
"       \"Elder mistreatment: Abuse, neglect, and financial exploitation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185141\">",
"    <span class=\"h3\">",
"     Abuse involving children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within the United States, domestic violence involving a child must be reported if the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Under the age of 18, and",
"     </li>",
"     <li>",
"      Abuse or neglect of the child is suspected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    State-specific guidelines about what constitutes the need to report and who is mandated to report are available through the",
"    <a class=\"external\" href=\"file://www.childwelfare.gov/responding/how.cfm\">",
"     Child Welfare Information Gateway",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Health providers and law enforcement officers, as well as teachers and child care providers, are mandated reporters in most states. State policies differ on whether the situation in which a child witnesses a parent being abused is considered child abuse. There has been concern that mandated reporting may be a barrier to the parent's being willing to reveal abuse or even be a barrier to clinic attendance by parents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link\">",
"     \"Child abuse: Social and medicolegal issues\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31097?source=see_link\">",
"     \"Childhood exposure to intimate partner violence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185148\">",
"    <span class=\"h2\">",
"     Protection order",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who feel they are in danger may consider initiating a Domestic Violence Protective Order (DVPO), legally preventing perpetrators from contact with patients. In general, a community advocate or legal advisor will assist the patient with obtaining this document. Evidence of the effectiveness of protection orders in preventing recurrent violence is inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In one US retrospective study, compared to abuse victims who did not obtain a protection order, women who were granted a temporary (usually two week) restraining order were more likely to be subsequently psychologically abused in the 12 months following the index incident, while women who obtained a permanent protection order (12 months) were less likely to be physically abused in the 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185155\">",
"    <span class=\"h1\">",
"     MANAGING THE CHALLENGING PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history of prior, rather than current abuse, may present with chronic health problems. It should be recognized that it is generally difficult for patients to disclose abuse situations.",
"   </p>",
"   <p>",
"    Some patients with an abuse history present with comorbid depression and somatic complaints, including chronic pain. It is important not to abandon these patients, even if their problems continue to be difficult to solve. There is some evidence that somatic complaints may decrease after disclosure and that well being may improve when root causes are addressed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians should be careful not to re-create the dynamics of power and control, typical of classic IPV, in the provider-patient relationship. The clinician must ensure trust and continuity, but also be alert to appropriate boundaries. Patients should be allowed to make autonomous decisions regarding health advice. Focusing care on the patient's safety and health, rather than life choices, can be helpful.",
"   </p>",
"   <p>",
"    Frequent scheduled follow-up as well as referral to mental health clinicians for cognitive behavioral (CBT) or dialectical behavioral (DBT) therapies may be helpful, as can ongoing contact with community or hospital-based advocates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23992?source=see_link\">",
"     \"The difficult patient encounter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18984?source=see_link\">",
"     \"Somatization: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185162\">",
"    <span class=\"h1\">",
"     CURBING SOCIETAL VIOLENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increasing move to work at the societal level to change cultural norms that perpetuate violence. Legal and policy reforms have little impact without first addressing change in cultural attitudes and institutional practices [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attempts to impact cultural norms include efforts targeted by and for men such as the White Ribbon campaign to change social norms away from power and control and towards equality. The White Ribbon campaign has organizations in multiple countries, including the United States, Canada, Scotland, England, and Australia.",
"   </p>",
"   <p>",
"    Increasingly, culturally-specific community based groups are trying to assist their members in ways that are acceptable within their life contexts. Partner violence organizations geared to specific groups include",
"    <a class=\"external\" href=\"file://www.searac.org/cease?page=3\">",
"     SEARAC",
"    </a>",
"    for IPV survivors of Asian descent,",
"    <a class=\"external\" href=\"file://wafahouse.org/history.html\">",
"     Wafa House",
"    </a>",
"    in New Jersey for survivors who are Muslim, and",
"    <a class=\"external\" href=\"file://www.dvalianza.org/\">",
"     Alianza",
"    </a>",
"    for Latina women.",
"   </p>",
"   <p>",
"    Worldwide, there has been attention given to stiffen penalties for violence and so decrease its occurrence. As an example, legislative action has been proposed in the United States to evaluate country-specific policies about violence against women in making decisions about foreign aid and diplomacy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/19\">",
"     19",
"    </a>",
"    ]. In 2012, the US Department of State and the US Agency for International Development (USAID) announced an official strategy to prevent and respond to gender-based violence globally, to coordinate efforts between multiple governmental groups, integrate gender violence prevention in US government work, and improve data collection and research efforts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14183/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24185169\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The expression of empathy, acknowledgement, and continued ability to support and assist the patient are the most important components of care immediately after a patient has disclosed abuse. Close follow-up is often warranted, especially if the patient is in crisis. (See",
"      <a class=\"local\" href=\"#H266712060\">",
"       'Support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All IPV patients should be assessed for safety. Many people experiencing IPV minimize or deny their danger. In an open ended way, patients should be asked about their concerns and fears. Patients should be offered referral to someone to talk to about options and safety. For patients who are not ready or are too fearful to follow through with referral, support and concern should be ongoing and referral options discussed on subsequent visits. (See",
"      <a class=\"local\" href=\"#H24185048\">",
"       'Assessing for safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If any significant risk factor for escalating abuse is present, it is imperative to devise a safety plan as the patient may be at risk of harm or death. A hospital or community domestic violence advocate, hospital social worker, or local domestic violence hotline can provide advice about the recommended plan in the community. (See",
"      <a class=\"local\" href=\"#H24185076\">",
"       'Safety plan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Counseling may strengthen the victim's sense of self-worth and provide ongoing support, although objective evidence to support these benefits is limited. Counseling can also assess the degree of danger for victims and their children. The abused patient should be reassured that the provider is available for support. Caution should be taken in providing the patient with written materials since safety may be jeopardized if the batterer finds this material. DO NOT confront the perpetrator, as this can endanger the patient and, potentially, the provider. (See",
"      <a class=\"local\" href=\"#H24185091\">",
"       'Intervention, counseling, and referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Careful documentation is important if the patient seeks legal redress. Reports should specify quotes from the patient about the occurrence, nature, and time of abuse, findings from the physical examination, and photographs if consented. Patients do have the right to ask that information regarding intimate partner violence not be included in their chart. Often information in the chart can help with incriminating the perpetrator; however in situations where perpetrators have access to the records (shared children) this information may increase danger to victims. (See",
"      <a class=\"local\" href=\"#H24185127\">",
"       'Documentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinician needs to be familiar with state or country law regarding situations for which reporting is mandated. Requirements for reporting vary by state in the US. Abuse involving disabled persons, older adults, children under the age of 18, or weapon use commonly require reporting. Protection orders are intended to legally prevent perpetrators from contact with victims, but evidence of their effectiveness is inconsistent. (See",
"      <a class=\"local\" href=\"#H24185119\">",
"       'Legal issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Tjaden P, Thoennes N. Extent, nature, and consequences of intimate partner violence: findings from the National Violence Against Women Survey. Publication No. NCJ-181867, US Department of Justice, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14183/abstract/2\">",
"      Nelson HD, Bougatsos C, Blazina I. Screening women for intimate partner violence: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med 2012; 156:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14183/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). Adverse health conditions and health risk behaviors associated with intimate partner violence--United States, 2005. MMWR Morb Mortal Wkly Rep 2008; 57:113.",
"     </a>",
"    </li>",
"    <li>",
"     The World Health Organization. World report on violence and health. Chapter 4. Violence by intimate partners. file://www.who.int/violence_injury_prevention/violence/global_campaign/en/chap4.pdf (Accessed on August 07, 2011).",
"    </li>",
"    <li>",
"     Warshaw C, Ganley AL. Improving the health care response to domestic violence: A resource manual for health care providers. The Family Violence Prevention Fund. 1996. file://www.futureswithoutviolence.org/userfiles/file/HealthCare/improving_healthcare_manual_intro.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14183/abstract/6\">",
"      Liebschutz JM, Rothman EF. Intimate-partner violence--what physicians can do. N Engl J Med 2012; 367:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14183/abstract/7\">",
"      Campbell JC, Webster DW, Glass N. The danger assessment: validation of a lethality risk assessment instrument for intimate partner femicide. J Interpers Violence 2009; 24:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14183/abstract/8\">",
"      Ramsay J, Carter Y, Davidson L, et al. Advocacy interventions to reduce or eliminate violence and promote the physical and psychosocial well-being of women who experience intimate partner abuse. Cochrane Database Syst Rev 2009; :CD005043.",
"     </a>",
"    </li>",
"    <li>",
"     World Heatlh Organization. Violence by intimate partners. Available at: file://www.who.int/violence_injury_prevention/violence/global_campaign/en/chap4.pdf (Accessed on April 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14183/abstract/10\">",
"      Nicolaidis C, Curry MA, Ulrich Y, et al. Could we have known? A qualitative analysis of data from women who survived an attempted homicide by an intimate partner. J Gen Intern Med 2003; 18:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14183/abstract/11\">",
"      Babcock JC, Green CE, Robie C. Does batterers' treatment work? A meta-analytic review of domestic violence treatment. Clin Psychol Rev 2004; 23:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14183/abstract/12\">",
"      Alexander PC, Morris E, Tracy A, Frye A. Stages of change and the group treatment of batterers: a randomized clinical trial. Violence Vict 2010; 25:571.",
"     </a>",
"    </li>",
"    <li>",
"     Bennett L and Williams Ol. Contrroversies and recent studies of batterer intervention programs.National Online Resource Center on Violence Against Women, August 2001 file://www.vawnet.org/summary.php?doc_id=373&amp;find_type=web_desc_AR (Accessed on August 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14183/abstract/14\">",
"      Stuart GL, Temple JR, Moore TM. Improving batterer intervention programs through theory-based research. JAMA 2007; 298:560.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute of Justice and American Bar Association. Legal interventions in family violence: research findings and policy implications. United States Department of Justice, Washington, DC 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14183/abstract/16\">",
"      Grau J, Fagan J, Wexler S. Restraining orders for battered women: issues of access and efficacy. Women and Politics 1984; 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14183/abstract/17\">",
"      Holt VL, Kernic MA, Lumley T, et al. Civil protection orders and risk of subsequent police-reported violence. JAMA 2002; 288:589.",
"     </a>",
"    </li>",
"    <li>",
"     Intimate Partner Violence in  Practical Gynecology: A Guide for the Primary Care Physician, 2nd ed, Ryden J, Blumenthal PD, Charney P (Eds), American College of Physicans, 2009.",
"    </li>",
"    <li>",
"     International Violence Against Women Act )I-VAWA) file://passivawa.org/aboutIVAWA.html (Accessed on June 25, 2012).",
"    </li>",
"    <li>",
"     file://www.state.gov/r/pa/prs/ps/2012/08/196342.htm (Accessed on September 05, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15306 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-FC043B0C43-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_54_14183=[""].join("\n");
var outline_f13_54_14183=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24185169\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24185041\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12233035\">",
"      INITIAL APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H266712060\">",
"      Support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24185048\">",
"      Assessing for safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24185055\">",
"      - Risk factors for escalating abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H24185062\">",
"      Perpetrator factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H24185069\">",
"      Victim factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24185076\">",
"      Safety plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24185091\">",
"      INTERVENTION, COUNSELING, AND REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5052650\">",
"      Effectiveness of intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24185098\">",
"      Counseling the victim",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24185105\">",
"      - Local resources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5052423\">",
"      Resources in the US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24185112\">",
"      Intervention for the perpetrator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24185119\">",
"      LEGAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24185127\">",
"      Documentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24185134\">",
"      Mandatory reporting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24185141\">",
"      - Abuse involving children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24185148\">",
"      Protection order",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24185155\">",
"      MANAGING THE CHALLENGING PATIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24185162\">",
"      CURBING SOCIETAL VIOLENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24185169\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/15306\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/15306|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/51/1841\" title=\"figure 1\">",
"      Safety packing list",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31097?source=related_link\">",
"      Childhood exposure to intimate partner violence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17850?source=related_link\">",
"      Elder mistreatment: Abuse, neglect, and financial exploitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=related_link\">",
"      Intimate partner violence: Diagnosis and screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5784?source=related_link\">",
"      Intimate partner violence: Epidemiology and health consequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18984?source=related_link\">",
"      Somatization: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23992?source=related_link\">",
"      The difficult patient encounter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_54_14184="Lidocaine (systemic): Drug information";
var content_f13_54_14184=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lidocaine (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/58/36772?source=see_link\">",
"    see \"Lidocaine (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/11/20663?source=see_link\">",
"    see \"Lidocaine (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8768558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xylocaine&reg;;",
"     </li>",
"     <li>",
"      Xylocaine&reg; Dental;",
"     </li>",
"     <li>",
"      Xylocaine&reg; MPF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8768559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Xylocard&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8768603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiarrhythmic Agent, Class Ib;",
"     </li>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8768809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiarrhythmic (ACLS, 2010):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      VF or pulseless VT (after defibrillation attempts, CPR, and vasopressor administration) if amiodarone is not available:",
"     </b>",
"     I.V., intraosseous (I.O.): Initial: 1-1.5 mg/kg. If refractory VF or pulseless VT, repeat 0.5-0.75 mg/kg bolus every 5-10 minutes (maximum cumulative dose: 3 mg/kg). Follow with continuous infusion (1-4 mg/minute) after return of perfusion. Reappearance of arrhythmia during constant infusion: 0.5 mg/kg bolus and reassessment of infusion (Zipes, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Endotracheal (loading dose only):",
"     </b>",
"     2-3.75 mg/kg (2-2.5 times the recommended I.V. dose); dilute in 5-10 mL NS or sterile water.",
"     <b>",
"      Note:",
"     </b>",
"     Absorption is greater with sterile water and results in less impairment of  PaO",
"     <sub>",
"      2",
"     </sub>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hemodynamically stable monomorphic VT:",
"     </b>",
"     I.V.: 1-1.5 mg/kg; repeat with 0.5-0.75 mg/kg every 5-10 minutes as necessary (maximum cumulative dose: 3 mg/kg). Follow with continuous infusion of 1-4 mg/minute (or 14-57 mcg/kg/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Reduce maintenance infusion in patients with CHF, shock, or hepatic disease; initiate infusion at 10 mcg/kg/minute (maximum dose: 1.5 mg/minute or 20 mcg/kg/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Anesthesia, local injectable:",
"     </b>",
"     Varies with procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient; maximum: 4.5 mg/kg/dose not to exceed 300 mg; do not repeat within 2 hours.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8768807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/11/20663?source=see_link\">",
"      see \"Lidocaine (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiarrhythmic:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V., intraosseous (I.O.):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     For use in VF or pulseless VT if amiodarone is not available; give after defibrillation attempts, CPR, and epinephrine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose: 1 mg/kg (maximum: 100 mg); follow with continuous infusion; may administer second bolus of 0.5-1 mg/kg if delay between bolus and start of infusion is &gt;15 minutes (PALS, 2000; PALS, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous infusion: 20-50 mcg/kg/minute (PALS, 2010). Per the manufacturer, do not exceed 20 mcg/kg/minute in patients with shock, hepatic disease, cardiac arrest, or CHF.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Endotracheal:",
"     </i>",
"     2-3 mg/kg; flush with 5 mL of NS and follow with 5 assisted manual ventilations (PALS, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anesthesia, local injectable:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8768812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8768813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, accumulation of metabolites may be increased in renal dysfunction. Not dialyzable (0% to 5%) by hemo- or peritoneal dialysis; supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8768815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; reduce maintenance infusion. Initial: 0.75 mg/minute or 10 mcg/kg/minute; maximum dose: 1.5 mg/minute or 20 mcg/kg/minute. Monitor lidocaine concentrations closely and adjust infusion rate as necessary; consider alternative therapy.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8768838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W, as hydrochloride: 0.4% [4 mg/mL] (250 mL, 500 mL); 0.8% [8 mg/mL] (250 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 1% [10 mg/mL] (2 mL, 10 mL, 20 mL, 30 mL, 50 mL); 2% [20 mg/mL] (2 mL, 5 mL, 20 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xylocaine&reg;: 0.5% [5 mg/mL] (50 mL); 1% [10 mg/mL] (10 mL, 20 mL, 50 mL); 2% [20 mg/mL] (10 mL, 20 mL, 50 mL) [contains methylparaben]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 0.5% [5 mg/mL] (50 mL); 1% [10 mg/mL] (2 mL, 5 mL, 30 mL); 1.5% [15 mg/mL] (20 mL); 2% [20 mg/mL] (2 mL, 5 mL, 10 mL); 4% [40 mg/mL] (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xylocaine&reg;: 2% [20 mg/mL] (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xylocaine&reg; MPF: 0.5% [5 mg/mL] (50 mL); 1% [10 mg/mL] (2 mL, 5 mL, 10 mL, 30 mL); 1.5% [15 mg/mL] (10 mL, 20 mL); 2% [20 mg/mL] (2 mL, 5 mL, 10 mL); 4% [40 mg/mL] (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [for dental use]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xylocaine&reg; Dental: 2% [20 mg/mL] (1.8 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, premixed in D",
"     <sub>",
"      7.5",
"     </sub>",
"     W, as hydrochloride [preservative free]: 5% [50 mg/mL] (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8768599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8768797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Local thrombophlebitis may occur in patients receiving prolonged I.V. infusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endotracheal (unlabeled administration route): Dilute in NS or sterile water. Absorption is greater with sterile water and results in less impairment of PaO",
"     <sub>",
"      2",
"     </sub>",
"     (Hahnel, 1990). Stop compressions, spray drug quickly down tube. Flush with 5 mL of NS and follow immediately with several quick insufflations and continue chest compressions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intraosseous (I.O.; unlabeled administration route): Intraosseous administration is a safe and effective alternative to venous access in children with cardiac arrest; the onset for most medications is similar to that of I.V. administration (PALS, 2010).  In adults, I.O. administration is a reasonable alternative when quick I.V. access is not feasible (ACLS, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14472683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1000 mg in 250 mL (concentration: 4 mg/mL)",
"     <b>",
"      or",
"     </b>",
"     2000 mg in 250 mL (concentration: 8 mg/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     8000",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8768696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, alteplase, amiodarone, argatroban, bivalirudin, caffeine citrate, cefazolin, ciprofloxacin, cisatracurium, daptomycin, dexmedetomidine, diltiazem, dobutamine, dobutamine with dopamine, dobutamine with nitroglycerin, dobutamine with nitroprusside, dopamine, dopamine with nitroglycerin, dopamine with nitroprusside, enalaprilat, eptifibatide, etomidate, famotidine, fenoldopam, haloperidol, heparin, heparin with hydrocortisone sodium succinate, hetastarch in lactated electrolyte injection (Hextend&reg;), inamrinone, labetalol, levofloxacin, linezolid, meperidine, micafungin, morphine, nicardipine, nitroglycerin, nitroglycerin with nitroprusside, nitroprusside, palonosetron, potassium chloride, remifentanil, streptokinase, theophylline, tigecycline, tirofiban, vasopressin, vitamin B complex with C, warfarin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, metoprolol, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Nesiritide, propofol, tenecteplase, thiopental.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Amikacin, caffeine citrate, clonidine, clonidine with fentanyl, cloxacillin, edentate calcium disodium, glycopyrrolate, heparin, hydroxyzine, ketamine, ketamine with morphine, morphine, metoclopramide, milrinone, nalbuphine, penicillin G sodium, vasopressin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cefazolin, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ampicillin, ceftriaxone, diazepam, epinephrine, fentanyl, insulin (regular), sodium bicarbonate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8768617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local and regional anesthesia by infiltration, nerve block, epidural, or spinal techniques; acute treatment of ventricular arrhythmias from myocardial infarction or cardiac manipulation (eg, cardiac surgery)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The routine prophylactic use of lidocaine to prevent arrhythmia associated with fibrinolytic administration or to suppress isolated ventricular premature beats, couplets, runs of accelerated idioventricular rhythm, and nonsustained VT is not recommended (Antman, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8768619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACLS guidelines: Hemodynamically stable monomorphic ventricular tachycardia (VT) (preserved ventricular function); polymorphic VT (preserved ventricular function); drug-induced monomorphic VT; when amiodarone is not available, pulseless VT or ventricular fibrillation (VF) (unresponsive to defibrillation, CPR, and vasopressor administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PALS guidelines: When amiodarone is not available, pulseless VT or VF (unresponsive to defibrillation, CPR, and epinephrine administration); consider in patients with cocaine overdose to prevent arrhythmias secondary to MI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. infusion for chronic pain syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8768552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration; I.V. formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lidosen [Italy] may be confused with Lincocin brand name for lincomycin [U.S., Canada, and multiple international markets]; Lodosyn brand name for carbidopa [U.S.]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8768665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Effects vary with route of administration. Many effects are dose related.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bradycardia, arterial spasms, cardiovascular collapse, defibrillator threshold increased, edema, flushing, heart block, hypotension, sinus node supression, vascular insufficiency (periarticular injections)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, apprehension, coma, confusion, disorientation, dizziness, drowsiness, euphoria, hallucinations, headache, hyperesthesia, hypoesthesia, lethargy, lightheadedness, nervousness, psychosis, seizure, slurred speech, somnolence, unconsciousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Metallic taste, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, transient radicular pain (subarachnoid administration; up to 1.9%), tremor, twitching, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchospasm, dyspnea, respiratory depression or arrest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylactic reaction, anaphylactoid reaction, sensitivity to temperature extremes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Following spinal anesthesia: Positional headache (3%), shivering (2%), double vision (&lt;1%), cauda equina syndrome, hypotension, nausea, peripheral nerve symptoms, respiratory inadequacy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Asystole, disorientation, methemoglobinemia, skin reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8768645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lidocaine or any component of the formulation; hypersensitivity to another local anesthetic of the amide type; Adam-Stokes syndrome; Wolff-Parkinson-White syndrome; severe degrees of SA, AV, or intraventricular heart block (except in patients with a functioning artificial pacemaker); premixed injection may contain corn-derived dextrose and its use is contraindicated in patients with allergy to corn or corn-related products",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8768646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is",
"     <b>",
"      not",
"     </b>",
"     an approved use; chondrolysis (primarily in the shoulder joint) has occurred following infusion, with some cases requiring arthroplasty or shoulder replacement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic dysfunction: Use extreme caution in patients with severe hepatic dysfunction; may have increased risk of lidocaine toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pseudocholinesterase deficiency: Use caution in patients with pseudocholinesterase deficiency; may have increased risk of lidocaine toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injectable anesthetic: Follow appropriate administration techniques so as not to administer any intravascularly. Solutions containing antimicrobial preservatives should not be used for epidural or spinal anesthesia. Some solutions contain a bisulfite; avoid in patients who are allergic to bisulfite. Resuscitative equipment, medicine and oxygen should be available in case of emergency. Use products containing epinephrine cautiously in patients with significant vascular disease, compromised blood flow, or during or following general anesthesia (increased risk of arrhythmias). Adjust the dose for the elderly, pediatric, acutely ill, and debilitated patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intravenous: Constant ECG monitoring is necessary during I.V. administration. Use cautiously in hepatic impairment, HF, marked hypoxia, severe respiratory depression, hypovolemia, history of malignant hyperthermia, or shock. Increased ventricular rate may be seen when administered to a patient with atrial fibrillation. Use is contraindicated in patients with Wolff-Parkinson-White syndrome and severe degrees of SA, AV, or intraventricular heart block (except in patients with a functioning artificial pacemaker). Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy. Correct any underlying causes of ventricular arrhythmias. Monitor closely for signs and symptoms of CNS toxicity. The elderly may be prone to increased CNS and cardiovascular side effects. Reduce dose in hepatic dysfunction and CHF.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CAST trial: In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, non-life-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide. An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8768686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2A6 (minor), CYP2B6 (minor), CYP2C9 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8768687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the arrhythmogenic effect of Lidocaine (Systemic). Disopyramide may increase the serum concentration of Lidocaine (Systemic). Specifically, the unbound/free fraction of lidocaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May enhance the arrhythmogenic effect of Lidocaine (Systemic). Saquinavir may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May enhance the adverse/toxic effect of Lidocaine (Systemic). Telaprevir may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8768691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort may decrease lidocaine levels; avoid concurrent use.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8768620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8768621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies with lidocaine have not shown teratogenic effects. Lidocaine and the MEGX metabolite cross the placenta. Use is not contraindicated during labor and delivery. Topical lidocaine is used locally to provide analgesia prior to episiotomy and during repair of obstetric lacerations. Administration by the perineal route may result in greater absorption than administration by the epidural route. Adverse events have been reported in the infant following maternal administration, however, when used in appropriate doses, the risk to the fetus is low. Cumulative exposure from all routes of administration should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8768623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8768644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of lidocaine and the MEGX metabolite are found in breast milk. The actual amount may depend on route and duration of administration. When administered topically at recommended doses, the amount of lidocaine available to the nursing infant would not be expected to cause adverse events. Cumulative exposure from all routes of administration should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8768796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Premixed injection may contain corn-derived dextrose and its use is contraindicated in patients with allergy to corn-related products.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lidocaine HCl (Cardiac) Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (5 mL): $4.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (5 mL): $2.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lidocaine HCl (PF) Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (50 mL): $3.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (30 mL): $2.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (5 mL): $2.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lidocaine HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (50 mL): $3.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (50 mL): $1.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5% (20 mL): $9.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (50 mL): $1.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (5 mL): $4.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lidocaine in D5W Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/mL 5% (250 mL): $4.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg/mL 5% (250 mL): $6.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lidocaine in Dextrose Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-7.5% (2 mL): $7.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Xylocaine (Cardiac) Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (5 mL): $4.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Xylocaine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (50 mL): $6.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (20 mL): $3.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (20 mL): $4.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Xylocaine-MPF Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (50 mL): $15.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (5 mL): $2.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5% (10 mL): $7.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (2 mL): $2.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (5 mL): $7.55",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15577078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, lidocaine concentrations, ECG",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F8768709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: 1.5-5.0 mcg/mL (SI: 6-21 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Potentially toxic: &gt;6 mcg/mL (SI: &gt;26 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: &gt;9 mcg/mL (SI: &gt;38 micromole/L)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dolocaine (PH);",
"     </li>",
"     <li>",
"      Esracain (IL);",
"     </li>",
"     <li>",
"      Ke Ze Pu (CL);",
"     </li>",
"     <li>",
"      Lidocard (DK);",
"     </li>",
"     <li>",
"      Locana (TH);",
"     </li>",
"     <li>",
"      Peterkaien (ZA);",
"     </li>",
"     <li>",
"      Rapidocain (CH);",
"     </li>",
"     <li>",
"      Xylo-Efa 10% Cardiologica (UY);",
"     </li>",
"     <li>",
"      Xylocaine (NZ, TW);",
"     </li>",
"     <li>",
"      Xylocard (AT, AU, BE, FR, IN, NO, NZ, SE, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8768707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Class Ib antiarrhythmic; suppresses automaticity of conduction tissue, by increasing electrical stimulation threshold of ventricle, His-Purkinje system, and spontaneous depolarization of the ventricles during diastole by a direct action on the tissues; blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8768710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Single bolus dose: 45-90 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.1-2.1 L/kg; alterable by many patient factors; decreased in CHF and liver disease; crosses blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 60% to 80% to alpha",
"     <sub>",
"      1",
"     </sub>",
"     acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: 90% hepatic; active metabolites monoethylglycinexylidide (MEGX) and glycinexylidide (GX) can accumulate and may cause CNS toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biphasic: Prolonged with congestive heart failure, liver disease, shock, severe renal disease; Initial: 7-30 minutes; Terminal: Infants, premature: 3.2 hours, Adults: 1.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;10% as unchanged drug, ~90% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Pain Society,",
"      <i>",
"       Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain",
"      </i>",
"      , 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benitz WE and Tatro DS,",
"      <i>",
"       The Pediatric Drug Handbook",
"      </i>",
"      , 2nd ed, Chicago, IL: Year Book Medical Publishers Inc, 1988.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Cardiac Electrophysiology: From Cell to Bedside&rdquo; 3rd ed, Zipes DP and Jalife J, WB, eds,  Philadelphia, PA: WB Saunders Co, 2000.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cavalli Rde C, Lanchote VL, Duarte G, et al, &ldquo;Pharmacokinetics and Transplacental Transfer of Lidocaine and Its Metabolite for Perineal Analgesic Assistance to Pregnant Women,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 2004, 60(8):569-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/15365654/pubmed\" id=\"15365654\" target=\"_blank\">",
"        15365654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow T, Galvin J, and McGovern B, &ldquo;Antiarrhythmic Drug Therapy in Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1998, 82(4A):58I-62I.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/9737655/pubmed\" id=\"9737655\" target=\"_blank\">",
"        9737655",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Christoph RA, Buchanan L, Begalla K, et al, &ldquo;Pain Reduction in Local Anesthetic Administration Through pH Buffering,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1988, 17(2):117-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/2827545/pubmed\" id=\"2827545\" target=\"_blank\">",
"        2827545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dix SK, Rosner GF, Nayar M, et al, &ldquo;Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2011, 39(4):872-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/21263316/pubmed\" id=\"21263316\" target=\"_blank\">",
"        21263316",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dorian P, Cass D, Schwartz B, et al, &ldquo;Amiodarone as Compared With Lidocaine for Shock-Resistant Ventricular Fibrillation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 346(12):884-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/11907287/pubmed\" id=\"11907287\" target=\"_blank\">",
"        11907287",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dryden RM and Lo MW, &ldquo;Breast Milk Lidocaine Levels in Tumescent Liposuction,&rdquo;",
"      <i>",
"       Plast Reconstr Surg",
"      </i>",
"      , 2000, 105(6):2267-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/10839430/pubmed\" id=\"10839430\" target=\"_blank\">",
"        10839430",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (Suppl 3):640-56.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foxall G, McCahon R, Lamb J, et al, &ldquo;Levobupivacaine-Induced Seizures and Cardiovascular Collapse Treated With Intralipid,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2007, 62(5):516-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/17448066/pubmed\" id=\"17448066\" target=\"_blank\">",
"        17448066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giuliani M, Grossi GB, Pileri M, et al, &ldquo;Could Local Anesthesia While Breast-Feeding Be Harmful to Infants?&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr,",
"      </i>",
"      2001, 32(2):142-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/11321382/pubmed\" id=\"11321382\" target=\"_blank\">",
"        11321382",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goetzl LM and ACOG Committee on Practice Bulletins-Obstetrics, &ldquo;ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists Number 36, July 2002. Obstetric Analgesial and Anesthesia,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2002, 100(1):177-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/12100826/pubmed\" id=\"12100826\" target=\"_blank\">",
"        12100826",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 10: Pediatric Advanced Life Support. The American Heart Association in Collaboration With the International Liaison Committee on Resuscitation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2000, 102(8 Suppl):I291-342.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/10966679/pubmed\" id=\"10966679\" target=\"_blank\">",
"        10966679",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hahnel JH, Lindner KH, Schurmann C, et al, &ldquo;Plasma Lidocaine Levels and PaO2 With Endobronchial Administration: Dilution With Normal Saline or Distilled Water?&ldquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1990, 19(11):1314-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/2240730/pubmed\" id=\"2240730\" target=\"_blank\">",
"        2240730",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Litz RJ, Popp M, Stehr SN, et al, \"Successful Resuscitation of a Patient With Ropivacaine-Induced Asystole After Axillary Plexus Block Using lipid Infusion,\"",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2006, 61(8):800-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/16867094/pubmed\" id=\"16867094\" target=\"_blank\">",
"        16867094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo JM, Dasta JF, Kleinschmidt KC, et al, &ldquo;State of the Art Review: Intravenous Fat Emulsions: Current Applications, Safety Profile, and Clinical Implications,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2010, 44(4):688-700.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/20332339/pubmed\" id=\"20332339\" target=\"_blank\">",
"        20332339",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore PA and Hersh EV, \"Local Anesthetics: Pharmacology and Toxicity,\"",
"      <i>",
"       Dent Clin North Am",
"      </i>",
"      , 2010, 54(4):587-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/20831923/pubmed\" id=\"20831923\" target=\"_blank\">",
"        20831923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neal JM, Mulroy MF, and Weinberg GL, &ldquo;American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2012 Version,&rdquo;",
"      <i>",
"       Reg Anesth Pain Med",
"      </i>",
"      , 2012, 37(1):16-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/22189574/pubmed\" id=\"22189574\" target=\"_blank\">",
"        22189574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson Textbook of Pediatrics, 17th ed, Behrman RE, Kliegman RM, and Jenson HB, eds, Philadelphia, PA: WB Saunders Co, 2004.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenblatt MA, Abel M, Fischer GW, et al, \"Successful Use of a 20% Lipid Emulsion to Resuscitate a Patient After a Presumed Bupivacaine-Related Cardiac Arrest,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2006, 105(1):217-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/16810015/pubmed\" id=\"16810015\" target=\"_blank\">",
"        16810015",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schnider TW, Gaeta R, Brose W, et al, &ldquo;Derivation and Cross-Validation of Pharmacokinetic Parameters for Computer-Controlled Infusion of Lidocaine in Pain Therapy,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1996, 84(5):1043-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/54/14184/abstract-text/8623997/pubmed\" id=\"8623997\" target=\"_blank\">",
"        8623997",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10274 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-07C1274D5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_54_14184=[""].join("\n");
var outline_f13_54_14184=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768558\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768559\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768603\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768809\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768807\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768812\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768813\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768815\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768838\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768599\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768797\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472683\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472684\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768696\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768617\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768619\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768552\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768665\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768645\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768646\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768686\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768687\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768691\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768620\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768621\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768623\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768644\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768796\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322268\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15577078\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768709\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276704\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768707\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768710\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10274\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10274|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/30/4579?source=related_link\">",
"      Lidocaine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/39/12915?source=related_link\">",
"      Lidocaine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/59/30642?source=related_link\">",
"      Lidocaine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/58/36772?source=related_link\">",
"      Lidocaine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/11/20663?source=related_link\">",
"      Lidocaine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/3/20535?source=related_link\">",
"      Lidocaine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/46/29413?source=related_link\">",
"      Lidocaine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/50/33574?source=related_link\">",
"      Lidocaine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_54_14185="Oral health in cancer survivors";
var content_f13_54_14185=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oral health in cancer survivors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/54/14185/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/54/14185/contributors\">",
"     Hani Haytham Mawardi, BDS, DMSc, DABOM, FDS RCSEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/54/14185/contributors\">",
"     Maha Ali Al-Mohaya, BDS, MS, DMSc, ABOM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/54/14185/contributors\">",
"     Nathaniel S Treister, DMD, DMSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/54/14185/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/54/14185/contributors\">",
"     Patricia A Ganz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/54/14185/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/54/14185/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/54/14185/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1145025465\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most cancer survivors there are no specific oral health considerations or expected late complications. However, cancer survivors prescribed bone-modifying agents, survivors of head and neck cancer, childhood cancer survivors, and patients treated on protocols involving high-dose chemotherapy and stem cell transplantation (HCT-SCT) constitute high-risk groups for oral health complications. These patients may require long-term dental follow-up well after completion of cancer therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/1\">",
"     1",
"    </a>",
"    ]. An overview of oral complications is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef85779 \" href=\"UTD.htm?34/63/35837\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Since most patients are usually followed and managed by their local community dentists, communication between medical and dental providers is critical prior, during, and after cancer therapy, in order to minimize or prevent oral health complications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review oral health considerations in cancer survivors at high risk for complications. Because head and neck cancer survivors, patients treated with hematopoietic cell transplantation who develop chronic graft-versus-host disease (GVHD), and patients taking bone modifying agents are at a significant risk for oral health complications, a detailed discussion of these patients is covered separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"       \"Management of late complications of head and neck cancer and its treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35530?source=see_link&amp;anchor=H94492429#H94492429\">",
"       \"The approach to hematopoietic cell transplantation survivorship\", section on 'Oral health'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42073?source=see_link&amp;anchor=H733754#H733754\">",
"       \"Cutaneous manifestations of graft-versus-host disease (GVHD)\", section on 'Oral lesions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799559488\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17362950\">",
"    <span class=\"h2\">",
"     Bone-modifying agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are currently being treated with or have been treated in the past with bone-modifying agents (ie, bisphosphonates or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    ) are at risk for developing osteonecrosis of the jaw, which can be associated with long-term pain and discomfort. Those at risk include survivors of more common cancers, such as prostate and breast cancer. (See",
"    <a class=\"local\" href=\"#H248884468\">",
"     'Osteonecrosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17363020\">",
"    <span class=\"h2\">",
"     Head and neck cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral and dental complications are common in head and neck cancer survivors because the treatment field often includes, by their proximity, organs required for breathing, eating, and communicating. As a result, a number of complications can arise that impact the oral cavity directly and the surrounding organs (eg, thyroid gland) and structures. These include facial disfigurement, salivary gland hypofunction, osteoradionecrosis, and trismus. In addition, these patients are at risk for both recurrence and a second primary lesion. (See",
"    <a class=\"local\" href=\"#H34521990\">",
"     'Facial disfigurement'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H248884158\">",
"     'Chronic salivary gland hypofunction'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H354997706\">",
"     'Due to radiation therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1317823764\">",
"     'Trismus'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1145025623\">",
"     'Malignancy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799559553\">",
"    <span class=\"h2\">",
"     Childhood cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cancer is the second leading cause of death in children [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/4\">",
"     4",
"    </a>",
"    ], childhood cancer survivors constitute a small proportion of cancer survivors. In the United States, for example, there are approximately 300,000 survivors of childhood cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. For these patients, chemotherapy and radiation therapy (RT) to the head and neck region can have an adverse impact on normal growth and development of teeth and surrounding structures.",
"   </p>",
"   <p>",
"    Abnormal findings include smaller than normal teeth (microdontia) and failure of the teeth to develop (hypodontia) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In one study involving 150 children, the prevalence of microdontia and hypodontia were 19 and 9 percent (compared to 0 and 4 percent among 193 age-matched controls) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H99498948\">",
"     'Abnormal dental development'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment-related risk factors for oral complications were identified in a report from the Childhood Cancer Survivor Study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/9\">",
"     9",
"    </a>",
"    ]. In this study, 8522 cancer survivors and 2831 of their siblings responded to questionnaires and an interview about oral health. The median age at cancer diagnosis was six years and median time from diagnosis to interview was 22 years. The majority of cancer survivors reported prior treatment with chemotherapy (76 percent)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy (64 percent). Risk factors associated with at least one dental problem included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RT dose to the jaw &mdash; A total dose &lt;20 Gy was associated with a 1.3-fold higher risk (OR 1.3, 95% CI 1.2-1.5), while a total dose &ge;20 Gy was associated with a nearly sixfold increase in risk (OR 5.6, 95% CI 3.7-8.5).",
"     </li>",
"     <li>",
"      Total dose of alkylating agents &mdash; The risk increased with increasing cumulative dose of alkylating drugs administered. There was a twofold higher risk for those who had the highest exposure to alkylating agents compared to those who were not treated with alkylating agents (OR 2.0, 95% CI 1.6-2.4).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, treatment at a younger age is associated with a greater potential for long-term effects [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/7\">",
"     7",
"    </a>",
"    ]. When there are complications affecting growth and development, patients may require the expertise of oral and maxillofacial surgeons, orthodontists, and prosthodontists for comprehensive management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248884016\">",
"    <span class=\"h2\">",
"     Chronic graft-versus-host disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with high-dose chemotherapy (HCT) followed by allogeneic hematopoietic stem cell transplantation (HCT-SCT) are at an increased risk for oral health complications if they develop chronic graft-versus-host disease (GVHD), particularly for the development of dental caries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Oral complications affect more than 80 percent of patients with GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/12\">",
"     12",
"    </a>",
"    ]. Although patients who undergo an autologous SCT are at risk of acute complications (eg, mucositis and infection) immediately following transplantation, following immune reconstitution, there are no specific associated late oral complications. (See",
"    <a class=\"local\" href=\"#H99499233\">",
"     'Oral chronic graft-versus-host disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with GVHD often require extended immunosuppressive therapy, putting them at long-term risk of oral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/13\">",
"     13",
"    </a>",
"    ]. These patients are also at an increased risk for squamous cell carcinoma of the oral cavity, likely due to a combination of chronic inflammation associated with GVHD, as well as long-term immunosuppression. (See",
"    <a class=\"local\" href=\"#H99499219\">",
"     'Oral candidiasis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H99499226\">",
"     'Recurrent herpes simplex virus infection'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42073?source=see_link\">",
"     \"Cutaneous manifestations of graft-versus-host disease (GVHD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799559710\">",
"    <span class=\"h1\">",
"     PREVENTING ORAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that newly diagnosed cancer patients be referred for a thorough oral examination prior to initiation of therapy, particularly if treatment will be administered to the head and neck region or if profound and prolonged immunosuppression is anticipated. The primary objective is to identify any actively infected teeth so that they can be treated definitively prior to the initiation of cancer-related therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. This is especially important for high risk patients as discussed above because dental extractions are a well-recognized risk factor for complications including osteonecrosis of the jaw in patients being treated with bone-modifying agents and osteoradionecrosis following radiation therapy (RT) in head and neck cancer survivors. (See",
"    <a class=\"local\" href=\"#H248884468\">",
"     'Osteonecrosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H354997706\">",
"     'Due to radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, dental screening and counseling will reinforce the importance of oral hygiene and the maintenance of an infection-free oral cavity to reduce the risk of developing localized",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic infection during anticipated periods of neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link&amp;anchor=H722455156#H722455156\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Dental issues'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42073?source=see_link&amp;anchor=H451212#H451212\">",
"     \"Cutaneous manifestations of graft-versus-host disease (GVHD)\", section on 'Oral lesions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H8702257#H8702257\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34521974\">",
"    <span class=\"h1\">",
"     TREATMENT-RELATED COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99498948\">",
"    <span class=\"h2\">",
"     Abnormal dental development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood cancer survivors are at risk for multiple developmentally-related dental complications as a consequence of RT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy. In the Childhood Cancer Study discussed above, cancer survivors had a higher risk of dental complications compared to their siblings including [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal dental roots (5 percent in cancer survivors versus 3 percent in their siblings, odds ratio [OR] 3.0, 95% CI 2.2-4.0)",
"     </li>",
"     <li>",
"      Microdontia (9 versus 3 percent, OR 3.0, 95% CI 2.4-3.8)",
"     </li>",
"     <li>",
"      Loss of six or more teeth (5 versus 2 percent, OR 2.6, 95% CI 1.9-3.6)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34521990\">",
"    <span class=\"h2\">",
"     Facial disfigurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck surgery may result in significant disfigurement, despite careful treatment planning, due to surgical excision involving the anatomic locations of the vital organs of speech, swallowing, and respiration [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Even relatively minor surgical defects can have a tremendous impact on social interaction, self-image, and psychological well-being. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43959?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of treatment for head and neck squamous cell cancer\", section on 'Reconstruction and rehabilitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248884158\">",
"    <span class=\"h2\">",
"     Chronic salivary gland hypofunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salivary gland hypofunction is common in patients with chronic GVHD and patients treated with RT to the head and neck. This may also occur in solid tumor patients as a result of chemotherapy, but is a temporary phenomenon that resolves within one year of the completion of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822348#H3822348\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Salivary gland damage and xerostomia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyposalivation is defined as a resting whole saliva flow rate of &le;0.1",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a stimulated whole saliva flow rate of &le;0.5",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Hyposalivation results in dry mouth (xerostomia), although qualitative changes in the composition of saliva can result in xerostomia without a significant decrease in flow [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Xerostomia can negatively impact normal functions, including eating, speaking, and swallowing. It is associated with alterations in taste and can cause symptoms of burning within the oral cavity. Xerostomia also increases the risk of oral candidiasis and dental caries, which can impact nutritional status, social interactions, and overall quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/25-28\">",
"     25-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of salivary gland hypofunction is discussed in detail separately, but relies upon frequent water sipping, use of moisturizing and saliva stimulating agents, and prescription sialogogue therapy (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12932?source=see_link\">",
"     cevimeline",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99499219\">",
"    <span class=\"h2\">",
"     Oral candidiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under normal conditions, candida coexist with the other microorganisms of the oral flora in humans and do not cause disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/29\">",
"     29",
"    </a>",
"    ]. However, alterations in the oral environment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic immunosuppression can result in fungal overgrowth, leading to clinical oral fungal infection or candidiasis. For cancer survivors, the primary risk factors for recurrent candidiasis are salivary gland hypofunction and long-term immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of Candida infections\", section on 'Oropharyngeal candidiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with oral candidiasis can be asymptomatic or can present with a range of symptoms that include burning, sensitivity, and taste changes. When symptomatic, oral candidiasis can have a significant impact on quality of life and may impair nutritional intake [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/31\">",
"     31",
"    </a>",
"    ]. Multiple presentations of oral candidiasis in cancer survivors have been described including [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pseudomembranous candidiasis &mdash; typically presents as patchy white papules and plaques throughout the oral cavity (",
"      <a class=\"graphic graphic_picture graphicRef86805 \" href=\"UTD.htm?21/10/21667\">",
"       picture 1",
"      </a>",
"      )",
"      <br/>",
"     </li>",
"     <li>",
"      Erythematous candidiasis &mdash; characterized by mucosal erythema only and may be more challenging to diagnose as the presentation features may be more subtle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperplastic candidiasis &mdash; Hyperplastic candidiasis presents as a distinct area of leukoplakia and requires biopsy for diagnosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of cases of oral candidiasis respond readily to topical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic antifungal therapy. The Infectious Diseases Society of America (IDSA) guidelines recommend the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    troches or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    <span class=\"nowrap\">",
"     suspension/pastilles",
"    </span>",
"    as first-line therapy for the management of mild oropharyngeal candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/33\">",
"     33",
"    </a>",
"    ]. It should be noted that most formulations of",
"    <span class=\"nowrap\">",
"     troches/pastilles",
"    </span>",
"    require saliva to dissolve and contain sugar for flavoring, which may exacerbate the risk for dental caries, especially in patients with hyposalivation. Further discussion of treatment is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of oropharyngeal and esophageal candidiasis\", section on 'Oropharyngeal candidiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99499226\">",
"    <span class=\"h2\">",
"     Recurrent herpes simplex virus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic GVHD who require long-term immunosuppressive therapy are at risk for reactivation of herpes simplex virus (HSV). Pain and discomfort are common with active HSV infection, and can lower intake of fluid and nutrients, which in severe cases can lead to dehydration and malnutrition, requiring hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/34\">",
"     34",
"    </a>",
"    ]. Although the risk of viral outbreaks can be reduced with antiviral prophylaxis, patients are still at risk for &ldquo;breakthrough&rdquo; infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\", section on 'Transplant recipients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HSV lesions generally appear as solitary or crop-like groupings of shallow mucosal ulcerations that are typically highly painful, even when the size is very small; a crusted appearance is generally only encountered on the lips (",
"    <a class=\"graphic graphic_picture graphicRef86806 \" href=\"UTD.htm?24/38/25184\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/35\">",
"     35",
"    </a>",
"    ]. The diagnosis of oral HSV infection can often be made clinically based on the history and presenting features. Confirmatory laboratory diagnosis with viral culture can be helpful in cases of breakthrough infection, or when the diagnosis is unclear.",
"   </p>",
"   <p>",
"    For patients with recurrent HSV infections, management is similar to the treatment of immunocompetent patients with HSV reactivation disease. This may entail episodic treatment using oral antiviral agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    ) during outbreaks, and chronic antiviral therapy as a means to suppress outbreaks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\", section on 'Recurrent infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99499233\">",
"    <span class=\"h2\">",
"     Oral chronic graft-versus-host disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with chronic GVHD, involvement of the oral mucosa is common, with upwards of 80 percent of patients affected [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/12\">",
"     12",
"    </a>",
"    ]. These patients are at an increased risk for dental caries due to chronic treatment-related salivary gland hypofunction. Despite systemic therapies, patients often require intensive localized ancillary measures to control symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/12,13,36,37\">",
"     12,13,36,37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H248884158\">",
"     'Chronic salivary gland hypofunction'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42073?source=see_link&amp;anchor=H733440#H733440\">",
"     \"Cutaneous manifestations of graft-versus-host disease (GVHD)\", section on 'Oral lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary symptom associated with oral mucosal chronic GVHD is sensitivity, such that normally tolerated foods and drinks become painful, potentially affecting nutrition and quality of life. As a result, patients need to modify their diets to avoid foods that are no longer tolerated. In rare cases, long-standing oral chronic GVHD inflammation can result in band-like fibrosis of the buccal mucosa leading to trismus. (See",
"    <a class=\"local\" href=\"#H1317823764\">",
"     'Trismus'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Lacy or reticulated white plaques that resemble Wickham striae of lichen planus may occur on the tongue, buccal mucosa, lips, or palate (",
"    <a class=\"graphic graphic_picture graphicRef86223 \" href=\"UTD.htm?27/62/28641\">",
"     picture 3",
"    </a>",
"    ). Hyperkeratotic plaques, mucosal erythema, erosions, and ulceration can also occur. Associated pain may inhibit oral intake [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/38\">",
"     38",
"    </a>",
"    ]. Criteria to make the diagnosis of oral chronic GVHD has been defined by a 2005 consensus panel of the National Institutes of Health (",
"    <a class=\"graphic graphic_table graphicRef86226 \" href=\"UTD.htm?13/44/14027\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Management of oral mucosal chronic GVHD is largely driven by symptoms, with the primary goals directed at diminishing pain and sensitivity and maintaining the patient's ability to eat. Although patients may be on systemic immunosuppressive therapy for management of chronic GVHD, aggressive ancillary measures such as topical corticosteroids or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    may be necessary to provide symptomatic relief [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/39-44\">",
"     39-44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42073?source=see_link&amp;anchor=H3496567#H3496567\">",
"     \"Cutaneous manifestations of graft-versus-host disease (GVHD)\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248884468\">",
"    <span class=\"h2\">",
"     Osteonecrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis can occur as a complication of bone modifying agents or as a consequence of RT to the head and neck. These are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616316330\">",
"    <span class=\"h3\">",
"     Due to bone modifying agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer survivors taking bone modifying agents are at risk for osteonecrosis of the jaw (ONJ), which is characterized by the presence of exposed bone in the oral cavity that persists for greater than eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/45-50\">",
"     45-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients suffering from ONJ may experience a substantial deterioration in their quality of life due to chronic pain, difficulty eating, and facial deformation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/51\">",
"     51",
"    </a>",
"    ]. Secondary infection of the surrounding soft tissue is common, presenting with painful erythema, swelling, and purulence. Some patients with ONJ may also present with complaints of dysesthesia or paresthesia in the affected area due to inflammatory or infectious involvement of the neurovascular bundle around the necrotic bone, or due to increased bone deposition and narrowing of the nerve canal. A clinical staging system for ONJ developed by the American Association of Oral and Maxillofacial Surgeons can be helpful in categorizing patients based on severity of symptoms and need for treatment (",
"    <a class=\"graphic graphic_table graphicRef69275 \" href=\"UTD.htm?5/27/5564\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928365#H1928365\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of ONJ is based primarily upon clinical signs of ulceration of the mucosa (ie, complete loss of overlying mucosa) with exposure of necrotic bone. Radiographic features of ONJ include mixed",
"    <span class=\"nowrap\">",
"     radiopaque/radiolucent",
"    </span>",
"    lesions, often with a mottled appearance. In more advanced cases, osteolytic changes can extend to the inferior border of the mandible. In most cases intraoral and panoramic radiography are sufficient; however, in cases of suspected pathological fractures, CT scans may be indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928351#H1928351\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients receiving anti-resorptive therapy, it remains unclear whether or not discontinuation of therapy (bisphosphonate &ldquo;holidays&rdquo;) reduces the risk of developing ONJ. Given the long half-life of bisphosphonates, discontinuation of treatment likely does not significantly impact on the course of ONJ [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H8703756#H8703756\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Discontinuation of bone modifying agent therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of cases of ONJ are associated with secondary soft tissue infection; therefore, management includes topical and systemic antimicrobial agents. Patients should be instructed to gently brush exposed bone to reduce plaque accumulations. Other treatment for ONJ is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928489#H1928489\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354997706\">",
"    <span class=\"h3\">",
"     Due to radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of exposed bone in a previously irradiated field in the absence of recurrent or residual tumor is defined as osteoradionecrosis. It is commonly precipitated by an injury (surgery, dental extractions, poor dentition, or infection) to hypoxic bone tissue. Symptoms of osteoradionecrosis can include pain, bad breath, dysgeusia, dysesthesia or anesthesia, trismus, difficulty with chewing and swallowing, speech difficulties, fistula formation, pathologic fracture, and infection. In some cases, it may be diagnosed shortly after completion of RT, while in other patients it may not be diagnosed for years after the original cancer treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822453#H3822453\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Osteoradionecrosis and soft tissue necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mandible is the most frequently affected bone, because a large part of the mandible is exposed to high doses of radiation in the majority of patients treated for head and neck cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/54\">",
"     54",
"    </a>",
"    ]. Maxillary osteoradionecrosis is rare, and seen most often in the setting of irradiation for nasopharyngeal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of osteoradionecrosis is complex. For mild cases of osteoradionecrosis, conservative debridement and antibiotics are usually successful [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/56\">",
"     56",
"    </a>",
"    ]. However, when bone and soft tissue necrosis are extensive, resection of the mandible with immediate microvascular reconstruction may provide better results [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Many dentists prescribe hyperbaric oxygen to treat or prevent osteoradionecrosis. However, its use is generally governed by institutional guidelines. For any patient with osteoradionecrosis, recurrent cancer must always be considered in the differential diagnosis of exposed mandible or maxilla. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822503#H3822503\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1317823764\">",
"    <span class=\"h2\">",
"     Trismus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trismus is the inability to fully open the mouth and is a common complication of treatment for head and neck cancer. Clinically, trismus is defined as a maximum interincisal opening &lt;35 mm, which is measured using a specialized device [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/60\">",
"     60",
"    </a>",
"    ]. Trismus can result in reduced nutrition due to impaired mastication, poor oral hygiene, pain and myospasms, and an overall reduced quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822571#H3822571\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Trismus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of trismus requires lifelong physical therapy, which involves self-directed passive range of motion exercises [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The most basic approaches involve using two hands to stretch the jaw passively (completely relaxed) or stacking tongue depressors into the oral cavity. Physical therapy devices engineered specifically for the management of trismus are available by prescription and should be considered in patients with more severe trismus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Maintenance of oral hygiene is of particular importance as dental care is difficult in patients with limited ability to fully open their mouth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1145025623\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of a new malignancy involving the oral cavity is related to the type of initial cancer, prior treatment received, and underlying personal risk factors such as smoking or family history [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In general, patients with head and neck squamous cell carcinoma, patients with GVHD, and those previously treated with HCT are at particular risk of a new primary and for recurrence involving the oral cavity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\", section on 'Other'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H707301933#H707301933\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Second malignancies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metastatic cancer to the oral cavity is uncommon from other solid tumors is rare, accounting for approximately 1 to 2 percent of all oral malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/68\">",
"     68",
"    </a>",
"    ]. The most frequent cancers that metastasize to the oral cavity include lung (22.5 percent), breast (18 percent), kidney (12 percent), and liver (8.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Routes of metastasis include arterial, venous and lymphatic circulation, and lesions can involve soft tissue and bone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/71\">",
"     71",
"    </a>",
"    ]. Management depends on the underlying primary diagnosis, whether or not the oral lesion is the only area of metastasis, and symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13826889\">",
"    <span class=\"h1\">",
"     APPROACH TO THE CANCER PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;All cancer survivors, regardless of their level of risk for developing oral and dental complications, require routine dental care including recall visits and",
"    <span class=\"nowrap\">",
"     scaling/prophylaxis.",
"    </span>",
"    For patients at high risk, we suggest evaluation at least twice a year.",
"   </p>",
"   <p>",
"    There is no consensus for what is considered &ldquo;necessary&rdquo; dental treatment for high-risk cancer survivors. However, dentists should play an active role in educating patients regarding the possible signs and symptoms of oral complications. Maintaining good gingival health with daily tooth brushing and flossing is important to reduce the risk of caries and periodontal disease (",
"    <a class=\"graphic graphic_table graphicRef86225 \" href=\"UTD.htm?19/26/19884\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H248884158\">",
"     'Chronic salivary gland hypofunction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355000222\">",
"    <span class=\"h2\">",
"     Communication with the dental provider",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important that the dentist and oncologist maintain communication so that each provider is aware of relevant findings and potential complications of treatment. Dentists should be provided with: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Information regarding the cancer diagnosis (ie, type of cancer, date of cancer diagnosis, treatment rendered, and current status)",
"     </li>",
"     <li>",
"      A history of complications or serious events during cancer therapy or since completion of therapy",
"     </li>",
"     <li>",
"      A list of medications, especially if patients were previously prescribed or continue to take a bone modifying agent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1145026193\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoral dental radiographs, particularly bitewing radiographs, are required to assess for decay. Whereas these are typically obtained every one to two years in otherwise healthy patients, they may be needed as frequently as every four to six months in patients with a history of significant dental caries developing after completion of cancer therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14185/abstract/72\">",
"     72",
"    </a>",
"    ]. Advanced imaging studies, such as computed tomography (CT",
"    <em>",
"     )",
"    </em>",
"    and",
"    <em>",
"    </em>",
"    magnetic resonance imaging (MRI), may be indicated to examine suspected lesions in the bone and salivary glands and to evaluate for the presence of possible metastatic lesions (",
"    <a class=\"graphic graphic_figure graphicRef85780 \" href=\"UTD.htm?4/7/4211\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1317823806\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most cancer survivors, there are no specific oral health considerations or expected late complications. However, cancer survivors prescribed bone-modifying agents, survivors of head and neck cancer, childhood cancer survivors, and patients treated on protocols involving high-dose chemotherapy and stem cell transplantation (HCT-SCT) constitute high-risk groups for oral health complications. (See",
"      <a class=\"local\" href=\"#H1145025465\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Newly diagnosed cancer patients be referred for a thorough oral examination prior to initiation of therapy to ensure any actively infected teeth are extracted prior to initiation of cancer therapy. (See",
"      <a class=\"local\" href=\"#H799559710\">",
"       'Preventing oral complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral health problems in childhood cancer survivors are due to chemotherapy and radiotherapy to the head and neck region, which can have a significant impact on growth and development of the teeth. Oral complications include an increased risk for microdontia, dental caries, and premature loss of teeth. (See",
"      <a class=\"local\" href=\"#H799559553\">",
"       'Childhood cancer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H99498948\">",
"       'Abnormal dental development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation (HCT-SCT) are at risk for oral health complications, particularly after an allogeneic HCT transplant because these patients are at risk for graft versus host disease (GVHD). Oral chronic GVHD also places patients at risk for recurrent infections (due to prolonged immunosuppression). (See",
"      <a class=\"local\" href=\"#H248884016\">",
"       'Chronic graft-versus-host disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H99499219\">",
"       'Oral candidiasis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H99499226\">",
"       'Recurrent herpes simplex virus infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H99499233\">",
"       'Oral chronic graft-versus-host disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dental and oral complications are common among head and neck cancer survivors, including facial disfigurement, chronic salivary gland dysfunction, and trismus. They are also at an increased risk for secondary malignancies or cancer recurrence. (See",
"      <a class=\"local\" href=\"#H17363020\">",
"       'Head and neck cancer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34521990\">",
"       'Facial disfigurement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H248884158\">",
"       'Chronic salivary gland hypofunction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1317823764\">",
"       'Trismus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1145025623\">",
"       'Malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are currently being treated with (or were treated with) bone modifying agents are at risk for developing osteonecrosis of the jaw. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"       \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/1\">",
"      Epstein JB, Emerton S, Kolbinson DA, et al. Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck 1999; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/2\">",
"      Schi&oslash;dt M, Hermund NU. Management of oral disease prior to radiation therapy. Support Care Cancer 2002; 10:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/3\">",
"      Hancock PJ, Epstein JB, Sadler GR. Oral and dental management related to radiation therapy for head and neck cancer. J Can Dent Assoc 2003; 69:585.",
"     </a>",
"    </li>",
"    <li>",
"     American Cancer Society. Cancer Facts &amp; Figures 2012. Atlanta: American Cancer Society; 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/5\">",
"      Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/6\">",
"      Barber&iacute;a E, Hernandez C, Miralles V, Maroto M. Paediatric patients receiving oncology therapy: review of the literature and oral management guidelines. Eur J Paediatr Dent 2008; 9:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/7\">",
"      Pedersen LB, Clausen N, Schr&oslash;der H, et al. Microdontia and hypodontia of premolars and permanent molars in childhood cancer survivors after chemotherapy. Int J Paediatr Dent 2012; 22:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/8\">",
"      Goho C. Chemoradiation therapy: effect on dental development. Pediatr Dent 1993; 15:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/9\">",
"      Kaste SC, Goodman P, Leisenring W, et al. Impact of radiation and chemotherapy on risk of dental abnormalities: a report from the Childhood Cancer Survivor Study. Cancer 2009; 115:5817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/10\">",
"      Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/11\">",
"      Gilliam AC. Update on graft versus host disease. J Invest Dermatol 2004; 123:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/12\">",
"      Imanguli MM, Alevizos I, Brown R, et al. Oral graft-versus-host disease. Oral Dis 2008; 14:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/13\">",
"      Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/14\">",
"      Andrews N, Griffiths C. Dental complications of head and neck radiotherapy: Part 1. Aust Dent J 2001; 46:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/15\">",
"      Andrews N, Griffiths C. Dental complications of head and neck radiotherapy: Part 2. Aust Dent J 2001; 46:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/16\">",
"      Koga DH, Salvajoli JV, Alves FA. Dental extractions and radiotherapy in head and neck oncology: review of the literature. Oral Dis 2008; 14:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/17\">",
"      McGuire DB, Johnson J, Migliorati C. Promulgation of guidelines for mucositis management: educating health care professionals and patients. Support Care Cancer 2006; 14:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/18\">",
"      Kerawala CJ. Complications of head and neck cancer surgery - prevention and management. Oral Oncol 2010; 46:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/19\">",
"      Kerawala CJ, Heliotos M. Prevention of complications in neck dissection. Head Neck Oncol 2009; 1:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/20\">",
"      Denaro N, Russi EG, Adamo V, et al. Postoperative therapy in head and neck cancer: state of the art, risk subset, prognosis and unsolved questions. Oncology 2011; 81:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/21\">",
"      Jensen SB, Mouridsen HT, Reibel J, et al. Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction. Oral Oncol 2008; 44:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/22\">",
"      Ghezzi EM, Lange LA, Ship JA. Determination of variation of stimulated salivary flow rates. J Dent Res 2000; 79:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/23\">",
"      Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res 1987; 66 Spec No:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/24\">",
"      Sreebny LM. Saliva in health and disease: an appraisal and update. Int Dent J 2000; 50:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/25\">",
"      Jensen SB, Pedersen AM, Vissink A, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 2010; 18:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/26\">",
"      Brosky ME. The role of saliva in oral health: strategies for prevention and management of xerostomia. J Support Oncol 2007; 5:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/27\">",
"      Jellema AP, Slotman BJ, Doornaert P, et al. Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/28\">",
"      Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, et al. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 2008; 26:3770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/29\">",
"      Cannon RD, Holmes AR, Mason AB, Monk BC. Oral Candida: clearance, colonization, or candidiasis? J Dent Res 1995; 74:1152.",
"     </a>",
"    </li>",
"    <li>",
"     Schubert MM. Oral complications of hematopoietic cell transplantation. In: Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Wiley-Blackwell, Oxford 2009. p.1589.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/31\">",
"      Lalla RV, Latortue MC, Hong CH, et al. A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer 2010; 18:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/32\">",
"      Epstein JB, Freilich MM, Le ND. Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol 1993; 76:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/33\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/34\">",
"      Elad S, Zadik Y, Hewson I, et al. A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea. Support Care Cancer 2010; 18:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/35\">",
"      Arduino PG, Porter SR. Herpes Simplex Virus Type 1 infection: overview on relevant clinico-pathological features. J Oral Pathol Med 2008; 37:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/36\">",
"      Treister NS, Woo SB, O'Holleran EW, et al. Oral chronic graft-versus-host disease in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/37\">",
"      Treister NS, Cook EF Jr, Antin J, et al. Clinical evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/38\">",
"      Imanguli MM, Pavletic SZ, Guadagnini JP, et al. Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/39\">",
"      Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/40\">",
"      Elad S, Zeevi I, Finke J, et al. Improvement in oral chronic graft-versus-host disease with the administration of effervescent tablets of topical budesonide-an open, randomized, multicenter study. Biol Blood Marrow Transplant 2012; 18:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/41\">",
"      Meier JK, Wolff D, Pavletic S, et al. Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. Clin Oral Investig 2011; 15:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/42\">",
"      Albert MH, Becker B, Schuster FR, et al. Oral graft vs. host disease in children--treatment with topical tacrolimus ointment. Pediatr Transplant 2007; 11:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/43\">",
"      Eckardt A, Starke O, Stadler M, et al. Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Oral Oncol 2004; 40:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/44\">",
"      Bauters T, Bordon V, Van de Velde V, et al. Highly effective treatment with tacrolimus ointment in an adolescent with oral graft-versus-host disease. Pharm World Sci 2010; 32:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/45\">",
"      Chrcanovic BR, Reher P, Sousa AA, Harris M. Osteoradionecrosis of the jaws--a current overview--part 1: Physiopathology and risk and predisposing factors. Oral Maxillofac Surg 2010; 14:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/46\">",
"      Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21:4253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/47\">",
"      Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/48\">",
"      Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/49\">",
"      Fusco V, Galassi C, Berruti A, et al. Osteonecrosis of the jaw after zoledronic acid and denosumab treatment. J Clin Oncol 2011; 29:e521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/50\">",
"      Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol 2012; 8:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/51\">",
"      Migliorati CA, Woo SB, Hewson I, et al. A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer 2010; 18:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/52\">",
"      Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J 2009; 35:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/53\">",
"      Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaws. Compend Contin Educ Dent 2008; 29:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/54\">",
"      Chopra S, Kamdar D, Ugur OE, et al. Factors predictive of severity of osteoradionecrosis of the mandible. Head Neck 2011; 33:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/55\">",
"      Cheng SJ, Lee JJ, Ting LL, et al. A clinical staging system and treatment guidelines for maxillary osteoradionecrosis in irradiated nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2006; 64:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/56\">",
"      Pitak-Arnnop P, Sader R, Dhanuthai K, et al. Management of osteoradionecrosis of the jaws: an analysis of evidence. Eur J Surg Oncol 2008; 34:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/57\">",
"      Shaha AR, Cordeiro PG, Hidalgo DA, et al. Resection and immediate microvascular reconstruction in the management of osteoradionecrosis of the mandible. Head Neck 1997; 19:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/58\">",
"      Hao SP, Chen HC, Wei FC, et al. Systematic management of osteoradionecrosis in the head and neck. Laryngoscope 1999; 109:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/59\">",
"      Notani K, Yamazaki Y, Kitada H, et al. Management of mandibular osteoradionecrosis corresponding to the severity of osteoradionecrosis and the method of radiotherapy. Head Neck 2003; 25:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/60\">",
"      Dijkstra PU, Kalk WW, Roodenburg JL. Trismus in head and neck oncology: a systematic review. Oral Oncol 2004; 40:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/61\">",
"      Bensadoun RJ, Riesenbeck D, Lockhart PB, et al. A systematic review of trismus induced by cancer therapies in head and neck cancer patients. Support Care Cancer 2010; 18:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/62\">",
"      Dijkstra PU, Sterken MW, Pater R, et al. Exercise therapy for trismus in head and neck cancer. Oral Oncol 2007; 43:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/63\">",
"      Grandi G, Silva ML, Streit C, Wagner JC. A mobilization regimen to prevent mandibular hypomobility in irradiated patients: an analysis and comparison of two techniques. Med Oral Patol Oral Cir Bucal 2007; 12:E105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/64\">",
"      Melchers LJ, Van Weert E, Beurskens CH, et al. Exercise adherence in patients with trismus due to head and neck oncology: a qualitative study into the use of the Therabite. Int J Oral Maxillofac Surg 2009; 38:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/65\">",
"      Stubblefield MD, Manfield L, Riedel ER. A preliminary report on the efficacy of a dynamic jaw opening device (dynasplint trismus system) as part of the multimodal treatment of trismus in patients with head and neck cancer. Arch Phys Med Rehabil 2010; 91:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/66\">",
"      Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989; 321:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/67\">",
"      Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87:3633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/68\">",
"      Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R. Metastatic tumours to the oral cavity - pathogenesis and analysis of 673 cases. Oral Oncol 2008; 44:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/69\">",
"      Zachariades N. Neoplasms metastatic to the mouth, jaws and surrounding tissues. J Craniomaxillofac Surg 1989; 17:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/70\">",
"      Pires FR, de Almeida OP, de Ara&uacute;jo VC, Kowalski LP. Prognostic factors in head and neck mucoepidermoid carcinoma. Arch Otolaryngol Head Neck Surg 2004; 130:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/71\">",
"      Rodan GA. The development and function of the skeleton and bone metastases. Cancer 2003; 97:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14185/abstract/72\">",
"      Castellarin P, Stevenson K, Biasotto M, et al. Extensive dental caries in patients with oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012; 18:1573.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16346 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_54_14185=[""].join("\n");
var outline_f13_54_14185=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1317823806\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1145025465\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H799559488\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17362950\">",
"      Bone-modifying agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17363020\">",
"      Head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H799559553\">",
"      Childhood cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H248884016\">",
"      Chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H799559710\">",
"      PREVENTING ORAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34521974\">",
"      TREATMENT-RELATED COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H99498948\">",
"      Abnormal dental development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34521990\">",
"      Facial disfigurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H248884158\">",
"      Chronic salivary gland hypofunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H99499219\">",
"      Oral candidiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H99499226\">",
"      Recurrent herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H99499233\">",
"      Oral chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H248884468\">",
"      Osteonecrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H616316330\">",
"      - Due to bone modifying agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H354997706\">",
"      - Due to radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1317823764\">",
"      Trismus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1145025623\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13826889\">",
"      APPROACH TO THE CANCER PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H355000222\">",
"      Communication with the dental provider",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1145026193\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1317823806\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16346\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16346|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/7/4211\" title=\"figure 1\">",
"      Metastatic breast cancer involving the mandible",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16346|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/10/21667\" title=\"picture 1\">",
"      Pseudomembranous candidiasis soft palate and buccal mucosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/38/25184\" title=\"picture 2\">",
"      HSV recrudescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/62/28641\" title=\"picture 3\">",
"      Oral chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16346|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/63/35837\" title=\"table 1\">",
"      Acute and late oral complications associated with cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/44/14027\" title=\"table 2\">",
"      NIH consensus criteria for diagnosis of GVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/27/5564\" title=\"table 3\">",
"      Clinical classification of ONJ related to bone modifying agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/26/19884\" title=\"table 4\">",
"      Prevention of dental caries in high-risk individuals",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42073?source=related_link\">",
"      Cutaneous manifestations of graft-versus-host disease (GVHD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43959?source=related_link\">",
"      Overview of treatment for head and neck squamous cell cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35530?source=related_link\">",
"      The approach to hematopoietic cell transplantation survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=related_link\">",
"      Treatment of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_54_14186="Approach to the patient with cutaneous blisters";
var content_f13_54_14186=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with cutaneous blisters",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/54/14186/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/54/14186/contributors\">",
"     Christopher Hull, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/54/14186/contributors\">",
"     John J Zone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/54/14186/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/54/14186/contributors\">",
"     Erik Stratman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/54/14186/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/54/14186/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/54/14186/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H35462837\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous blisters can occur in a wide variety of clinical settings, including autoimmune disorders, drug reactions, infections, genetic disorders, and physical injury. The ability to narrow the differential diagnosis for patients with blistering skin lesions is essential for the prompt recognition of life-threatening disorders and the appropriate management of other blistering diseases.",
"   </p>",
"   <p>",
"    The clinical approach to the diagnosis of disorders that present with cutaneous blisters and a summary of common investigative tests used to assist with diagnosis is discussed here. Blistering disorders in the newborn infant and specific blistering disorders are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15864?source=see_link\">",
"     \"Vesiculobullous and pustular lesions in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48262289\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blistering skin disorders are characterized by the presence of fluid-filled lesions on the skin that occur as a result of a loss of adhesion between cells within the epidermis (",
"    <strong>",
"     acantholysis",
"    </strong>",
"    ), edema between epidermal cells (",
"    <strong>",
"     spongiosis",
"    </strong>",
"    ), or disassociation of the epidermis and dermis. Pathologic events that may lead to the formation of blisters include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Disruption of cellular or extracellular adhesion molecules",
"      </strong>",
"      (eg, autoimmune blistering disorders, congenital epidermolysis bullosa)",
"     </li>",
"     <li>",
"      <strong>",
"       Epidermal cell injury or death",
"      </strong>",
"      (eg, toxic epidermal necrolysis, erythema multiforme)",
"     </li>",
"     <li>",
"      <strong>",
"       Accumulation of excessive edema (spongiosis) within the epidermis",
"      </strong>",
"      (eg, contact dermatitis, acute and chronic vesicular palmoplantar dermatitis)",
"     </li>",
"     <li>",
"      <strong>",
"       Traumatic injury",
"      </strong>",
"      (eg, friction blisters)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific terms are used to describe cutaneous blisters based upon lesion size.",
"    <strong>",
"     Vesicles",
"    </strong>",
"    are usually designated as lesions that are less than 1 cm in diameter (",
"    <a class=\"graphic graphic_picture graphicRef81443 \" href=\"UTD.htm?5/57/6039\">",
"     picture 1A",
"    </a>",
"    ). In contrast,",
"    <strong>",
"     bullae",
"    </strong>",
"    are classified as lesions that are greater than 1 cm in size (",
"    <a class=\"graphic graphic_picture graphicRef57569 \" href=\"UTD.htm?6/25/6551\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The watery clear fluid content of vesicles and bullae distinguishes these lesions from pustules, which contain thicker, yellow-white purulent material. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28423?source=see_link\">",
"     \"Approach to the patient with pustular skin lesions\"",
"    </a>",
"    .) Although the clear fluid contents of vesicles and bullae may develop a more turbid quality over time, the watery quality is retained and such lesions are still easily distinguished from pustules. In cases in which blister formation is associated with damage to the blood vessels in the dermis, red blood cells may enter the blister cavity, resulting in red-colored blister fluid. The term &rdquo;",
"    <strong>",
"     hemorrhagic blister",
"    </strong>",
"    &rdquo; is used to refer to such lesions.",
"   </p>",
"   <p>",
"    Blisters may occur at a variety of sites within the skin, and the location in which blisters form is often useful for diagnosis and can be determined via histopathologic examination (",
"    <a class=\"graphic graphic_table graphicRef74129 \" href=\"UTD.htm?22/31/23036\">",
"     table 1",
"    </a>",
"    ). The general categories used to describe the location of blister formation include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Intracorneal or subcorneal",
"      </strong>",
"      &ndash; Cleavage plane within the stratum corneum or immediately beneath the stratum corneum (eg, pemphigus foliaceus, staphylococcal scalded skin syndrome) (",
"      <a class=\"graphic graphic_picture graphicRef57313 \" href=\"UTD.htm?24/20/24904\">",
"       picture 3",
"      </a>",
"      ) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Intraepidermal",
"      </strong>",
"      &ndash; Cleavage plane within the malpighian layer of the epidermis, excluding subcorneal and suprabasilar disorders (eg, contact dermatitis, viral infections) (",
"      <a class=\"graphic graphic_picture graphicRef82841 graphicRef82840 \" href=\"UTD.htm?35/36/36426\">",
"       picture 4A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Suprabasilar",
"      </strong>",
"      &ndash; Cleavage plane within the epidermis with only an intact basal layer (",
"      <a class=\"graphic graphic_picture graphicRef60749 \" href=\"UTD.htm?32/25/33173\">",
"       picture 5A",
"      </a>",
"      ) (eg, pemphigus vulgaris, paraneoplastic pemphigus)",
"     </li>",
"     <li>",
"      <strong>",
"       Subepidermal",
"      </strong>",
"      &ndash; Cleavage plane within or below the basement membrane zone (",
"      <a class=\"graphic graphic_picture graphicRef66267 \" href=\"UTD.htm?43/15/44279\">",
"       picture 5B",
"      </a>",
"      ) (eg, bullous pemphigoid, porphyria cutanea tarda)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical features of a blistering disorder often correlate with the histopathologic subtype. Whereas subcorneal blistering disorders tend to present with extremely fragile blisters that quickly evolve to scale and desquamation, slightly less fragile flaccid vesicles or bullae are characteristic of intraepidermal or suprabasilar blisters. Lastly, tense bullae are typically seen in subepidermal blistering disorders due to the relatively greater proportion of epidermis overlying the blister cavity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4714603\">",
"    <span class=\"h1\">",
"     LIFE-THREATENING EMERGENCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several blistering disorders represent potentially life-threatening emergencies, warranting the need for early diagnosis and therapy. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Toxic epidermal necrolysis",
"      </strong>",
"      &ndash; Widespread sloughing of skin in this disorder is associated with risk for sepsis (",
"      <a class=\"graphic graphic_picture graphicRef67632 graphicRef68458 graphicRef59418 \" href=\"UTD.htm?36/39/37497\">",
"       picture 6A-C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H32804630\">",
"       'Generalized blisters with systemic illness'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Staphylococcal scalded skin syndrome",
"      </strong>",
"      &ndash; A high mortality rate occurs in adults with this disorder (",
"      <a class=\"graphic graphic_picture graphicRef80198 graphicRef72261 \" href=\"UTD.htm?3/9/3225\">",
"       picture 7A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H32804630\">",
"       'Generalized blisters with systemic illness'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Disseminated herpes simplex or herpes zoster infection in immunosuppressed patients",
"      </strong>",
"      &ndash; May result in life-threatening internal complications (",
"      <a class=\"graphic graphic_picture graphicRef77688 \" href=\"UTD.htm?11/48/12034\">",
"       picture 8",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H32804630\">",
"       'Generalized blisters with systemic illness'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Purpura fulminans",
"      </strong>",
"      &ndash; Although retiform purpura are the primary feature of purpura fulminans, associated necrotic bullae may also be present (",
"      <a class=\"graphic graphic_picture graphicRef57103 \" href=\"UTD.htm?15/39/15987\">",
"       picture 9",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39608?source=see_link&amp;anchor=H136707379#H136707379\">",
"       \"Approach to the patient with retiform (angulated) purpura\", section on 'Life-threatening emergency (purpura fulminans)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35462844\">",
"    <span class=\"h1\">",
"     PATIENT ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blistering skin lesions can present a diagnostic challenge since the differential diagnosis is vast. The recognition of the distribution of the lesions is a useful clinical tool to begin to narrow the differential diagnosis. A thorough patient history, the identification of additional clinical features, and pathologic and laboratory studies are often of additional value.",
"   </p>",
"   <p>",
"    Examples of questions that may be useful during the assessment of the patient with cutaneous blisters include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Where are the lesions located (generalized, localized, specific sites)?",
"     </li>",
"     <li>",
"      Are mucous membranes involved?",
"     </li>",
"     <li>",
"      What is the size and configuration of blisters?",
"     </li>",
"     <li>",
"      If bullae are present, are they flaccid or tense?",
"     </li>",
"     <li>",
"      What is the patient&rsquo;s age?",
"     </li>",
"     <li>",
"      Does the patient have a history of exposure to a new medication?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H320145\">",
"    <span class=\"h2\">",
"     Lesion distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of cutaneous blisters as generalized, localized, or associated with mucous membrane involvement can offer valuable clues for diagnosis (",
"    <a class=\"graphic graphic_table graphicRef60255 graphicRef82490 graphicRef67630 \" href=\"UTD.htm?6/7/6271\">",
"     table 2A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32804617\">",
"    <span class=\"h3\">",
"     Generalized distribution",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32804630\">",
"    <span class=\"h4\">",
"     Generalized blisters with systemic illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute or chronic signs or symptoms of systemic illness are frequent features of several disorders that present with generalized blisters. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Stevens-Johnson syndrome and toxic epidermal necrolysis",
"      </strong>",
"      &ndash; Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN) are acute, severe disorders characterized by epidermal sloughing of the skin and mucous membranes. These conditions most commonly occur as a result of exposure to an inciting medication [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/2\">",
"       2",
"      </a>",
"      ]. Following a brief prodromal period of fever and flu-like symptoms, patients develop painful erythematous and purpuric macules or areas of diffuse macular erythema that progress to vesicles, bullae, and skin sloughing (",
"      <a class=\"graphic graphic_picture graphicRef67632 graphicRef68458 graphicRef59418 graphicRef68682 \" href=\"UTD.htm?30/3/30778\">",
"       picture 6A-D",
"      </a>",
"      ). The extent of body surface area involvement differentiates Stevens-Johnson syndrome (&lt;10 percent) from TEN (&gt;30 percent). Skin biopsies of fully developed lesions demonstrate epidermal-dermal separation and full-thickness epidermal necrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Staphylococcal scalded skin syndrome",
"      </strong>",
"      &ndash; Staphylococcal scalded syndrome occurs as a reaction to toxin released by",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      , and most commonly occurs in infants, young children, and adults with renal failure. Fever, malaise, and skin tenderness typically precede the eruption. The fragile subcorneal bullae often demonstrate the appearance of wrinkled skin with subsequent desquamation (",
"      <a class=\"graphic graphic_picture graphicRef80198 graphicRef72261 graphicRef50249 \" href=\"UTD.htm?17/53/18266\">",
"       picture 7A-C",
"      </a>",
"      ). Examination of a frozen tissue specimen of sloughed epidermis can be used to rapidly distinguish staphylococcal scalded skin from the epidermal sloughing of toxic epidermal necrolysis. Frozen sections taken from staphylococcal scalded skin syndrome demonstrate cleavage at the granular layer, whereas full-thickness epidermal necrosis and cleavage at the dermal-epidermal junction characterize toxic epidermal necrolysis. The site of the primary staphylococcal infection also should be identified. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15864?source=see_link&amp;anchor=H8#H8\">",
"       \"Vesiculobullous and pustular lesions in the newborn\", section on 'Staphylococcal scalded skin syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Varicella zoster virus infection",
"      </strong>",
"      &ndash; Varicella (chicken pox) is a disorder that most frequently occurs in children who are not vaccinated against the disease. Patients experience a prodrome of fever and malaise followed by the development of a generalized eruption of 1 to 3 mm intraepidermal or subepidermal vesicles surrounded by erythema. These lesions are often described as &ldquo;dew drops on a rose petal,&rdquo; and subsequently evolve to form pustules and crusts (",
"      <a class=\"graphic graphic_picture graphicRef72210 graphicRef55533 \" href=\"UTD.htm?20/55/21369\">",
"       picture 10A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=see_link\">",
"       \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Disseminated herpes zoster",
"      </strong>",
"      &ndash; Disseminated herpes zoster can occur in immunocompromised patients. Unlike classic herpes zoster, the vesicular lesions are not restricted to a dermatome (",
"      <a class=\"graphic graphic_picture graphicRef77688 \" href=\"UTD.htm?11/48/12034\">",
"       picture 8",
"      </a>",
"      ). Disseminated herpes zoster may also result in life-threatening infection including pneumonia, hepatitis, encephalitis, or other organ involvement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=see_link&amp;anchor=H22#H22\">",
"       \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\", section on 'Complications in immunocompromised hosts'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Disseminated herpes simplex virus",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Immunocompromised patients and patients with a compromised skin barrier (eg, atopic dermatitis, Darier disease) may develop widespread vesicles, pustules, and crusts due to herpes simplex virus infection. The term eczema herpeticum is used to describe this occurrence in patients with atopic dermatitis (",
"      <a class=\"graphic graphic_picture graphicRef62779 graphicRef51337 graphicRef74838 \" href=\"UTD.htm?17/51/18234\">",
"       picture 11A-C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link\">",
"       \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Sweet syndrome (acute febrile neutrophilic dermatosis)",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Although edematous, erythematous plaques with a pseudovesicular quality are most characteristic of Sweet syndrome, the plaques occasionally exhibit frank vesicle or bulla formation (",
"      <a class=\"graphic graphic_picture graphicRef50526 graphicRef62314 \" href=\"UTD.htm?21/9/21657\">",
"       picture 12A-B",
"      </a>",
"      ). &nbsp;The plaques are most frequently found on the upper body; fever and leukocytosis are also typically present. Sweet syndrome may occur in the setting of malignancy, infection, drug exposure, autoimmune disease, or inflammatory bowel disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40905?source=see_link\">",
"       \"Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bullous systemic lupus erythematosus",
"      </strong>",
"      &ndash; Bullous systemic lupus erythematosus presents as widespread, tense, subepidermal bullae in patients with systemic lupus erythematosus. The skin lesions may resemble bullous pemphigoid or dermatitis herpetiformis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/3\">",
"       3",
"      </a>",
"      ]. Antibodies against type VII collagen have been associated with this disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link&amp;anchor=H10#H10\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Bullous skin lesions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Paraneoplastic pemphigus",
"      </strong>",
"      &ndash; Paraneoplastic pemphigus is an uncommon mucocutaneous suprabasilar or subepidermal blistering disorder that occurs in the setting of malignancy. Stomatitis is characteristically severe (",
"      <a class=\"graphic graphic_picture graphicRef59594 \" href=\"UTD.htm?6/26/6562\">",
"       picture 13",
"      </a>",
"      ), but the morphology of skin lesions is variable [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/4\">",
"       4",
"      </a>",
"      ]. In some cases, the skin lesions may resemble blisters of pemphigus vulgaris or erythema multiforme. Non-Hodgkin lymphoma, chronic lymphocytic leukemia, and Castleman&rsquo;s disease are the conditions most commonly associated with this disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/4\">",
"       4",
"      </a>",
"      ]. Serological testing reveals reactivity with multiple antigens including desmoplakins, desmogleins, and bullous pemphigoid antigen 1 (BPAg1, BP230) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18121?source=see_link\">",
"       \"Paraneoplastic pemphigus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32805760\">",
"    <span class=\"h4\">",
"     Other generalized blistering disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of generalized blistering disorders that are not necessarily associated with systemic illness are listed below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Miliaria crystallina",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Miliaria crystallina results from the obstruction of the ducts of eccrine sweat glands, and usually occurs in the setting of excessive warmth. The fragile intracorneal or subcorneal 1 mm vesicles typically occur on the face and trunk (",
"      <a class=\"graphic graphic_picture graphicRef76069 \" href=\"UTD.htm?6/59/7095\">",
"       picture 14",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21878?source=see_link&amp;anchor=H4#H4\">",
"       \"Heat illness (other than heat stroke) in children\", section on 'Miliaria (heat rash)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bullous impetigo",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Subcorneal vesicles and bullae containing clear or yellow fluid on the face, trunk, perineum, or extremities characterize bullous impetigo, a disorder that most frequently occurs in neonates and children (",
"      <a class=\"graphic graphic_picture graphicRef63992 \" href=\"UTD.htm?0/48/768\">",
"       picture 15",
"      </a>",
"      ). The bullae rupture easily, leaving erosions with a collarette of scale. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=see_link&amp;anchor=H4#H4\">",
"       \"Impetigo\", section on 'Bullous impetigo'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pemphigus",
"      </strong>",
"      &ndash; The formation of multiple, large, flaccid bullae that quickly evolve to erosions are typical of pemphigus vulgaris (",
"      <a class=\"graphic graphic_picture graphicRef53425 \" href=\"UTD.htm?26/56/27526\">",
"       picture 16",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/7\">",
"       7",
"      </a>",
"      ]. Mucous membrane erosions are a frequent associated finding (",
"      <a class=\"graphic graphic_picture graphicRef57924 graphicRef77462 \" href=\"UTD.htm?21/18/21800\">",
"       picture 17A-B",
"      </a>",
"      ). The level of bulla formation in pemphigus vulgaris is suprabasilar. In contrast, the most prominent feature of pemphigus foliaceus, a subcorneal blistering disorder, is erythematous plaques with overlying scale or crust (",
"      <a class=\"graphic graphic_picture graphicRef54341 graphicRef72419 \" href=\"UTD.htm?5/49/5912\">",
"       picture 18A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bullous pemphigoid",
"      </strong>",
"      &ndash; Bullous pemphigoid is a subepidermal blistering disorder that most commonly occurs in older adults (",
"      <a class=\"graphic graphic_picture graphicRef78910 graphicRef72866 \" href=\"UTD.htm?5/15/5370\">",
"       picture 19A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/8\">",
"       8",
"      </a>",
"      ]. The classic skin lesions are urticarial plaques and tense bullae on the trunk and extremities. Intense pruritus is common, and lesions typically do not scar. Localized forms of bullous pemphigoid may also occur [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pemphigoid gestationis",
"      </strong>",
"      &ndash; Pemphigoid gestationis is a subepidermal blistering disorder that occurs during pregnancy or in the immediate postpartum period. Urticarial plaques and vesicles typically begin around the umbilicus prior to spreading elsewhere with large bulla formation (",
"      <a class=\"graphic graphic_picture graphicRef78383 graphicRef52776 graphicRef72690 \" href=\"UTD.htm?23/31/24057\">",
"       picture 20A-C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29657?source=see_link&amp;anchor=H2#H2\">",
"       \"Dermatoses of pregnancy\", section on 'Pemphigoid gestationis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Linear IgA bullous dermatosis",
"      </strong>",
"      &ndash; Linear IgA bullous dermatosis is a subepidermal blistering disorder associated with the deposition of IgA at the basement membrane zone of skin and mucosal tissues [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/10\">",
"       10",
"      </a>",
"      ]. This disorder may occur as a primary autoimmune disease or as a drug reaction. The cutaneous bullae often have a distinctive grouped appearance that resembles a cluster of jewels (",
"      <a class=\"graphic graphic_picture graphicRef56434 \" href=\"UTD.htm?15/62/16359\">",
"       picture 21",
"      </a>",
"      ). The term chronic bullous disease of childhood is used to refer to this disorder in children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14922?source=see_link\">",
"       \"Linear IgA bullous dermatosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dermatitis herpetiformis",
"      </strong>",
"      &ndash; Dermatitis herpetiformis is a cutaneous manifestation of gluten sensitivity that presents with grouped vesicles and excoriated papules with a predilection for the extensor extremities, scalp, and buttocks (",
"      <a class=\"graphic graphic_picture graphicRef78315 \" href=\"UTD.htm?23/38/24163\">",
"       picture 22",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. The lesions of this subepidermal blistering disorder are intensely pruritic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35369?source=see_link\">",
"       \"Dermatitis herpetiformis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Epidermolysis bullosa",
"      </strong>",
"      &ndash; Congenital epidermolysis bullosa is a rare genetic disorder that consists of multiple variants. Depending on the type of epidermolysis bullosa, lesions may be intraepidermal or subepidermal, localized or generalized, and detected as early as birth or not until adulthood (",
"      <a class=\"graphic graphic_picture graphicRef68938 \" href=\"UTD.htm?36/38/37475\">",
"       picture 23",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H13#H13\">",
"       \"The genodermatoses\", section on 'Epidermolysis bullosa'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Epidermolysis bullosa acquisita",
"      </strong>",
"      &ndash; Epidermolysis bullosa acquisita is a rare, acquired subepidermal blistering disorder that may affect both skin and mucous membranes (",
"      <a class=\"graphic graphic_picture graphicRef62505 \" href=\"UTD.htm?21/36/22085\">",
"       picture 24",
"      </a>",
"      ). Scarring and milia formation are common associated features. Antibodies against type VII collagen are pathogenic in this disease and can be measured in serum [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4858?source=see_link\">",
"       \"Epidermolysis bullosa acquisita\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32804610\">",
"    <span class=\"h3\">",
"     Localized distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recognition that blisters are primarily located in certain body locations, such as dependent areas, acral areas, or sun-exposed skin may assist with diagnosis (",
"    <a class=\"graphic graphic_table graphicRef82490 \" href=\"UTD.htm?39/5/40028\">",
"     table 2B",
"    </a>",
"    ). In addition, a linear distribution of skin lesions suggests the possibility of an external insult as the cause of blistering.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32804638\">",
"    <span class=\"h4\">",
"     Dependent areas",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Coma blisters",
"      </strong>",
"      &ndash; Coma blisters are tense, subepidermal bullae that have been reported to occur in sites of pressure in comatose patients. These lesions have been associated with exposure to drugs (eg, opiates, tricyclic antidepressants, antipsychotics) and a variety of medical conditions, such as chronic renal failure, diabetic ketoacidosis, hyperparathyroidism, and neurologic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/14\">",
"       14",
"      </a>",
"      ]. Erythematous or ecchymotic patches or plaques may precede the development of bullous lesions. The blisters spontaneously resolve within two to four weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Bullous disease of diabetes (bullous diabeticorum)",
"      </strong>",
"      &ndash; Bullous disease of diabetes is a term used to describe the abrupt development of noninflammatory, tense, subepidermal bullae in patients with diabetes in sites of otherwise normal appearing skin (",
"      <a class=\"graphic graphic_picture graphicRef57569 \" href=\"UTD.htm?6/25/6551\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/15\">",
"       15",
"      </a>",
"      ]. Lesions most commonly occur on the feet or lower legs and may be up to several centimeters in diameter. The bullae spontaneously resolve over the course of a few weeks. The term bullous diabeticorum has also been used to refer to this disorder.",
"     </li>",
"     <li>",
"      <strong>",
"       Bullous leukocytoclastic vasculitis",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Hemorrhagic vesicles or bullae may occur among the purpuric macules, papules, or plaques of cutaneous leukocytoclastic vasculitis (",
"      <a class=\"graphic graphic_picture graphicRef57440 \" href=\"UTD.htm?18/26/18850\">",
"       picture 25",
"      </a>",
"      ). Necrosis of the skin overlying areas of small vessel vasculitis leads to the development of these subepidermal bullous lesions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4345?source=see_link\">",
"       \"Evaluation of adults with cutaneous lesions of vasculitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Edema (stasis) blisters",
"      </strong>",
"      &ndash; Bullae may form in areas of edema. These asymptomatic lesions often occur on the lower legs and resolve upon resolution of the cause of edema (",
"      <a class=\"graphic graphic_picture graphicRef78581 \" href=\"UTD.htm?1/23/1396\">",
"       picture 26",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/14\">",
"       14",
"      </a>",
"      ]. There is little published information on edema blisters, and it is not definitively known whether the majority of these blisters are subepidermal or intraepidermal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29288?source=see_link&amp;anchor=H310245#H310245\">",
"       \"Stasis dermatitis\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4714027\">",
"    <span class=\"h4\">",
"     Hands or feet",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Acute palmoplantar (dyshidrotic) eczema",
"      </strong>",
"      &ndash; Intensely pruritic vesicles on the hands or feet are consistent with this disorder (",
"      <a class=\"graphic graphic_picture graphicRef55722 \" href=\"UTD.htm?42/57/43925\">",
"       picture 27",
"      </a>",
"      ). The palms, soles, and sides of the digits are typical sites for involvement. Spongiotic intraepidermal vesicles are present on histopathologic examination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link&amp;anchor=H22#H22\">",
"       \"Overview of dermatitis\", section on 'Dyshidrotic eczema'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dermatophytosis",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Blistering tinea pedis is most often associated with",
"      <em>",
"       Trichophyton mentagrophytes",
"      </em>",
"      or",
"      <em>",
"       Epidermophyton floccosum",
"      </em>",
"      infection [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/16\">",
"       16",
"      </a>",
"      ]. The associated intraepidermal spongiotic vesicles and bullae are often present on the soles or between the toes (",
"      <a class=\"graphic graphic_picture graphicRef54214 \" href=\"UTD.htm?38/11/39103\">",
"       picture 28",
"      </a>",
"      ). In addition, dermatophytid reactions (autoeczematization or id reactions that occur in the setting of dermatophyte infection) may result in vesicular eruptions on the hands (",
"      <a class=\"graphic graphic_picture graphicRef52664 \" href=\"UTD.htm?7/8/7300\">",
"       picture 29",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link&amp;anchor=H16#H16\">",
"       \"Dermatophyte (tinea) infections\", section on 'Acute tinea pedis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link&amp;anchor=H4733135#H4733135\">",
"       \"Dermatophyte (tinea) infections\", section on 'Dermatophytid (id) reactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Friction blister",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Friction blisters are intraepidermal blisters that result from trauma induced separation within the epidermis. They most frequently occur on the heels and soles of the feet due to friction from shoes during walking or running. The possibility of epidermolysis bullosa simplex should be considered in patients with frequent and excessive blistering.",
"     </li>",
"     <li>",
"      <strong>",
"       Sucking blisters",
"      </strong>",
"      &ndash; Blisters on the hands or feet due to intrauterine sucking may be detected in neonates (",
"      <a class=\"graphic graphic_picture graphicRef67302 graphicRef78479 \" href=\"UTD.htm?5/46/5864\">",
"       picture 30A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link&amp;anchor=H11#H11\">",
"       \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Sucking blisters'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Erythema multiforme",
"      </strong>",
"      &ndash; The acral extremities are a site of predilection for lesions of erythema multiforme, a disorder that most commonly occurs in association with herpes simplex virus infection. The classic dusky erythematous target lesions of erythema multiforme may exhibit a central subepidermal blister (",
"      <a class=\"graphic graphic_picture graphicRef79955 \" href=\"UTD.htm?18/53/19283\">",
"       picture 31",
"      </a>",
"      ). Mucosal involvement is also frequently present (",
"      <a class=\"graphic graphic_picture graphicRef75314 graphicRef58969 \" href=\"UTD.htm?31/60/32712\">",
"       picture 32A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=see_link&amp;anchor=H5#H5\">",
"       \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Epidermolysis bullosa simplex",
"      </strong>",
"      &ndash; The Weber-Cockayne variant of epidermolysis bullosa simplex is a rare autosomal dominant genetic disorder in which intraepidermal blisters form in sites of friction or trauma. The hands and feet are frequently affected (",
"      <a class=\"graphic graphic_picture graphicRef59364 graphicRef73201 \" href=\"UTD.htm?16/14/16616\">",
"       picture 33A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H13#H13\">",
"       \"The genodermatoses\", section on 'Epidermolysis bullosa'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32804646\">",
"    <span class=\"h4\">",
"     Photodistributed",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Polymorphous light eruption",
"      </strong>",
"      &ndash; Polymorphous light eruption is a fairly common disorder that usually develops within hours of sun exposure. Although the most common manifestations are pruritic erythematous papules or plaques, vesicles or bullae may also occur as a manifestation of extensive dermal edema (",
"      <a class=\"graphic graphic_picture graphicRef64270 \" href=\"UTD.htm?5/9/5269\">",
"       picture 34",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/62/20455?source=see_link\">",
"       \"Polymorphous light eruption\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Porphyria cutanea tarda",
"      </strong>",
"      &ndash; Photosensitivity is a key feature of porphyria cutanea tarda, an inherited or acquired metabolic disorder that may present with the formation of predominantly noninflammatory vesicles and bullae (",
"      <a class=\"graphic graphic_picture graphicRef74528 graphicRef78547 \" href=\"UTD.htm?25/16/25863\">",
"       picture 35A-B",
"      </a>",
"      ). Sun-exposed areas are typically affected. The dorsal hands and forearms are common sites of involvement, and crusts, scars, and milia are often present. Other cutaneous features of porphyria cutanea tarda include hyperpigmentation, hypertrichosis, and localized sclerodermoid plaques [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link&amp;anchor=H3066774#H3066774\">",
"       \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Porphyria cutanea tarda'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pseudoporphyria",
"      </strong>",
"      &ndash; Although pseudoporphyria presents with clinical and histopathologic features that resemble porphyria cutanea tarda, abnormalities of porphyrin metabolism are absent. Like porphyria cutanea tarda, subepidermal bullae, crusts, and scarring on the dorsal hands are common clinical findings (",
"      <a class=\"graphic graphic_picture graphicRef80856 \" href=\"UTD.htm?18/42/19109\">",
"       picture 36",
"      </a>",
"      ). A number of medications have been associated with this condition [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link&amp;anchor=H24#H24\">",
"       \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\", section on 'Other manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Sunburn and phototoxic reactions",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Severe sunburns can result in blister formation on the skin (",
"      <a class=\"graphic graphic_picture graphicRef52112 \" href=\"UTD.htm?19/6/19555\">",
"       picture 37",
"      </a>",
"      ). Phototoxic eruptions, which usually occur due to sun exposure after ingestion of a photosensitizing drug, resemble sunburns and can also present with blistering. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30136?source=see_link\">",
"       \"Sunburn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link&amp;anchor=H22#H22\">",
"       \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\", section on 'Phototoxicity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H323939\">",
"    <span class=\"h4\">",
"     Dermatomal",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Herpes zoster",
"      </strong>",
"      &ndash; Herpes zoster (shingles) presents with a grouped eruption of painful intraepidermal vesicles in a dermatomal distribution (",
"      <a class=\"graphic graphic_picture graphicRef81443 graphicRef58282 \" href=\"UTD.htm?9/46/9962\">",
"       picture 1A-B",
"      </a>",
"      ). In immunocompromised patients, disseminated lesions may occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=see_link\">",
"       \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32804661\">",
"    <span class=\"h4\">",
"     Linear distribution",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Contact dermatitis",
"      </strong>",
"      &ndash; Intensely pruritic dermatitis and intraepidermal spongiotic bullae often develop in patients with severe contact dermatitis, such as can occur after exposure to poison ivy (",
"      <a class=\"graphic graphic_picture graphicRef74631 \" href=\"UTD.htm?29/19/30005\">",
"       picture 38",
"      </a>",
"      ). Lesions develop in sites of contact of the inciting substance with the skin. A linear distribution is common.",
"     </li>",
"     <li>",
"      <strong>",
"       Phytophotodermatitis",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Erythema, edema, and vesiculation occurring in a linear or odd configuration may develop after topical exposure to certain of plant-derived substances (eg, lemons, limes, celery, wild parsnip, or parsley) followed by sun exposure (",
"      <a class=\"graphic graphic_picture graphicRef57871 graphicRef81457 \" href=\"UTD.htm?19/33/19993\">",
"       picture 39A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/19\">",
"       19",
"      </a>",
"      ]. The term &ldquo;berloque dermatitis&rdquo; has been used to refer to lesions secondary to natural oil of bergamot in products used on the skin. Significant postinflammatory hyperpigmentation after resolution of the acute process is common. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link&amp;anchor=H23#H23\">",
"       \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\", section on 'Phytophotodermatitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32804669\">",
"    <span class=\"h4\">",
"     Other localized blistering disorders",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Herpes simplex virus",
"      </strong>",
"      &ndash; A localized eruption composed of grouped, small, often umbilicated intraepidermal vesicles or vesicopustules is characteristic of herpes simplex virus infection (",
"      <a class=\"graphic graphic_picture graphicRef58485 graphicRef73975 \" href=\"UTD.htm?20/2/20520\">",
"       picture 40A-B",
"      </a>",
"      ). The lips, genitals, and buttocks are common sites of involvement. Primary infections tend to be most severe, and can be accompanied by lymphadenopathy and flu-like symptoms. Extensive lesions may occur in patients with atopic dermatitis, a condition referred to as eczema herpeticum (also referred to as Kaposi&rsquo;s varicelliform eruption). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link\">",
"       \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bullous arthropod bite",
"      </strong>",
"      &ndash; Occasionally, vesicles or bullae occur at sites of arthropod bites (",
"      <a class=\"graphic graphic_picture graphicRef52794 graphicRef60230 \" href=\"UTD.htm?31/28/32198\">",
"       picture 41A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=see_link\">",
"       \"Insect bites\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Fixed drug eruption",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Central bullae may appear in lesions of fixed drug eruptions, which present as single or multiple dusky erythematous to violaceous round plaques (",
"      <a class=\"graphic graphic_picture graphicRef67733 \" href=\"UTD.htm?22/6/22629\">",
"       picture 42",
"      </a>",
"      ). The lips, genitalia, face, and acral areas are common sites of involvement. The lesions tend to heal with significant postinflammatory hyperpigmentation and typically recur in the same sites with subsequent drug exposure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link&amp;anchor=H11#H11\">",
"       \"Drug eruptions\", section on 'Fixed drug eruption'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Transient acantholytic dermatosis (Grover&rsquo;s disease)",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Transient acantholytic dermatosis is a disorder that is most commonly detected in middle-aged Caucasian men. Pruritic, erythematous papules and papulovesicles are typically localized to the trunk (",
"      <a class=\"graphic graphic_picture graphicRef76504 \" href=\"UTD.htm?37/5/37983\">",
"       picture 43",
"      </a>",
"      ). Acantholysis and dyskeratosis are evident on histopathologic examination of papulovesicular lesions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31381?source=see_link\">",
"       \"Grover's disease (transient and persistent acantholytic dermatosis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hailey-Hailey disease",
"      </strong>",
"      &ndash; Hailey-Hailey disease is an uncommon genetic disorder that presents with fragile acantholytic blisters that quickly evolve to erosions that are primarily localized to the neck and intertriginous areas (",
"      <a class=\"graphic graphic_picture graphicRef80862 graphicRef61689 graphicRef74552 \" href=\"UTD.htm?25/4/25674\">",
"       picture 44A-C",
"      </a>",
"      ). Erythematous vegetative plaques develop in involved areas as the disease progresses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/40/11912?source=see_link\">",
"       \"Hailey-Hailey disease (benign familial pemphigus)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bullous pyoderma gangrenosum",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Atypical variants of pyoderma gangrenosum may present with subepidermal bullous lesions in conjunction with superficial ulcers (",
"      <a class=\"graphic graphic_picture graphicRef55967 \" href=\"UTD.htm?30/56/31618\">",
"       picture 45",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2328?source=see_link&amp;anchor=H24503928#H24503928\">",
"       \"Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32804576\">",
"    <span class=\"h3\">",
"     Mucous membrane involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a significant proportion of blistering disorders, involvement is not limited to the skin. When blistering disorders involve the mucous membranes, frank vesicles and bullae often are not seen. Rather, mucosal inflammation or erosions tend to be the predominant clinical finding.",
"   </p>",
"   <p>",
"    The following disorders are examples of blistering diseases that may present with both cutaneous and mucosal findings (",
"    <a class=\"graphic graphic_table graphicRef67630 \" href=\"UTD.htm?6/34/6701\">",
"     table 2C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mucous membrane pemphigoid",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Mucous membrane pemphigoid (MMP) is defined as a diverse group of blistering disorders characterized by mucous membranes as the primary site of involvement. Inflamed, eroded, or scarred mucosa may be present (",
"      <a class=\"graphic graphic_picture graphicRef52208 graphicRef63997 graphicRef75723 graphicRef54207 graphicRef77654 \" href=\"UTD.htm?41/3/42042\">",
"       picture 46A-E",
"      </a>",
"      ). Cutaneous blisters accompany the mucosal lesions in some patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Pemphigus vulgaris",
"      </strong>",
"      (See",
"      <a class=\"local\" href=\"#H32805760\">",
"       'Other generalized blistering disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Paraneoplastic pemphigus",
"      </strong>",
"      (See",
"      <a class=\"local\" href=\"#H32804630\">",
"       'Generalized blisters with systemic illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Bullous pemphigoid",
"      </strong>",
"      (See",
"      <a class=\"local\" href=\"#H32805760\">",
"       'Other generalized blistering disorders'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Linear IgA bullous dermatosis",
"      </strong>",
"      (See",
"      <a class=\"local\" href=\"#H32805760\">",
"       'Other generalized blistering disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Epidermolysis bullosa acquisita",
"      </strong>",
"      (See",
"      <a class=\"local\" href=\"#H32805760\">",
"       'Other generalized blistering disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Erythema multiforme",
"      </strong>",
"      (See",
"      <a class=\"local\" href=\"#H4714027\">",
"       'Hands or feet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Stevens-Johnson syndrome and toxic epidermolytic necrolysis",
"      </strong>",
"      (See",
"      <a class=\"local\" href=\"#H32804630\">",
"       'Generalized blisters with systemic illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Herpes simplex virus infection",
"      </strong>",
"      (See",
"      <a class=\"local\" href=\"#H32804669\">",
"       'Other localized blistering disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H320485\">",
"    <span class=\"h2\">",
"     Additional clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the recognition of the distribution of cutaneous blisters, knowledge of the patient&rsquo;s age, blister characteristics, and the patient&rsquo;s drug history may help to narrow the differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H320123\">",
"    <span class=\"h3\">",
"     Patient age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although patient age cannot be used to definitively exclude most blistering disorders, this information may provide additional clues for diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Neonates",
"      </strong>",
"      &ndash; In neonates, blistering lesions can occur due to intrauterine or postpartum exposure to infections or trauma, congenital disorders, miliaria crystallina, or other disorders. The differential diagnosis for neonates with cutaneous blisters is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15864?source=see_link\">",
"       \"Vesiculobullous and pustular lesions in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Young children",
"      </strong>",
"      &ndash; Disorders such as bullous impetigo and staphylococcal scalded skin occur with greater frequency in infants and young children than in other age populations.",
"     </li>",
"     <li>",
"      <strong>",
"       Elderly adults",
"      </strong>",
"      &ndash; Pemphigus and pemphigoid occur with greater frequency in older adults than in younger individuals. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H320462\">",
"    <span class=\"h3\">",
"     Blister configuration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grouped blisters are characteristic of herpes simplex virus infection (",
"    <a class=\"graphic graphic_picture graphicRef81443 \" href=\"UTD.htm?5/57/6039\">",
"     picture 1A",
"    </a>",
"    ), herpes zoster (",
"    <a class=\"graphic graphic_picture graphicRef58282 \" href=\"UTD.htm?11/25/11669\">",
"     picture 1B",
"    </a>",
"    ), dermatitis herpetiformis (",
"    <a class=\"graphic graphic_picture graphicRef78315 \" href=\"UTD.htm?23/38/24163\">",
"     picture 22",
"    </a>",
"    ), and linear IgA bullous dermatosis. An annular configuration is often present in linear IgA bullous dermatosis (",
"    <a class=\"graphic graphic_picture graphicRef56434 \" href=\"UTD.htm?15/62/16359\">",
"     picture 21",
"    </a>",
"    ) and a linear arrangement of bullous lesions suggests the possibility of contact dermatitis or phytophotodermatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H320477\">",
"    <span class=\"h3\">",
"     Blister size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small vesicles are the primary lesions in miliaria crystallina, acute palmoplantar eczema, herpes simplex virus or varicella zoster virus infection, and dermatitis herpetiformis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5172250\">",
"    <span class=\"h3\">",
"     Blister quality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tense blisters are a characteristic feature of subepidermal blistering disorders, such as bullous pemphigoid, pemphigoid gestationis, linear IgA bullous dermatosis, epidermolysis bullosa acquisita, and porphyria cutanea tarda. More flaccid blisters are typically seen in conditions in which the level of bulla formation is more superficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5170792\">",
"    <span class=\"h3\">",
"     History of drug exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug exposure is frequently associated with fixed drug eruptions, pseudoporphyria, Stevens-Johnson syndrome, toxic epidermal necrolysis, and linear IgA dermatosis (",
"    <a class=\"graphic graphic_table graphicRef55836 \" href=\"UTD.htm?29/35/30267\">",
"     table 3",
"    </a>",
"    ). Occasionally, erythema multiforme, pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, and mucous membrane pemphigoid are linked to an inciting pharmacological agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H320493\">",
"    <span class=\"h2\">",
"     Nikolsky sign",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Nikolsky (or Nikolskiy) sign is a clinical finding that describes the elicitation of skin blistering as a result of gentle mechanical pressure on the skin. Depending on the clinical scenario, a positive Nikolsky sign may be observed at the edge of an existing lesion, in an area of normal-appearing skin, or in both locations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Nikolsky sign is often cited as a feature of the acantholytic, suprabasilar blistering disorder pemphigus vulgaris; however, the absence of this finding does not rule out this diagnosis. In addition, the Nikolsky sign has been detected in multiple blistering diseases with divergent modes of blister formation and levels of blister cleavage, including among them toxic epidermal necrolysis, staphylococcal scalded skin syndrome, and a subset of patients with bullous pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link&amp;anchor=H181679718#H181679718\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4714325\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because many blistering disorders share clinical features, diagnostic tests are essential. The principle tests utilized in the evaluation of blistering diseases include, light microscopy, direct immunofluorescence, indirect immunofluorescence, antigen-specific serologic testing, and microbiological studies. The selection of the most appropriate studies to order is patient-specific and based upon the suspected diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4714350\">",
"    <span class=\"h2\">",
"     Skin biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A skin biopsy with or without direct immunofluorescence studies is often the first step in the evaluation of patients with an unknown skin blistering disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4714340\">",
"    <span class=\"h3\">",
"     Light microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of a skin biopsy with light microscopy is useful for identifying the histopathologic features that characterize specific disorders. Light microscopy can detect the level of blister formation, the type of inflammatory cell infiltrate, the presence of dyskeratotic cells, and histopathologic features suggestive of infection (",
"    <a class=\"graphic graphic_picture graphicRef60749 graphicRef66267 \" href=\"UTD.htm?21/49/22298\">",
"     picture 5A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Specimens for light microscopic examination are usually obtained from lesional tissue. If small vesicles are present, removal of an entire lesion is preferred. For larger lesions, the specimen should be obtained from the edge of a blister; the specimen should contain both portions of the blister and intact skin.",
"   </p>",
"   <p>",
"    <br/>",
"    Punch biopsies are most frequently utilized for the evaluation of blistering lesions, as they allow for evaluation of the full thickness of the epidermis and dermis, which can be useful in cases in which dermal findings may offer additional clues for diagnosis. A deep shave biopsy that extends into the reticular dermis can also be utilized, but may result in a larger, scoop-like scar. Specimens for light microscopy can be placed in formalin for preservation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link&amp;anchor=H12#H12\">",
"     \"Skin biopsy techniques\", section on 'Punch biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link&amp;anchor=H10#H10\">",
"     \"Skin biopsy techniques\", section on 'Shave biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4714358\">",
"    <span class=\"h3\">",
"     Direct immunofluorescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct immunofluorescence is a technique that allows for the detection of antibody or complement deposition within the skin. Direct immunofluorescence studies are typically utilized when an autoimmune blistering disorder is suspected. The recognition of the pattern and location of antibody binding can offer valuable insight for diagnosis. For example, intercellular antibody deposition in the epidermis characterizes pemphigus vulgaris and pemphigus foliaceus, whereas linear antibody deposition along the basement membrane zone is detected in bullous pemphigoid (",
"    <a class=\"graphic graphic_picture graphicRef82837 graphicRef82838 graphicRef53466 \" href=\"UTD.htm?33/42/34474\">",
"     picture 47A-C",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    The specimen should be taken from normal-appearing skin adjacent to the blister, which is referred to as a",
"    <strong>",
"     perilesional",
"    </strong>",
"    biopsy. A biopsy of lesional skin is more likely to result in false negative results because of destruction of the immunoreactants by the inflammatory process. Tissue obtained for direct immunofluorescence should not be placed in formalin; rather, Michel&rsquo;s medium or Zeus medium can be used for preservation. Fresh specimens also may be sent to the laboratory provided they are kept moist with saline, and processing within 24 hours is feasible.",
"   </p>",
"   <p>",
"    The basic procedure for direct immunofluorescence is as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cut sections from the specimen are placed on microscope slides",
"     </li>",
"     <li>",
"      A solution containing antisera against IgG, IgA, IgM, complement factor C3 and fibrinogen conjugated to fluorescent dye is incubated with the sections",
"     </li>",
"     <li>",
"      The sections are subsequently washed and mounted for examination utilizing an epifluorescence microscope",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H320553\">",
"    <span class=\"h2\">",
"     Serological tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indirect immunofluorescence studies and antigen-specific serological testing may be useful for the evaluation of autoimmune blistering disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4714372\">",
"    <span class=\"h3\">",
"     Indirect immunofluorescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indirect immunofluorescence can be used to detect antibodies within the circulation. In this technique, the presence of antibodies in the patient&rsquo;s serum that are capable of binding to components of an epithelial specimen that is not from the patient is assessed (",
"    <a class=\"graphic graphic_picture graphicRef82839 \" href=\"UTD.htm?32/53/33621\">",
"     picture 48",
"    </a>",
"    ). Similar to direct immunofluorescence, this test is typically utilized to aid in the diagnosis of autoimmune blistering disease.",
"   </p>",
"   <p>",
"    The basic procedure for indirect immunofluorescence is as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood is drawn from the patients and centrifuged to separate serum",
"     </li>",
"     <li>",
"      The selected substrate (eg, monkey esophagus, guinea pig esophagus, rat bladder, or human skin depending upon the suspected diagnosis) is incubated with progressive dilutions of patient serum",
"     </li>",
"     <li>",
"      The tissue is incubated with antibodies conjugated to a fluorescent dye that are directed against the antibodies bound to the substrate",
"     </li>",
"     <li>",
"      The slides are washed, mounted, and examined utilizing an epifluorescent microscope",
"     </li>",
"     <li>",
"      Results are reported as the limiting dilution in which specific fluorescence is detected",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4714441\">",
"    <span class=\"h3\">",
"     Antigen-specific serological testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the target of circulating antibodies associated with specific autoimmune blistering diseases is known, antigen-specific testing can be used to detect the presence of antibodies in serum. Enzyme-linked immunosorbent assay (ELISA) is the most common test utilized, and is frequently employed in disorders such as bullous pemphigoid, pemphigoid gestationis, and pemphigus vulgaris. Other antigen specific serological tests, such as immunoblotting and immunohistochemistry have also been utilized for the diagnosis of autoimmune blistering diseases. These tests are more labor intensive than ELISA, but may be the only way to definitively identify epidermolysis bullosa acquisita and laminin 332 pemphigoid. These disorders may be associated with inflammatory bowel disease or malignancy, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H320546\">",
"    <span class=\"h2\">",
"     Basement membrane zone-split skin technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue specimens with an artificially induced cleavage zone between the epidermis and dermis (known as basement membrane zone-split skin or salt-split skin) are utilized to obtain more precise information on the localization of antibody binding within the basement membrane zone in direct and indirect immunofluorescence studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/54/14186/abstract/21\">",
"     21",
"    </a>",
"    ]. Incubation of the skin substrate in a 1 M sodium chloride (NaCl) or ethylenediaminetetraacetic acid (EDTA) solution induces separation at the level of the lamina lucida. The location of antibody binding to the epidermal (roof) or dermal (floor) side of the split can be used to further narrow the differential diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef82836 \" href=\"UTD.htm?16/21/16722\">",
"     picture 49",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H20007014#H20007014\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Laboratory tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4714451\">",
"    <span class=\"h2\">",
"     Microbiologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;If infection is suspected, microbiological tests can be useful for diagnosis. A potassium hydroxide (KOH) preparation is a quick diagnostic test for bullous tinea pedis (",
"    <a class=\"graphic graphic_picture graphicRef60102 \" href=\"UTD.htm?4/2/4132\">",
"     picture 50",
"    </a>",
"    ). In addition, bacterial cultures of the blister site may aid in the diagnosis of bullous impetigo, and in staphylococcal scalded skin syndrome, culture of the potential sites of the primary staphylococcal infection can be of value. In patients with suspected herpes simplex virus or varicella zoster virus infection, studies such as Tzanck smear (",
"    <a class=\"graphic graphic_picture graphicRef79784 \" href=\"UTD.htm?18/41/19102\">",
"     picture 51",
"    </a>",
"    ), viral culture, polymerase chain reaction, and direct fluorescent antibody testing may be used to confirm a diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"     \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H12#H12\">",
"     \"Dermatologic procedures\", section on 'Tzanck smear'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4714460\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to a dermatologist is indicated if an autoimmune blistering disease is suspected, if the cause of blistering is unknown, or if disease continues to progress despite appropriate treatment. Patients with suspected toxic epidermal necrolysis require immediate transfer to an experienced burn unit. Patients with staphylococcal scalded skin syndrome require hospital admission for intravenous antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15864?source=see_link&amp;anchor=H8#H8\">",
"     \"Vesiculobullous and pustular lesions in the newborn\", section on 'Staphylococcal scalded skin syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/60/5058?source=see_link\">",
"       \"Patient information: Blisters (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4714632\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A wide variety of disorders can result in the formation of blisters on the skin. Autoimmune disorders, drug reactions, infections, genetic disorders, and traumatic injury are among the potential causes of cutaneous blistering. (See",
"      <a class=\"local\" href=\"#H35462837\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H48262289\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous blisters may occur at various sites within the skin (",
"      <a class=\"graphic graphic_table graphicRef74129 \" href=\"UTD.htm?22/31/23036\">",
"       table 1",
"      </a>",
"      ). Blisters that form within the epidermis tend to be more fragile and flaccid than the tense blisters that are typically associated with subepidermal blistering diseases. (See",
"      <a class=\"local\" href=\"#H48262289\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Life-threatening cutaneous blistering disorders include toxic epidermal necrolysis, staphylococcal scalded skin syndrome, disseminated herpes simplex virus infection, disseminated herpes zoster, and purpura fulminans. Identification of these disorders should be prompt to reduce the risk of fatal complications. (See",
"      <a class=\"local\" href=\"#H4714603\">",
"       'Life-threatening emergencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The distribution of cutaneous blisters is often useful for narrowing the differential diagnosis (",
"      <a class=\"graphic graphic_table graphicRef60255 graphicRef82490 graphicRef67630 \" href=\"UTD.htm?6/7/6271\">",
"       table 2A-C",
"      </a>",
"      ). Blistering conditions may be divided in to generalized or localized disorders, and additional features such as the patent age, blister characteristics, and the patient&rsquo;s drug history may also offer clues for diagnosis (",
"      <a class=\"graphic graphic_table graphicRef55836 \" href=\"UTD.htm?29/35/30267\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H35462844\">",
"       'Patient assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic tests commonly utilized in the evaluation of blistering skin disorders include light microscopy, direct and indirect immunofluorescence studies, antigen-specific serologic studies, and microbiological tests. The specific disorders considered in the differential diagnosis determine the selection of the most appropriate test(s). (See",
"      <a class=\"local\" href=\"#H4714325\">",
"       'Diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Weedon D. The vesicobullous reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.123.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/2\">",
"      Gerull R, Nelle M, Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Crit Care Med 2011; 39:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/3\">",
"      Sebaratnam DF, Murrell DF. Bullous systemic lupus erythematosus. Dermatol Clin 2011; 29:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/4\">",
"      Frew JW, Murrell DF. Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis. Dermatol Clin 2011; 29:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/5\">",
"      Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc 2004; 9:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/6\">",
"      Czernik A, Camilleri M, Pittelkow MR, Grando SA. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol 2011; 50:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/7\">",
"      Ioannides D, Lazaridou E, Rigopoulos D. Pemphigus. J Eur Acad Dermatol Venereol 2008; 22:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/8\">",
"      Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin 2011; 29:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/9\">",
"      Tran JT, Mutasim DF. Localized bullous pemphigoid: a commonly delayed diagnosis. Int J Dermatol 2005; 44:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/10\">",
"      Venning VA. Linear IgA disease: clinical presentation, diagnosis, and pathogenesis. Dermatol Clin 2011; 29:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/11\">",
"      Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis. Part I. Epidemiology, pathogenesis, and clinical presentation. J Am Acad Dermatol 2011; 64:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/12\">",
"      Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis. Part II. Diagnosis, management, and prognosis. J Am Acad Dermatol 2011; 64:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/13\">",
"      Caux F. Diagnosis and clinical features of epidermolysis bullosa acquisita. Dermatol Clin 2011; 29:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/14\">",
"      Sami N, Yeh SW, Ahmed AR. Blistering diseases in the elderly: diagnosis and treatment. Dermatol Clin 2004; 22:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/15\">",
"      Toonstra J. Bullosis diabeticorum. Report of a case with a review of the literature. J Am Acad Dermatol 1985; 13:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/16\">",
"      Romano C, Rubegni P, Ghilardi A, Fimiani M. A case of bullous tinea pedis with dermatophytid reaction caused by Trichophyton violaceum. Mycoses 2006; 49:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/17\">",
"      Bleasel NR, Varigos GA. Porphyria cutanea tarda. Australas J Dermatol 2000; 41:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/18\">",
"      Green JJ, Manders SM. Pseudoporphyria. J Am Acad Dermatol 2001; 44:100.",
"     </a>",
"    </li>",
"    <li>",
"     McGovern TW. Dermatoses due to plants. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Elsevier Limited, 2008. p.243.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/20\">",
"      Uzun S, Durdu M. The specificity and sensitivity of Nikolskiy sign in the diagnosis of pemphigus. J Am Acad Dermatol 2006; 54:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/54/14186/abstract/21\">",
"      Pohla-Gubo G, Hintner H. Direct and indirect immunofluorescence for the diagnosis of bullous autoimmune diseases. Dermatol Clin 2011; 29:365.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13684 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-122.72.76.133-B89E15691A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_54_14186=[""].join("\n");
var outline_f13_54_14186=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4714632\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35462837\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48262289\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4714603\">",
"      LIFE-THREATENING EMERGENCIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35462844\">",
"      PATIENT ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H320145\">",
"      Lesion distribution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32804617\">",
"      - Generalized distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H32804630\">",
"      Generalized blisters with systemic illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H32805760\">",
"      Other generalized blistering disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32804610\">",
"      - Localized distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H32804638\">",
"      Dependent areas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4714027\">",
"      Hands or feet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H32804646\">",
"      Photodistributed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H323939\">",
"      Dermatomal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H32804661\">",
"      Linear distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H32804669\">",
"      Other localized blistering disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32804576\">",
"      - Mucous membrane involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H320485\">",
"      Additional clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H320123\">",
"      - Patient age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H320462\">",
"      - Blister configuration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H320477\">",
"      - Blister size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5172250\">",
"      - Blister quality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5170792\">",
"      - History of drug exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H320493\">",
"      Nikolsky sign",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4714325\">",
"      DIAGNOSTIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4714350\">",
"      Skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4714340\">",
"      - Light microscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4714358\">",
"      - Direct immunofluorescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H320553\">",
"      Serological tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4714372\">",
"      - Indirect immunofluorescence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4714441\">",
"      - Antigen-specific serological testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H320546\">",
"      Basement membrane zone-split skin technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4714451\">",
"      Microbiologic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4714460\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4714632\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13684\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13684|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/57/6039\" title=\"picture 1A\">",
"      Herpes zoster vesicle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/25/11669\" title=\"picture 1B\">",
"      Herpes zoster vesicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/25/6551\" title=\"picture 2\">",
"      Bulllous diabeticorum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/20/24904\" title=\"picture 3\">",
"      Pemphigus foliaceus histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/11/19641\" title=\"picture 4A\">",
"      Allergic contact dermatitis histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/63/40950\" title=\"picture 4B\">",
"      Varicella histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/25/33173\" title=\"picture 5A\">",
"      Pemphigus vulgaris biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/15/44279\" title=\"picture 5B\">",
"      Bullous pemphigoid pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/48/25345\" title=\"picture 6A\">",
"      Cutaneous changes of Stevens Johnson Syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/1/39953\" title=\"picture 6B\">",
"      Toxic epidermal necrolysis - back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/27/13747\" title=\"picture 6C\">",
"      Toxic epidermal necrolysis - abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/55/42866\" title=\"picture 6D\">",
"      Stevens-Johnson syndrome - oral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/3/25654\" title=\"picture 7A\">",
"      Staphylococcal scalded skin syndrome close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/52/13121\" title=\"picture 7B\">",
"      Staphylococcal scalded skin syndrome - trunk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/15/44273\" title=\"picture 7C\">",
"      Staphylococcal scalded skin syndrome - face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/48/12034\" title=\"picture 8\">",
"      Disseminated herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/39/15987\" title=\"picture 9\">",
"      Purpura fulminans large lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/49/1816\" title=\"picture 10A\">",
"      Varicella lesion close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/3/36927\" title=\"picture 10B\">",
"      Rash of primary varicella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/57/23443\" title=\"picture 11A\">",
"      Eczema herpeticum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/22/39268\" title=\"picture 11B\">",
"      Eczema herpeticum arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/29/7634\" title=\"picture 11C\">",
"      Eczema herpeticum hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/13/43221\" title=\"picture 12A\">",
"      Sweet syndrome vesicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/42/33443\" title=\"picture 12B\">",
"      Sweet syndrome bulla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/26/6562\" title=\"picture 13\">",
"      Paraneoplastic pemphigus oral findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/59/7095\" title=\"picture 14\">",
"      Miliaria crystallina vesicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/48/768\" title=\"picture 15\">",
"      Bullous impetigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/56/27526\" title=\"picture 16\">",
"      Pemphigus vulgaris bullae and erosions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/48/769\" title=\"picture 17A\">",
"      Pemphigus vulgaris - oral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/38/26213\" title=\"picture 17B\">",
"      Pemphigus vulgaris oral lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/5/35922\" title=\"picture 18A\">",
"      Pemphigus foliaceus face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/24/9603\" title=\"picture 18B\">",
"      Pemphigus foliaceus chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/53/24406\" title=\"picture 19A\">",
"      Bullous pemphigoid axillae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/16/26885\" title=\"picture 19B\">",
"      Bullous pemphigoid multiple lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/56/20353\" title=\"picture 20A\">",
"      Pemphigoid gestationis umb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/34/29216\" title=\"picture 20B\">",
"      Pemphigoid gestationis ext",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/49/18195\" title=\"picture 20C\">",
"      Pemphigoid gestationis bull",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/62/16359\" title=\"picture 21\">",
"      Linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/38/24163\" title=\"picture 22\">",
"      Dermatitis herpetiformis elbows",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/38/37475\" title=\"picture 23\">",
"      Dystrophic epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/36/22085\" title=\"picture 24\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/26/18850\" title=\"picture 25\">",
"      Leukocytoclastic vasculitis - bullous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/23/1396\" title=\"picture 26\">",
"      Stasis dermatitis with bulla formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/57/43925\" title=\"picture 27\">",
"      Dyshidrotic eczema hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/11/39103\" title=\"picture 28\">",
"      Acute tinea pedis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/8/7300\" title=\"picture 29\">",
"      Autoeczematization on hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/47/18161\" title=\"picture 30A\">",
"      Sucking blister",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/32/23044\" title=\"picture 30B\">",
"      Intrauterine sucking lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/53/19283\" title=\"picture 31\">",
"      Erythema multiforme target2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/51/14131\" title=\"picture 32A\">",
"      Erythema multiforme genital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/4/9284\" title=\"picture 32B\">",
"      Erythema multiforme tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/12/4291\" title=\"picture 33A\">",
"      Epidermolysis bullosa simplex - hands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/60/20419\" title=\"picture 33B\">",
"      Epidermolysis bullosa simplex - feet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/9/5269\" title=\"picture 34\">",
"      PMLE forearms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/30/13794\" title=\"picture 35A\">",
"      Porphyria cutanea tarda",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/47/14066\" title=\"picture 35B\">",
"      Porphyria cutanea tarda 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/42/19109\" title=\"picture 36\">",
"      Pseudoporphyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/6/19555\" title=\"picture 37\">",
"      Sunburn blistering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/19/30005\" title=\"picture 38\">",
"      Contact dermatitis bullae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/24/34182\" title=\"picture 39A\">",
"      Phytophotodermatitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/11/13490\" title=\"picture 39B\">",
"      Contact dermatitis berloque 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/36/15940\" title=\"picture 40A\">",
"      Female genital HSV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/0/17410\" title=\"picture 40B\">",
"      Herpes simplex labialis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/29/41424\" title=\"picture 41A\">",
"      Bullous reaction to arthropod bite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/55/39793\" title=\"picture 41B\">",
"      Bullous arthropod bite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/6/22629\" title=\"picture 42\">",
"      Fixed drug eruption with bulla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/5/37983\" title=\"picture 43\">",
"      Grovers disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/63/35828\" title=\"picture 44A\">",
"      Hailey Hailey",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/47/19186\" title=\"picture 44B\">",
"      Hailey-Hailey 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/51/3893\" title=\"picture 44C\">",
"      Hailey-Hailey 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/56/31618\" title=\"picture 45\">",
"      Pyoderma gangrenosum 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/48/20226\" title=\"picture 46A\">",
"      Mucous membrane pemphigoid lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/49/38674\" title=\"picture 46B\">",
"      Mucous membrane pemphigoid palate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/24/6535\" title=\"picture 46C\">",
"      Mucous membrane pemphigoid vaginal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/12/31937\" title=\"picture 46D\">",
"      Ocular cicatricial pemphigoid stage 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/51/16178\" title=\"picture 46E\">",
"      Cicatricial pemphigoid - gingiva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/58/10152\" title=\"picture 47A\">",
"      Pemphigus vulgaris DIF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/27/20917\" title=\"picture 47B\">",
"      Pemphigus foliaceus DIF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/47/43775\" title=\"picture 47C\">",
"      Bullous pemphigoid DIF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/53/33621\" title=\"picture 48\">",
"      Pemphigus vulgaris IIF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/21/16722\" title=\"picture 49\">",
"      Bullous pemphigoid IIF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/2/4132\" title=\"picture 50\">",
"      Dermatophyte KOH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/41/19102\" title=\"picture 51\">",
"      Tzanck preparation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13684|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/31/23036\" title=\"table 1\">",
"      Histopathology of cutaneous blisters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/5/21597\" title=\"table 2A\">",
"      Generalized cutaneous blistering disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/5/40028\" title=\"table 2B\">",
"      Localized cutaneous blistering disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/34/6701\" title=\"table 2C\">",
"      Blistering disorders with mucous membrane involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/35/30267\" title=\"table 3\">",
"      Bullous drug eruptions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28423?source=related_link\">",
"      Approach to the patient with pustular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39608?source=related_link\">",
"      Approach to the patient with retiform (angulated) purpura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=related_link\">",
"      Benign skin and scalp lesions in the newborn and young infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=related_link\">",
"      Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35369?source=related_link\">",
"      Dermatitis herpetiformis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29657?source=related_link\">",
"      Dermatoses of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4858?source=related_link\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4345?source=related_link\">",
"      Evaluation of adults with cutaneous lesions of vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31381?source=related_link\">",
"      Grover's disease (transient and persistent acantholytic dermatosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/40/11912?source=related_link\">",
"      Hailey-Hailey disease (benign familial pemphigus)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21878?source=related_link\">",
"      Heat illness (other than heat stroke) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=related_link\">",
"      Impetigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=related_link\">",
"      Insect bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14922?source=related_link\">",
"      Linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18121?source=related_link\">",
"      Paraneoplastic pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/60/5058?source=related_link\">",
"      Patient information: Blisters (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=related_link\">",
"      Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/62/20455?source=related_link\">",
"      Polymorphous light eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=related_link\">",
"      Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2328?source=related_link\">",
"      Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29288?source=related_link\">",
"      Stasis dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30136?source=related_link\">",
"      Sunburn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40905?source=related_link\">",
"      Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15864?source=related_link\">",
"      Vesiculobullous and pustular lesions in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_54_14187="PP family receptor subtypes";
var content_f13_54_14187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pancreatic polypeptide family receptor subtypes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Receptor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Size",
"       </td>",
"       <td class=\"subtitle1\">",
"        Location",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Y1",
"       </td>",
"       <td>",
"        384 aa",
"       </td>",
"       <td>",
"        Hypothalamus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Y2",
"       </td>",
"       <td>",
"        381 aa",
"       </td>",
"       <td>",
"        Brain, hippocampus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Y3",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Brainstem",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Y4",
"       </td>",
"       <td>",
"        375 aa",
"       </td>",
"       <td>",
"        Colon, intestine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Y5",
"       </td>",
"       <td>",
"        455 aa",
"       </td>",
"       <td>",
"        Hypothalamus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Y6",
"       </td>",
"       <td>",
"        371 aa",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     aa: number of amino acids; NA: not available.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_54_14187=[""].join("\n");
var outline_f13_54_14187=null;
var title_f13_54_14188="Medical eval IEI";
var content_f13_54_14188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medical evaluation for patients with symptoms of idiopathic environmental intolerance",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Complete medical and environmental history; medication history. Focus on exposures at home and in the workplace",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Thorough physical examination, including neurologic examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Mental status examination and formal psychiatric evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Routine laboratory studies, which may include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Complete blood count, with differential",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Serum electrolytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Serum glucose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Blood urea nitrogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Creatinine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Liver function tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Thyroid function tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Urinalysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Electrocardiogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Chest x-ray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Neuropsychological testing for patients with cognitive complains (eg, memory impairment), or to rule out alternate diagnoses (eg, dementia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Immunologic tests for patients reporting allergies or immune dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Skin tests or in vitro assays with common allergens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Immunoglobulin levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Complement levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Selected auto-antibody assays",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Simple T- and B-cell assays",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Other tests will be guided by the patient's complaints (eg, spirometry for patients whose primary complaints are respiratory, nerve conduction tests for patients with persistent numbness and tingling in the extremities)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_54_14188=[""].join("\n");
var outline_f13_54_14188=null;
var title_f13_54_14189="Left atrial compliance";
var content_f13_54_14189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left atrial pressure-volume relationship",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 281px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The relationship between the volume within a chamber and the resulting pressure defines chamber compliance or distensibility. The top curve (red) is from a left atrium with low compliance; small changes in volume result in marked changes in pressure. In this situation large \"v\" waves due to mitral regurgitation will be seen. The lower curve (blue) is from a left atrium that is very compliant; changes in volume result in only small changes in pressure. In this situation, the same degree of mitral regurgitation will cause small \"v\" waves.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_54_14189=[""].join("\n");
var outline_f13_54_14189=null;
var title_f13_54_14190="Penetrating cervical or mediastinal esophageal trauma";
var content_f13_54_14190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Algorithm for managing patients with penetrating esophageal trauma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 295px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted by permission from: Macmillan Publishers Ltd: Srinivasan R, Haywood T, Horwitz B, et al. Role of flexible endoscopy in the evaluation of possible esophageal trauma after penetrating injuries. Am J Gastroenterol 2000; 95:1725. Copyright &copy; 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_54_14190=[""].join("\n");
var outline_f13_54_14190=null;
var title_f13_54_14191="Thyroid physiology in the fetus and newborn";
var content_f13_54_14191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 637px\">",
"   <div class=\"ttl\">",
"    Thyroid physiology in the fetus and newborn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 617px; height: 617px; background-image: url(data:image/gif;base64,R0lGODlhaQJpAuYAAP///wAz/wAAAP8AAO7u7r/M/z9l/3+Z/4iIiHd3dyIiIjMzM0RERFVVVZmZmf9/f93d3REREaqqqmZmZszMzP8/P4CAgIig//+/vyJO/7u7u0Rp/4+l/7vJ/+/y/y9Z/19//93k/x9M/6+//09y/9/l/2+M/8/Z/zNc/5+y/w8///8REf+IiP+fn//v75mt//8PD+7x///f3/8fH/8zM/8vLxFB/1V3/2aF///Pz/9vb/+vr/9ERP9fX8BAQP/MzP+qqneS//+Zmf8iIv/u7v+Pj9/f38zW//9VVf9PT//d3f93d/+7u/9mZqq7/6BgYM/Pz+AgID8/P5+fnw8PDw8w8H9/f+/v7+9vb19fX88KMAAagL+/vx8v4g8z898GIAANQO/j8J8wfZ8TYJ+AzW8dkHB2kI+c9m9Ux+8DEHh7iHNAjV9z8+enp8+KsW84qwAmwB8t4M89Y8/M8gAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABpAmkCAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyLChw4cQI0qcGBGBAEUOFFDcyHEjAwEgFWhINGGCoIwdU6pkyACBoAYMSJoEgHKlzZsCWwrSiTIjBQEKQApg4CDCApAjcSpdWu9jSJc9I7gEUPJkBAdUFzDdyrWdTgAaBGjoqVFQVZpla3Zdy1bcVwAK/xyQHXS2ptq2ePNi++pAAIW5ghLERHuyrN7DiKE5FXCVsFoKEYbaNZy4suXLmDNr3sy5s+fPoEOLHk26tOnTuC6iXs2alOrWsGNrei27tm1ItG/r3m0oN+/fun0DHx5bOPHjqI0jXz5aOfPnnp1Dn55ZOvXria1j397VCBRBqqEY4U4e7xUBUqYImCJFwJXy8NdmEQoyS/z7W6HQF/Adv3+c7YEkxX8E2qQeSFMUqGBKVAhAxYIQbmSFAFZEaGFERggw3oUcNsRFhyCGKOKIJJZooiqLgbQTSIOd6KI8EzQAAAIKEECAAlO9WKAF/kAgAAQANDAVAjLquKM/DcwU1/9JWhlJII/8hAUkXFjR1CR4+zm5HZT7MDBTkFMlUOQh2mn5G5f5aBDBlDPWeGOOvZmpjAT7gZQAABQ4pUACEgQpQJE/CdDnPGjig2MhTrVIppzMJCDAlWFFQAEABExwZwN/ChLooPHs4MMOEJXJaC+OXlmqIZgCChKn8MAwAAyhjqrMqYJY9GgCOaaq6arzDOBrrLIiQyulKUrqZ52svuPrAMAGa8ywmorJop+qCtrrr9XYqG0tojqLC7SEnKornrzKs2w1jtIXwZeEbItKt97aMmwDCUx5lEvjbnots9Sku1+OBCRwFEgLwDkKvPHSMqwDCQT1aJX5lhvPsjn0u4D/jT8V1SQCkT26wMAKTOpawsMtiwE1Hwvio8BaEQAUAgQMAkECRpWCMMmkmUwNpgwIJgACKVcasyEQsBvKzTiLpvM0EHQMFAQFy4J00qAtPQ0BCOA6tCJRmzI11Z4tW4Q12m6NiMt3RkLBwEklqsjXYHO27APUUOCwnYqgHUnTadfq5qGIwB23ZnNTk6IAfQtSto2IRyJmIULWOmacg9dW+DQMKACBu4P4S1/ijSzgcMhUMpmI4JVf5uoAdE8jgZs2FuK5UKAzsqdZWi1pJSF1pi5bBb62Ls3soC8eeyRfhQVmYJMXgrrviQE/QAX97le74pw/QiOQMLVpI+CLQt+a//TURzP04ofY/bkkmD46pduniz++r+U/gzbxhhx+PSjPy58X+eZDHP4QtYDNHc9r/lsNAM2HvewN4nVle1cCUbNAaSDgSwmoHWTWh8AJmqaC0AjYxWw0gSsNQn+n6J8HuyI9WEWDTnVS1E4K6MCDrbA00uMXNGBIH9IVAoI1FIUKb8iUHF7tgkEEwABtRsTRGBEcSxxZE0PzxGlkLYN8OgT6UjhFKp7LitajxRC7aJMqRoMBEchcw6pkFpGxYoxkVIkZobEAXGkkg4Nw2VCSFYmwCGUw8AtcHD0zx2csYAJ0KqEJKUCzl5ntEcojBI2+ZzDeDbIzhXRGw26EN0MAjf8xE3CjIyI5iMjNqHmWvORmMumMmM2skoSQQPsYwCZG+NF9pdudIFWpGVYqw3gHTAQjI8BHRhBgATLSnQNM2DteZsaXyNBjnfZniEc6AgExMeXjdunMy0DzGNIMY7siOIkJuARqLpnkm+LXTW9+MYTAlN1+IkDNRBQFJGMKZPjaWZlvJiOKswMJLPnHT8v4U1jizGPZ1CRDIRa0nxSjRtkUUExCpKyDDz1MDk92NRtBQAEyXBxDuZhRjVoNGrNTVEB/RtKS/u+kz/CcDwMzz3p6Ao4uVchGJRrELUowp3jZKU+DCQAIJEsCtbQhUNsi1Gioj3bhEsDiGofRpbIQps7/QGHn6kRVJlp1LU1VDA2JulKbcgKnXyVIWJ8BRLJKtWxdlWJat7JWZ2wQqjLrU9mQSonMnXBa7JxrEbHaDK1GlYOOi0BZ1Ak+ygl2KQ8gLDMYMFZrKjGh2sNRWUxJpMA+FieR9RVHXwg7y1JKWxTt45pqokwTOu+zkJXsMqKoUAJ8tKGKaNpIWFulZfIuS7AFrWxnhVma0ge3ibilUCCgTVQOAq3B5UdoBzBa85FTnkKZaSRqwtiBAgC60dXHdKvbjPNdtxDnlYRa9OnY8KZkvCEUYHFfAV733mO6wiuvfBErtEMUzav27Qh+GXja7LkMR1ubWc3kGuCNDNiCGEwc/8cI9rGQiPJoDRbw5UIoMG2VEL0CA4lRvHvTDHPkwWzlKnKJCmATSwTFzuBhdi9MXxdTBMatRCKLYVFfG78Dx+UdhAaSIkYfv3jDzrCISSYA2Fn02MjsAPIyMAUBP97rEA6g7NrYyGAoM0TKykiZRWKygIb2BSQEYIBzFaGBgRVwRUN5m5cfAuZkpOwjLrmoRQsmVYFFImuUqqP31snNOS+kzgidQGRGsmCL8kmqDXDtIz7aJ86u+buGbgiiwdmxmNCpkor+CKZInIigFKm1ns00QjZ9jFfGLGtJDbRQLkaJY7oE1c8FrqoTwupkIIDEWNOaJbC5PCVe+sm7Jsd0k/9QDT2fLYmKiNxH0/k37yI72eKYbv2k4exCPLWT2utYPpu8T2wXRNvNlvRfEdtlcwsE3dT4dSIyZ0DTEtTd517WtssbT0O01d6fuDa+uzFdF7aSq3E1Ll5bPHCATFeH+uVq7Wjr0Ia/e1kQ53cJUVtMnzLc4v14uAy4bZgyJwLg9wb5Px5O3mbwTFq4pdHLfqpyf2AA46CKxkeFYqxC2EooXFZqzftxcyQz43wXRACNAaBlAqwNuQEfus0xnt9l3G++h6SLulMudX0UnX722+/C6fInaRmt4l33OsZrEMIG7piTIUG5ITLCoqGx97VpVzvGs5W3pMvdEOYsqlQG3Vj/vOcdH1/3VcWiIfPCa+puCYcEUYrd2UIfvh6JH0DOn/FzkASd6fN1BAWmgutyX54ema/6ZBdAAaebnID1psR/BVH67+r69PXA+PSikXXc+bu0k9CAopqbatybS/fRYDK9MHX2u4L7mjWSZLWLb3x4LGt1i2/l3aKPqNArIkVluXsqq7+vJPhqbM8watZgdgjKxr6l5J/Y+cHOeakq4t80j7/1fSWDZbkg/WsSRBSHYfonf8wyA77SAjE1XwPIdQXYDueiA77CbJoUeh7Xbg+oDueSA/5nP+mlMhWFgRmIDl+EgAOAftlgEX9XYiMIgdhSBL4yA0nWAETmXwG4YwTY/4Lr8EUusCwK2CgEw36G0IBRp4M7iC0A0AP0xwwaoGiMQYPYNXZCZ4QkiIT9l4B21XnNc4FTSIXm8E5JGIP/NyeLUUeU5XNB4Xho54VfiIQAIAOro3rF4CgRAIWaIkn78XmNIBiEIH7PxYZVmHHTlX3H4AAwE0RN93R702TdRX2ACA5gKAg1IIbJ8G2R13tZMQnE9hJDcmyP2IYZBwAcOIHJYFhkt3wCcHaNsIm55FuW94nfUHRsZwgw6Cs9gAz01lPbt4I+1yK110ywGA5Ft2+DoIS2WAw2gn9atH682IulFCaeGIzh0AJLWAguMInHKAzhxG6cwIqN+IrSuA2hJf+HgnCNy5IEY/gL2zh2RiUB7viOsbYIPiIUU+GH4BGO4GB+J6gI5hiDhNgLwPRIZQV/+LgNYjAGX9By1miMwQMMRrUIQCM6HtM1H1eQ1lAAZ1AFARAAc9AItRiDm7cLjvJ3I6kKAmeRq1AABXAAB2AAH7CRMOkFj5ADJkg/ClkLJckIOZl/KDkMKlkAI8CSJmAABiACMHmUSBkAZBAJDzcAM9AC6SgvE/kxFIk9I4mDDtiTrPCTXMmSXkkCREmUSTmWZLmRIkACKWAGkyADDOkrMNADITkLA7lV00SQ/3ECXJmXermXfNmXfvmXgBmYgtmXHOCVhnmYiJmYirmYYdn/mI75mJBJlEZZlpRZmZZ5lCJgACBwAClQAB4wCIUCCWype68Cl1H5Co7yjvB4WN5XhOHgAYOZl0G5mLQ5lJF5m0T5kpe5m7zZm775m8AZnMI5nMRZnMZ5nJX5AWHplT/JCKEZCTLwADW5djqwAyPnCjv5bFy4hotQArHJlSlAm7QJAriJm7qJnOiZnuq5nuzZnu75nvC5nsrpmCZgmBzAlZ+JCc85CTvQA6tDmjNQAQ+wA/9YCkCzC/GZoAq6oAyqoPNZnhAaoRI6oRRaoZG5meKZoRp6mN/plyeQC/tZCTugA9hImstSAwJaBBhQoNrQoC7amxa6nBuKmB3anGkV/6KXIAMtQKIm2qMVUAE68AAPgAErag29qQIxagAkMKM0WqMFoJWygAFFoAMV8J892qMw8KMCKqQtcJ3JcJJQug0ugAEt8AA9UAHTeaUmSo61YI+YFqYLMaYYIKRUiqZqGpe38I2mB6cRIQNEugNC+gBJwKK1YGmOyKfIUXuGh6jQ8Yu3x6jMQXyQ2g0bAhB6OqnagKP54KaYOg2a2qnU8amgCh2iOqrMUaqmihyomqrEsaqsChyu+qqyOqu0Wqu2equ4mqu6uqu8Cg+VGg9tRjBAolyARG69agyxKg6Adkx3Qkp+Q0nHigzJSg6UBha5YajRiqz2YGqCcEtvpqjZGv8M0zoOttYuyNSKzPSo4WoL4zoOrFgr2QSNh7qusdCu3iBthxJ46ER41oZtKxWC92Cv3TBhmUIT4rZuUPem5nYUZhWwEQGm3cSwCQSxziSx/kOxvGSx8oOxqqSxZzYUSxcvHHtJGjsBWNEXCRssIztIGjsIfdGwjLKycdSygbImcSOz/PQTlGEPv9oQOMtLDNAnYbGz9SCw+fCzqsRkLBKy8mC0+IC09EoITqsNwYpLoBdncJawUBu1gjC1KXgnzMqvYguOXAsLXrsN1Wqo2LqnZWu221qwqAauf9i2tHC22lCucdtb6UofdFu3+EBsxCepbNu3rpADhJoO+Ept0Hr/qYtKuK8wjvBAsOOGtVertY4rCzV5mgextWWLcSiYEJzLtRhHjAYRuvSaeZpbEKa7rpmHp6p7ubDQBrqnAwuxuuH6BLpHugRhu9mKu04ZiaULu6/gu3ZKXQrBu9FKvPrIpgGBvMdKvLVIgQjhvL1KvEUng6ArvK5AvACwLF6aDnQ3FDFDrFkrZ9rLCtyLja7bSli5CPo6eM46toN7vqQwjAAggawjDSI0a6S2CJMXv2vbXvR7CvZLjbsHDQRLlRY2CaPXrbMGJHJ7jwOcCqFFu6NocPqFYDJDM1uXW2d3TMmkt7/FtxOMCpDbvfxnPxNgWbMHScgFuPJKtiUMCics/z3r667cZxbnFDWMO34zTAonjL/M2wxV6QjgZ7D4hLDm+8NA3JAAYMC6e3Awm4NMLApY4MQXTDaRlwrUy6s+4MQoPADfe3RTNcVZWcWe8MX5Kwg2vIB16QpdvKtqLDxC7MatWVVo/AlzPAhQDE/bycV5LAp7LAhZzL7Gw2OBHAqDLAgRdXQIZ8aumcidsMgAID0/aHWPXGOSnMZgfL++QrsaN0I3ArAVucmXcMKCsAPVyAyiMwiv1wpxrKuo/IbAqwwvxzOabMqbMMsAgH3pdzc9BwnhywB212RuGsu5ysuWHELrF4+M8L6Ku049PLe6rAm8XMHsMHlq24nzWs1M2f/JAKDKAzCLyxBKnNDA6JrOMuzN37zGg3CFoWgMehS0mdDCeWs6uUbC7HwJV+zOg2CCN0kMw+RIlSB8hBC4MTy/+/wIlCwI+vi5y/BJ68K0iTBJ0re407fOC90IDQ0A0ftCs+TMiHDElavE3bzRi9DR1zsNw0TK3InSkNDRYTzGybBFzdgJyIyrMr3MQKguqmiXMO0IMo2/oDxbXNW/VBzUDA3Oqewr5NwKckqkZWoJHeZ0AqAxsKzUkiDTPegrqasJOQCoQnqmWmqlpGkJF7Uy3caTWs0IvDwI6rsJZPoAFVCianqlAc0IL4dnaw3UbZ0Iby0IRF0Jc128d32lWlr/AUnwADQ9aU6jOUXM1n8N2Ezd1E4JCS7QAj2QplgKpIFKpETa2JoQbEIIx5PtCIENAF0txo3gAg9g1roXoA/QAnlNCh9okqfdCKldyee3CDngn6SJorNd26dgiZDMgrmtCLtdi09NCNFp105ZnV/9CqYICXzowH9Uvied27sNz2PcAtDtlEMMC7nYvokwjy0Sv9MswcmdCP3MvNIjvS3A2RVww7SgjJqY3tfKzRqd3DI9CF+nomlaAV36C0QIkfotrOqs0O3934OQQxgHAzog2rpw4Irwropzro6qz+19CA4uCHA4u9PNC3+8ijEXr8yz3af94SBufjPQAxSODayo/688nNEM7t+V3Uor7F8/jQjzKFBIXLAlreKTzeK/RNAqw8FZ3eGIYOTKkMAVBhQU3YVMPghO/kshxhiRDchVbgi7bV1S0+VenuPBK+aE8OW7a+ZnTuavq+aCgOYSZdpuDgBwznkLwDCpuORuXufN8ONGcdVvNOcA8N7aQCcUEGkAIGirkNO3euXMQCdYYxKKjttzHgW+Yt/Q4CNsNHjWrSiBdMyCbunGW+hTMjMiTTSMOH3rrbBqLurErQwPqQmsuM2SQ+R/7erWkJ3D5osiHMGsbua4ji72lwmseM+6hCUcDuyiletT+TFIfQizLq+CK8BiHuzV88aS4I2qbuPU3v/l0vPq/yQoqslXi0iP2j3k/Z3b387sNy2CTL7u1XCg3CLo8M4QjG6rJni4be7mtTy9gt7vm/vvbli7Ah/P/u7mV4jBBO/m9usQ906r4hzFZd7lKjkCbxAHaXCLDg/TeKmS4cmS5CmZZFkGEE0P5IvuN0643vmThSmUjWmcXRDj76De3N640cqVs8mSYBmWCTqfaLAGYaAPAMzfKQ+pePmVjakCC4qkRLmkzKmSHyoQ3grBIpzuWgmbhemS79mYGMqS+MkRILzgtpfsYQqUB0CexPmgBmCfX58XMJziVu+F3skBQzmZlomkGNqZP1kCoEHj0ayG7A2LBRCeJHCelvn/AUvambBxT0IO6l549OSp9JeZmSZwn3wPHw8fR1jfkoZfmZp5ACPwpAWS+Stk9mi/m8p5APeZn9nQs/aednNf97uJ9wdQAFEPDnY7D6RPNYN/AIXPm4jPmaJ/DrkvD7v/Ih0vm4YZ+btJ+Zb/DsUfD8f/HLC5ly1/mCH/mOz5+aFvD9EPD9O/GcmP84oZmXb/osm59qvPD9//DuEPESuvl4qZ/Y3Z+ehvnJkJmRx6+wABCBYAg4SFhoeIiYqLjI2Oj5CRigKSlZaXmJmam5seBZ+gnxwHpKUHJgapqqkqAa6vsLGys7S1tre1q6sgpqUcoaEenMPExcaWgsfKy8yV/5TN0NHShSXA1gUjvb2ouqy43+Dh4rEi3anapCPXJ9Pt7u/HyfDz9I/P9fie18Cj6Kbc5laNG0iwYLiAJtD9uiYMn8OHECNKnKjpnrQT+0Jl82cqoC4RBkOKHDkwIAl/+0pQXMmypcuXKxkIEMBgEZh+HA+A8CiQpM+fQL+p4Kkq54GUMJMqXcq0qUQECggQUIBAUdCrWGN9IGqAl9GjGUE1dEq2rNmzaGE2qAoAQQOrWWmV4/r1gLqwBdil3cu3r9+/gAEocDDIwQJFcLzmXIh3bODHkCNLnkyZ0ODChwnN3GyxsufPoEOL3rt2UIK3o1OrXs36kZHWzaBKpQq7tv/t257l4SYmk+bu38CDl9UtvLjx48j3Ek/OvLnz5/iWQ59Ovbr1S9Kva9/OvXr27uDDi9/9fbz58+grl0/Pvr379/Djy59Pv779+/jz69/Pv7///wAGKOCABBZo4IEIJqjggom8xuCDEDq3XoQUVsjahBZmqKF63SVQEyEULDCTBhuWOB6GyEEw04cAQBBBAibGKB6KySHA4mky5tgdjcjZSMgCCsykAAU6Fjkdj8f5OIgCMAIwQWaDcDaTkVT+hqRxSgLAAFsadFaIl1WGKeYyWUIFAQANsHgImGPCl4CUM0nQJlMqbsZWAzMtcGYibM4Jn4hN+klZn4K2Byh7GPT/8IAL8RFaaHqHoifDAJTW0Oij9EV6ng6UUvqAZ1IRAJGjmJqn6SBdCiDndhV0OgAMjEZGQAIi5slWPaSWKt6pECgQgaravQYDpcMO0ENkCPwqwALMCkkkPbnqCt6pCzSA56rWCdJpC8TGChgBAlAl6iAQJBABlPBEKy13mjJw2LXaaUspADN4+hgBE4xrCAQT4LoufRTAiS11FrjQKQBFEOueuv+aB+91FmBAaQUAuFBsC54tcCu0Ddv3cLYSD0AxAJwOYCll4Aa6iYeHMKDAIgx3LDNEEU88yKSU5oCyACpjUqeaAJj78iQzF62UBdyKTEgSlB4bWKih8kxMlm1R/zU0n0Zn7ZIFD9g7SMgDeNvXm3D2nEmWGkQAgQNXIxKz1nBL0/UAnxJSL92AkS2l2Zgo6SKJbBsCZ9yERzR33YMkDcO3UIdajJKpcrbnmoVXjg/TA2BMiMWUas4XuHBKPQzVhbVNueWov9PqABgYMvcMfoFeNid1zrRx4ESnrrs0q7deCM6Zx47vAqEqMPA8b++ufCQ1UOp7IT1QCvtfQP4IdLrLZ3/MwYcA7zlfeDJwmm/4JK/9+YcYwf0h0Q8wfV+9bhbBs/6ibz926xsCPOKfI5AAApOr3/0GCIknVEoRcxuAzsJjPgJqz4BKU0TzXrXAs0yAfhJpoAOXB8GRJf8iB8WCgQzOAjoGHM8hGtzg7nxAKR0wImkmE5tTKGCucCFAX+VToQ4RwUK8vbBTNZAhWRAgoghckBgsK92KcCi4HTqRED3knyJgGMS9SABPNAmgJX5GiAlUxUUba+ITnRgFSu3gEVQUYlloGIETWoJ0g2AAYbA2xh32DhIJq5QazcLES8CRAmEUYx1VeLfnOaJ9MSzLuCTQx7MBjV9rktIgdZi/RyCyik1JFgRkorapqUkD1zvdJB1YSTR2CgYVVEq1Auarfo2ORbJpRApHabSQvU8SMEQlUxaQAAcIwH/o8hlnqtIbIeWOlvcLmQcrkcvvvaQBCpCJBGiFQmQOcG7/TrvEDorlQ5hIwJgLcKUArXm+kkmxEiDsVBL2OBEJXJACR8whOdEnBy0M4IyakMEE3ZfKlVAgSJvhmztmOc9SVeMAbKhCFbTQz0u4AJHdjMneqllQwlVjFAb4wCy6UIw8VqqhEHEXBBxH0Yo2zBPZ2AlIcFEFNxgjB/scgA7YSQ8JRIWk8jSpoFB6ioyOoytHUYMyXFAyYjnTIRRQ1kwE2g6C6tRAPEWFRsUxlJOkoACOAcCVIIGBmM7gqPQo5lJL+tQMVSMFPZ2qOLZCik84YquRKAI33QfWd4gUp5xIYhxXBLOyPggjo1DpQLaSEHVkFRJwjcRDXUVXmkLDplAb/wYXByGbqQRSM34dkD5I4Y1xENYuWC2LDCD6Kh2MEB56G+srCVGatqDGbZnVz1l14tOSGKCtof3LaBkrshYYMhqpFR0nsnQZABjmmLGdzwkOoFZwVPUACwGNDB4wVyAm4QE7OC0zGvc4FhX3uJqRZHLjUwATrNQWn72qSmrTgtXxtlMV0EERMODYp7CotTii43jT44ERgKAVsmArWA77m+lW4G7v7dQMKvCAFoBUEv5LgITd6EdY3pQ2+t2veDyQAhLQggQpIHBzXICBIujAvQl239kmuona/XKv5MuwhrdTAg409xUqAMEIRHwdGWDgAUmIKaWSkAkGRMBlCSjuOP9nXJ0TmODGrhCBCUbgFwcpBQMteEAFYHDOSPASKkFj6jScymTVjMC8s/iACfTyl8SiJZzffFIwsVfm5nD4v7MwAAfW+xg3nyXJU1HtkuscnBJ0+MMhpoyfzQIBOZXrsu8gM6EfU2MoByDHVP7MosuCAAE0kmOTxo2TzwsLKRdgNJsmi4tGKpWHSDrUaPEvqV/xgQOwGdWjCa6YpfFqWDeFwyQAcCxIsGfYpNopuiarrytTYw/LQgUg5jGuR8NdZS8bMiew8SwwratqK4MAvdETcq8NmFHPQsq3xlRwjaiMJw2iWuMm9178K2xYfIAD6dZVcG13jAmgJgHiFKW8zwL/7Hq/AsR87hitpBIwB5zrGARYgBEZ8GkA9Hrg06ixAbYNgkRnjVnk4hnIjeEjqGxscBhnynItLQIdFy58HvrlyIsRARIZ13RfSnlSzjzrKK8ZdS7ajAIgoLFjLOBDDAhllHTOkmbT4t4JD1ZqCIAAL1Z8EyHKkxZzzvSI8BzR0vZOaqBiQ1d3HR9OP7eOww6x0XSaM3Mc9Nmh0V8Q9NwVes63eY7dFHdRgAAhUnpT534RDmxc7TuOD993KU5355Twxqj73QOQ9/osfikTEEADxhdw5EG+GNk+vCyknPj7XF4pgRbS1Xn9eU3c2eAHL/Z+To96/93Q7K2vxMrlMmUA/9EeJo2eyMV9/foPy76inV79MLIuAJvDNveLKABzn26CU/t11Xg1hot2bXHoH8LQwd42wsebbGXklxHDH295LR0ANVtfw+U3OkCHFO+zgx/2lx5/nQkggb/zX/mXwCSD4HhRIl5zd2bsV2t6x2SZRyIEwG7KsCWo0ifpR05p92wdx3YaNnMzR3JDhyaCV4Gj9HVpZmtFYmWgUT1LMmfEgEXiJmOhdoHkkIFV8nsv0WniIxOQNngxKGu0UHljYoMuEXGbQTzWllz9dQAGgH8B0HKlNydCOIS2B4DQIILZ4wkHQAKTh3f4VipRSBHj4m1yN08FwAEgwH6vYABTpoFh8v+FEpEy8Qdq83QCKfBkt6BmKbCAXggacMhiY+hEJXBmoicXIPALcOOGbzgIYiiHToSFS2gLInASuUU4iLgSkXWE9yN9WmgLQ2EXUed9lvBPnMF9VUhAZXiGt6CGKfCJoFhkfsiIykOHqHCHHaeHragJd9Vq0OAyfaU7gaiEt9ByhniLj3VTusgMQtOLhOOITOgK0HYUbEiMnJBUo8gMJodzXJc1ZbiJtdCJI8CK0hgNYiVcxpA2a4ONmCUz2YaKtqCKthiO0pCLVFgJf3NzgmOApVIAdTiIaVaI70hLKPgZkJV9xBA5m7F1Sycov0gCaBhlxPZ+sVWJEhGHyoA7MKj/I57AAbN4C884iRomkRFBkcdgkc+XI3SohFv4CuXgibAGkhGxiJ63IQfFjqloAr8QjePlkrthhe2hj6jQjLR2Et/YdTpJD/jSSJAEiwQCCqTAjZx4W1fVekU5D+AiLoRQLg+nlPeBEdLHWanwU7zgkbk3lfOQLHnSLOGCQZEWH1zZDyTQWQWxkiPwj59HllRJKzNxLjs4ZuHRlk0JlyIxF7wwjPBoG8eIicXhl1kImCEhmKRwVQUAjoX5HzxJFor5lo9IEo55AJApmZOZIJVJEdWgj6SwE5k5EpvZmZ8JIWyzRPW3F6OJVrRlAClJValwEtD1CZ65mu7Bf+32RRGw/4OhWQyxWZqpUJvhMBQGgJsLQZe8OR8SEJ2dJgEIOQxy9JoOUZyziZzOdZuk0JzPqSCyE1DLAEjK6A76IJumyZ1C4Z25mRfhGRkBGRrnMj4JQGGakJRfgo/EoA8bwQ0N+VPL+Z2f4JzxGRh2iQ9ENwHfNI+RAEqyZAn+SQoA+hNFgVsQeaC2kaD4QADQ5GnHEEvohwgT2lO1RRIXChYZqqHHwaHtEHyGQIDFIFboCABbYKIBKg4pCgosuiOh8SYOKg0GsaNu1aPt4aLTAKQUUQtboYbpUKRGano/uizMUqV7KQ03ClpiGaX+gaTSsG/kGJNcaiBeClyqEp1oWp08OP+mOqWkwsemT0VEKzGccBpqdFqnhHaneFpRvSF43ben3ldZGFaSgNp6reUW2Fmo9zGf3PFdLJiQitofZfoXjrqfm0EFoZOpmrqpnNqpnvqpoBqqojqqpFqqpnqqqJqqqrqqrNqqrvqqsBqrsMoU+PVaAlcM6Td8ucoMu6oMvXoMvwqsyxCsxkCsxKCnfnRhwjmsvMqszuqrzQqtz1qs0Sqtwjqt1Iqtx9p3fJWomWCswwCu4Vqt2Wqt5Xqt5oqr5Hqu7LqtgKGr6+qu6aqu2jqu9coJ4oqv96qv+7oJ8Pqu/VoRAfut8Sqv7Wqw9DqvCLuwDGuvCsuvkRqxEjuxFFv/sRZ7sRg7HVyQsa1oBALAqOkRAjbQAYMQAzfgCjbwApkgsiRbCB0QACq7siNbCBfgChsgsy0LAC9gA65wAZjwAhlgszEwCBtgs5kAtEKrs0EbABswtJeAtEzrtESbAT+7tE07CEeAAq6Qs5UAtVcbA0UbACgQApfQAVortmQLAGF7s5hgtq4wtkqbtGV7tnBLCBtAtXP7tmmbtVvbtnRLtmCrt8NgBQJgBcZABEhAKSsgBMfABAPAuGiBA30LACGAAkcAAEEQAJgguQHAtSKbspnAuTkbBJarCaI7CCEQAE4AAE4QAJdrCTjgsyLrsxeQATEQAxngs5cQu5RrAz7L/7uzu7my67uEEAQ2gLewO7zDGwSbALzEiwMoMAgocAOXcAHMGwMowLy1e7u5iwnWCwDYy7zOq7uW8L3hW7zH673Xm729y7yaYL7sC73SS72cgKlUYAxKQAM/AABLMAD4uwKLyxedewgdgLyXMMAlm7sZELOZgMAx4LrDgMCpe7kPnLaZsAEqewO6ewH0qwkYbAgfvAkhXLu1ywkfHAQdPAwfjAP0GwQ4oAkhkAGrq8GDwMGbEMOrWwghvLIyXMMKfMM9jMLFgMMAwMKD4MKcMAWbMQXLwARDUAxEMAQsMASQmxYIXAg4YMEHnLMbwLwLvAkI3LpL+8INnLMvwLQowP/AmHAEuvvFOhu9msDGhiDHm0DHHWADIQC0day7KLC0GfC6mUDH2GsDOHC1mBC09OvGLwDHhxwAKQwAdJwJiDwId5zHBmwJkwwAfewKf6wJmTzIhSy1mSAFmyEFy9AESlAMPLAEAEDFAsy1AHABgIwJCBwEbOvGZTwIO0u2R2ADObzFqJsBHXAEN2C7K0vGAKDIjHwJIYDMqOvMmNDMqDuzenzMhJAB7iu/1lzDN0vCmoC9PqvMmwDOhCDNnADOLKu044wC4ZzNy3wJ5HwB3dy9mgAFUgIFx8AC+0sMS8ADg+DKe3HFavvLuay2sQDNlYDAd2y35GsJCCzP16zGktD/AWw7CDSMuY880RVNyRvdthX9srGgxZFA0Tqsuy+bCSRNCDOrzu97sxctxJsA0QCQ0sMgzyANCyJdCRC9ASatuTF9sytdzZmQBVKSBcbAA0Bw1IzVBAHdspXb0AVdCLhMyy0bA8R7BAKd0C3buiT7srAMCdtLs7aLu1AdCWFNCGedCWldCEKt08aM1hlAtjfQ0Wb91tLLthtA149AwzFMu2NNz5bA19271pcg2A3d1pJg2LEc1wAw15ig2CiA13odCVcgAFKgxFNAylcwDPnLAs0A0GfBua4w07Eg0ZAg2j4d0aELC5S8tGV92qwdy6/w2o8QtpxMtEaLCbYdAFS7/9uXHAm+zda/DQnB3diCewnBzbdoW70868h2m9vM7Qr0W9zl29yPjNhmbd2EcLLLHd3ODcl/qwlGgM9/CgUgWwmO6ypVTAygzbGpg6zubU3wHd+0NN/0PUn2fd91lN/6/UT83d879N8ArkICPuAOVOAGPkAInuD2s+AMfj4O/uASPuEUXuEWfuEYnuEaXiqdtggkWQ80MACeveGFUkwK4HyHMAGu9OGRoASUksosMAArMAg8IOKQEOIjTuJ+IoEgqAgqXjqZEOKMW+MDwAQAsAJFfuM2ruM7zhYSGDhsw0qbIUfnMiKVEONMjeQi7rgzDgBCMASUwgOp/ANEPgRJjf/jUTwASR3jisvkOmLiVQHlwTmAKx4BhCGjj+C4Q+C4Nc4DMY4EAMDnABDjPBDFQ0AEPyDjAIDjNe7ZMU4Dbm4kPN4lGgDlV/Pj9pjpkoDkievEK1DjjNsEjLW4vPUDIY7k/uzllEIDS7DPkW4iPC4YDmDpXbTiQ8PijlDjAAwAov7ivD4ATE0IQjAAT1wIIa64qTzovT4Ayf7qG8LjvkQBtG4aH4I7uN4IbO7Pw07sgwAEMr6/QIAERIDknq0EhR7iS9C/kE4ILs7szl4ixWTn9miR1ChHt16ji5DoNt7uwe7lx27jZN4pgI7jrSzi/Usp7f3uCr/wDN/wDv/wEB//8QnyK2ppiTNR8RLPHLMSUFdaCG9iq4bwTRFAWZq3CRQPE6CD8YXSv4AOeSLCFnL6CB+vCCJvDCf/Ein/LywPeZ0G8iQ/E6jxdgIQnJwxTfLjAAHD8SXfFuQJOjX0FuNJcQBw84rIGVJvU0N/8Te3ItWpg07yYplXFUKPGq2ZRSnfJUPnoZvh8wgS4kSe6gE/APoLAIgr8GxOKUl9dngSSJ1WFXvfaegy84WQKo029CT/FjOfeQkAOoz0KyguE/1C9YYA+Q/YfGfvGziYCJn/KzURJBDQ92jyS11SEzjI+L5CJHhCigSC7gDQ6OM+AD+gBABc96xMCDtPeHs/9Xkp/xhS0gC+tCwJQCSCTwFYdPE1z/RvESSE8U1RofW/IidkB/S6r5bRr3nMDwApn3mcMfKIoCI1RxPNtyy8zxkNoP3yAzq/whbaLz5B2h8ET+jDXuxC3uurTAT8OwAtP3eZDwA1DwgKAg4AhYUIEwKKEAkCDYURAggEihQSAhGHjgCChJcKlAIUAJESCAILBI2PkaOGp6mrnwChFIkThrm6AAsCDBEavpKcg7m3uaGKC4YJDIoKu9HS09TV1tfY2drb3NY0AywALAM8QgNDhd9CAEs8A+fsA0jd9PX29/j5+vv8/dsEghIAuJSpUSoACAQWgrDoFANaijQEExUsE8JNq/8AJEpQi5QACY0eOmMlKldIACMZRoBAoRLBURIeOUOg65QvYiUNEkCY4OXABqEk9FJYyIEAaP6SKl3KNNq3cE+JrBjwQ8mKFUQMmUM3jkfTr2DDih1LVhuBRM9oIox0FKSio4Qg9Ppoc+4oZwISnHp0UZHAjqXkKtvUKpdgVJscRJoLAYCDucMiIM3VcliiyQjYKpDgGPKkSpU1QGbgqqzp02C/DXm3pNAPdwNo/ADw7R2P2UpqA0HNu7fv38CD8zM6WVcwtcKTKw/+dLnz59CjSx/b4C1paQiKT9/O/V7z7uDDix9Pvrz58+jTq1/Pvr379/Djy59Pv779pUAGrOj/ln///f8ABijggL71p8s48+hCxDuzGUjggxBGKOGE1jhozYJUAWAhhRx26OGH7vWHxDvrIEjbAE0MQcNU79DQXxPvhAPijDTWaKNw/RHBhH7iyHNiixg2qB8RG95o5JFIJomPg1MxYeJ3QWrI4w/vZKXklVhmqaWU/jX5JDiFRGkglQNYueWZaKY5oYFb9TjPdwA0ySUAZJqp5p145hlffy3O9qWMPcY2ZpV6FmrooYgmquiijDbq6KOQRirppJRWaumlmGaq6aacdurpp6CGKuqopJZq6qmopqrqqqy26uqrsMYq66y01mrrrbjmquuuvPbq66/ABivssMQWa+yxEsgmq+yyzDbr7LPQRivttL4GAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal patterns of change for thyroid-stimulating hormone (TSH), total T4, and total T3 are depicted for the fetus (beginning at 12 weeks gestation) and continuing for the first four weeks of life in the newborn.",
"    <br>",
"     <strong>",
"      Note:",
"     </strong>",
"     To convert T3 in ng/dL to nmol/L, multiply by 0.01536. To convert T4 in mcg/dL to nmol/L, multiply by 12.87.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Data from:",
"      <br>",
"       <ol>",
"        <li>",
"         Thorpe-Beeston JG, Nicolaides KH, Felton CB, et al. Maturation of the secretion of thyroid hormone and thyroid-stimulating hormone in the fetus. N Engl J Med 1991; 324:532.",
"        </li>",
"        <li>",
"         Fisher DA. Thyroid physiology in the perinatal period and during childhood. In: Werner's and Ingbar's The Thyroid, Braverman LE, Utiger RD (Eds), Lippincott-Raven, Philadelphia, 1996. p.974.",
"        </li>",
"        <li>",
"         Williams FL, Simpson J, Delahunty C, et al. Developmental trends in cord and postpartum serum thyroid hormones in preterm infants. J Clin Endocrinol Metab 2004; 89:5314.",
"        </li>",
"       </ol>",
"      </br>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_54_14191=[""].join("\n");
var outline_f13_54_14191=null;
       